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ABSTRACT 
 
Inherited abnormalities of the kidney are frequently observed and represent a significant 
cause of morbidity and mortality. The globally increasing number of patients with end-
stage renal disease (ESRD) urges the identification of molecular pathways involved in 
renal pathophysiology, to serve as targets for therapeutic intervention. 
Data from 2010 estimates the Saudi Arabian population to be 27 million, with one of 
the highest growth rates in the world. The population is characterized with high 
consanguinity rate, large family size, and a tribal structure. The consanguinity rate 
results in a high incidence of autosomal recessive genetic disorders. The population is at 
high risk of renal failure, with 133 incident cases per million populations per year that 
require renal replacement therapy. In such a population, characterization of new kidney 
disease gene loci using homozygosity mapping and positional cloning within 
consanguineous families is a powerful strategy.  This study aimed to adopt this 
approach in order to search for known and novel molecular causes of inherited kidney 
diseases in the Saudi population. We studied patients and families with nephrotic 
syndrome, renal ciliopathies, nephrocalcinosis and renal agenesis. For nephrotic 
syndrome, we found that the most common genetic cause was a homozygous mutation 
in the NPHS2 gene. Novel and reported mutations in known nephrosis genes were 
detected. In a family with Bardet Biedl Syndrome, we utilized zebrafish and renal 
epithelial cells to determine the functional significance of a novel BBS5 mutation. In 
another consanguineous family with an autosomal recessive syndrome of distal renal 
tubular acidosis, small kidneys, and nephrocalcinosis we identified a novel locus on 
chromosome 2. We also describe the molecular genetic investigation of families with 
bilateral renal agenesis. In conclusion, in the highly consanguineous Saudi population 
we have utilized a variety of genetic approaches to identify and characterize novel 
genetic variants causing inherited renal disease.   
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Chapter 1: INTRODUCTION 
 
1.1 Genetics of Kidney 
The human kidneys serve important physiological functions to excrete waste products 
from the body and balance the body’s fluids. The kidneys also have endocrine roles and 
are a key regulator of blood pressure and mineral metabolism. 
There is now extensive evidence from a wide variety of approaches that suggests renal 
disease in the general population has a genetic component. The most numerous studies 
take the form of evaluating familial aggregation (Bowden, 2003). 
At least 40 genes have been shown to be involved in kidney development and many 
more genes are expressed within the kidney and regulate renal physiology (Drummond, 
2008).  
Development of the kidney in mammals progresses through three spatially and 
temporally distinct stages: pronephros, mesonephros and metanephros. The first two 
stages are transient structures in mammalians and do not contribute to the formation of 
the mature kidney, but they play major roles in the development of the gonads, adrenal 
gland and hematopoetic precursors. The third stage, the metanephros persists and gives 
rise to the functional kidneys. The metanephric or adult kidney is derived from the 
reciprocal interactions of two primordial mesodermal derivatives, the ureteric bud and 
the metanephric mesenchyme.(Lechner and Dressler, 1997). Mesenchymal cells near 
the bud become induced and convert to an epithelium which goes on to generate the 
functional filtering unit of the kidney, the nephron.  
 Genetic studies in mice have allowed researchers to begin to unravel the molecular 
basis of kidney development in human. Transcription factors such as Lim-1, Foxc-1, 
Wilms’ Tumor gene 1 (WT1), Eya1 and Pax2, are all act in the metanephrogenic 
mesenchyme (MM) to induce the expression of Glial cell-derived neurotrophic factor 
(Gdnf) and Six2 (Gong et al., 2007). GDNF signaling is the main regulator of ureteric 
budding and branching morphogenesis, whereas Six2 is required for MM cell renewal 
(Self et al., 2006). Proteins of the Bone morphogenetic proteins (BMP) family modulate 
ureteric bud branching and keep bud development. As nephrons form, they express 
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critical transcription factors such as WT-1, Pax-2, and Hoxa11 and d11, condense, and 
secrete Wnt-4.Wnt-4 acts in an autocrine loop to stimulate its own synthesis and are 
required for cells to differentiate into epithelia. As nephrons mature, regions of them 
differentiate to perform specific physiological functions, a process that requires the 
proteins WT-1, Lmx-1b, Notch-2, Jagged-1, and Hnf-1. (Davies and Fisher, 2002). 
Congenital abnormalities of the kidney are frequently observed in children and 
represent a significant cause of morbidity and mortality. These conditions are 
phenotypically variable, leading to a spectrum of renal diseases. Many inherited renal 
disorders are quite rare, with an incidence of 1:10,000 to 1: 100,000 (National 
Organization for Rare Disorders., 1992). The following universal principles concerning 
inherited renal disease can be identified: 
1) More than one child in a family may be affected. 
2) The child with hereditary renal disease frequently presents with growth failure. 
3) The inherited pattern is usually autosomal recessive, but it may also be 
autosomal dominant or X-linked. 
Diseases caused by recessive genes usually manifest prenatally, or in childhood or 
adolescence (e.g. nephrotic syndrome). Those caused by dominant genes typically 
manifest in adulthood (e.g. autosomal dominant polycystic kidney disease)(Hildebrandt, 
2010). Genotype-phenotype correlation is strong in recessive single-gene renal 
disorders, this correlation is reduced in those caused by dominant genes because of 
incomplete penetrance and variable expression in different organs (Hildebrandt, 2010). 
Figure 1.1 illustrated classification of genetic renal diseases. 
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Figure 1.1: Classification of pathological effect of genetics renal disease. 
 
The globally increasing number of patients with end-stage renal disease (ESRD) urges 
the identification of molecular pathways involved in renal pathophysiology, to serve as 
targets for intervention. The study of most common genetic cause of renal failure may 
lead to reduction in the number of kidney diseases progressing to ESRD. Moreover, 
kidney disease is a growing financial problem. For example, from 1993 to 2005, the 
total costs of medical care for patients with ESRD increased from US$8 to $20 billion 
in the US (de Borst et al., 2008). Here in the Kingdom of Saudi Arabia, the estimated 
cost per annum incurred toward maintenance hemodialysis is US $19,400 and, 
considering that there are more than 7200 patients on regular dialysis (Shaheen and Al-
Khader, 2005). 
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1.2 Genetics of Saudi population 
Saudi Arabia is the largest Arab country occupying most of Arabian Peninsula.  
It is bounded on the north by Jordan and Iraq and on the south by Yemen and Oman. It 
is bounded by Red Sea on the west and Arabian Gulf (Persian Gulf) on the east. The 
country's total area (2,250,000 km²) is barren desert. The population is cosmopolitan 
and comprised of large and small minorities. According to a 2010 census, the Saudi 
population estimated to be 27 million, 70% Saudi native and 30% immigrants, the 
majority of whom were Arabs. Those considered to be Saudi natives are the early 
settlers of the urban centres or those originating mostly from neighboring Arab 
countries in addition to Bedouins (the nomadic Arabs of the desert). Saudi Arabia has 
one of the highest growth rates in the world (approximately 400000 live births per year). 
Typically, family size is large, with six children being an average number of offspring 
per family. Bedouins form tribal communities which are quite isolated. It is estimated 
that, 8 tribes account for around 10% of the country’s population. Islam is the 
predominant religion among Saudis. Despite the westernization of a significant sector of 
the population, many still maintain their cultural ties and religious principles. Because 
they are forbidden by Islam, uncle-niece/aunt-nephew marriages are virtually non-
existent. Prenatal diagnosis and pre-implantation genetic diagnosis (PGD) are 
acceptable for purposes of reassurance or of therapy. Although Islam, according to 
many religious scholars, discourages consanguineous marriages, such marriages have 
been traditionally practiced over many generations because of social, economic, and 
geographical factors. In Saudi Arabia the overall rate of consanguineous marriage is 
reported to be 57.7% with regional variation from a low of 34.0% to an astounding high 
of 80.6% (el-Hazmi et al., 1995, al Husain and al Bunyan, 1997, al-Abdulkareem and 
Ballal, 1998). The most frequent were first cousin marriages (28.4%) followed by 
distant relative marriages (15.2%) and second cousin marriages (14.6%) (el-Hazmi et 
al., 1995). 
 
1.3 Inherited Kidney disease in Saudi population 
Through years of health services it has become clear that Arabs have a high frequency 
of genetic disorders, and in particular autosomal recessive traits. The consanguinity rate 
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together with a cultural preference for endogamous unions results in a high incidence of 
recessive disorders such as sickle-cell anemia, beta-thalassaemia, inborn errors of 
metabolism, hereditary hearing impairments (Teebi et al., 2002, Zakzouk, 2002), and a 
multitude of novel Mendelian diseases. Many novel primarily recessive Mendelian 
diseases are also very evident in the Saudi population and characterization of new gene 
loci is facilitated in the population where the average family size is such that pedigrees 
with multiple affected individuals are readily available.  
In 2010, according to Saudi Centre for Organ Transplantation (SCOT Data), the number 
of Saudi patients with end stage renal failure (ESRF) was 12,633 patients; 11437 
patients were treated by haemodialysis and 1196 patients were treated with peritoneal 
dialysis. Causes of renal failure among haemodialysis patients are presented in Table 
1.1. The estimation of new affected cases is 133 for each million yearly (2012).  
 
Cause of Renal Failure No. % 
Diabetic Nephropathy 3941 34.5 
Hypertensive Nephropathy 3805 33.3 
Unknown Aetiology 1272 11.1 
Primary Glomerular Disease 697 6.1 
Obstructive Uropathy 365 3.2 
Hereditary Renal Disease 330 2.9 
Congenital Malformation 240 2.1 
Primary Tubulo-Interstial Disease 188 1.6 
Vasculitis 173 1.5 
Pregnancy Related 78 0.7 
Others 348 3 
Total 11437 100 
Table 1.1: Causes of End Stage Renal Failure in Haemodialysis patients - 2010 
 
In contrast to the genetically well studied populations of North America and Europe, 
Saudi population remained unstudied. Most of studies conducted were describing 
clinical observation and statistics of inherited kidney diseases. Almost all the studies 
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published are from referral centres in regions. Preliminary observations indicate that the 
children in the Saudi Arabia probably have a higher incidence of polycystic kidney 
disease, familial juvenile nephronophthisis, congenital urological anomalies and 
familial nephrotic syndrome (Mattoo, 1998, Kari, 2006, Al Harbi, 1997, Al-Ghwery and 
Al-Asmari, 2004). Studying histological biopsies of patients with glomerular disease 
was much abundant in many centres in the country. These studies concluded that 
minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the 
most common primary glomerular disorder en-countered in children in Saudi Arabia 
(Al-Sabban, 1997, al-Rasheed et al., 1996, Mattoo et al., 1990, Kari, 2002, Jalalah and 
Jamal, 2009, Mitwalli et al., 1996).  Molecular studies were conducted lately and 
covered rare syndromes that have kidney phenotype such as nephrogenic diabetes 
insipidus (Carroll et al., 2006), cystinosis (Aldahmesh et al., 2009) Bardet Biedl 
Syndrome (BBS) (Abu Safieh et al., 2010), Joubert syndrome (Alazami et al., 2012) and 
Meckele Gruber syndrome (Shaheen et al., 2012). 
 
The cohorts of patients studied in this thesis depended upon local referral rates and the 
use of unique families presenting with possible novel causes.  A molecular genetic 
diagnosis in families with nephrotic syndrome (NS) is useful for the clinician to aid 
further management. A molecular genetic diagnosis in such families was frequently 
requested. 
NS is characterized namely by heavy proteinuria, hypoproteinaemia, and oedema 
starting soon after birth, sometimes progressing to ESRD. The incidence of familial 
cases is from 3 to 5% (Obeidova et al., 2006). Several genes have been implicated in 
inherited forms of nephrotic syndrome occurring in children.  Proteins encoded by these 
genes influence the function of the podocytes. Mutations in the NPHS2 gene, encoding 
protein podocin, are a common cause of childhood steroid-resistant NS. Kidney 
transplantation is often required as curative therapy for patients with NS. Patients with 
NS with homozygous or compound heterozygous mutations in the NPHS2 gene have a 
reduced risk for recurrence after transplantation (Ruf et al., 2004a), again highlighting 
the clinical importance of a molecular genetic diagnosis. 
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Patients with ciliopathies may present with a bizarre and wide spectrum of clinical 
phenotypes that cause diagnostic uncertainty. A referral for a molecular genetic 
diagnosis may aid a unifying diagnosis and allow screening of at risk individuals. 
Bardet–Biedl Syndrome (BBS; OMIM 209900) is an autosomal recessive disorder 
clinically characterized primarily by obesity, progressive early-onset retinal 
degeneration, polydactyly, hypogenitalism, cognitive impairment and renal failure. 
BBS is the archetypal ciliopathy, with the multisystem syndrome secondary to defects 
in ciliary / basal body structure and function. To date, 16 BBS genes have been 
identified (Forsythe and Beales, 2012). A precise molecular genetic diagnosis also 
allows genotype phentotype correlations to be made. 
 
The high degree of consanguinity in Saudi Arabia sometimes results in families with a 
unique phenotype presenting. One such family has recently been identified and reported 
(Faqeih et al., 2007). The phenotype included a constellation of features including 
nephrocalcinosis, renal tubular acidosis and learning difficulties. Nephrocalcinosis is an 
etiologically heterogeneous disorder associated with an increase in the calcium content 
of the kidneys with underlying complex pathology. It is often seen as a complication of 
various renal disorders or metabolic disturbances but may be part of inherited 
syndromes, including rare and exotic syndromes (e.g. Blue Diaper syndrome 
(Drummond et al., 1964). Distal renal tubular acidosis (dRTA) is caused by a defect in 
the kidney tubes that causes acid to build up in the bloodstream. It may be caused by a 
variety of systemic conditions and may be inherited. 
 Molecular genetic diagnosis has a role in families where stillbirth and early neonatal 
death has occurred; such cases are not uncommon in the Arabian Peninsula. Such 
devastating phenotypes need further understanding and investigation to allow insights 
into disease pathogenesis and to allow screening, if appropriate, of future pregnancies. 
Bilateral renal agenesis is an example of neonatal fatal kidney disease. The failure of 
both kidneys to develop in utero results in oligohydramnios. The lack amniotic fluid 
may cause compression of the fetus and further fetal malformations. Bilateral renal 
agenesis is more common in infants with a parent who has a renal anomaly, particularly, 
unilateral renal agenesis. Studies have shown that unilateral and bilateral renal agenesis 
Chapter 1_____________________________________________________Introduction 
 
8 
 
may be genetically related (Kerecuk et al., 2008). For the isolated non-syndromic renal 
agenesis, only segregation studies have been performed and no loci and/or genes have 
been mapped so far. 
Thus, in this study we used an opportunistic approach to identify disease causing kidney 
genes in a variety of diseases, using clinical need, diagnostic need and the desire to 
further our understanding of human renal diseases. 
 
1.4 Approaches to identify inherited kidney Disease 
There are many techniques to identify disease causing genes. These include 
homozygosity mapping, LOD score analysis, association studies, candidate gene 
screening, Genome-wide knockdown studies, and Whole exome sequencing. 
Genetic linkage analysis is the relatively close physical association between a set of 
genetic markers which lie on the same chromosome. Genome-wide linkage allows 
finding causal genes without having to know anything on their position on the genome, 
as necessary in the case of candidate gene studies. It will find such a causal gene, even 
if there is no assumption for its connection or contribution to the trait. 
 Homozygosity mapping is a term used to describe in a series of markers (SNPs 
or microsatellite markers) homozygosity that is identical by descent. Identity by descent 
(IBD) mapping generally uses marker arrays to survey known polymorphic sites 
throughout the genome of affected individuals and their parents and/or siblings, both 
affected and unaffected. People with recessive diseases in consanguineous families are 
likely to be homozygous for markers linked to the disease locus. If parents are 
consanguineous by a 2nd degree marriage they would be expected to share 1/32 of all 
their genes because of their common ancestry, and a child would be homozygous at 
only 1/64 of all loci (Bittles, 2001, Bittles, 2003). Homozygosity mapping becomes a 
powerful tool for linkage analysis if families can be found where two or more siblings 
are affected and they are inbred. It is a model-free analysis, in that no assumptions need 
to be made about penetrance or gene frequency, although in straightforward applications 
recessive inheritance is assumed. Homozygosity mapping is an efficient strategy for 
mapping human genes that cause recessive traits (Lander and Botstein, 1987).  
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Homozygosity mapping can also be applied in sporadic consanguineous patients (Papic 
et al., 2011) and in individuals from outbred populations (Hildebrandt et al., 2009).  
 Homozygosity mapping for a Saudi population would be applicable to identify new 
gene loci for inherited kidney diseases and would therefore be a useful approach to 
identify target genes in heterogenetic diseases.  
Autozygosity mapping is an extension of homozygosity, in the genomes of affected 
individuals.  It is a form of genetic mapping for autosomal recessive disorders in which 
affected individuals are expected to have two identical disease alleles by descent. 
Individuals are frequently observed to have long segments of uninterrupted sequences 
of homozygous markers. These long homozygous segments arise through numerous 
mechanisms, including consanguineous marriages, in which parents pass shared 
chromosomal segments to their child. In a small population, possibly created by the 
founder effect, there will be a limited gene pool, and thus any inherited disease will 
probably be a result of two copies of the same mutation segregating on the same 
haplotype. By taking into consideration the population allele frequencies for all SNPs 
via autozygosity mapping, the results of homozygosity can be confirmed.  The 
autozygosity mapping can be accomplished by plotting a cumulative LOD score. 
LOD score analysis is a statistical test often used for linkage analysis in human, animal, 
and plant populations.  LOD stands for “logarithm of the odds”. It is applied to compare 
the likelihood that two loci are linked against the likelihood that the two loci are 
unlinked. Furthermore, if two suspicious regions appear as a result of homozygosity 
mapping, LOD score analysis may be able to distinguish between the two. A LOD score 
greater than 3.0 is considered evidence for linkage. A LOD score of +3 indicates 1000 
to 1 odds that the linkage being observed did not occur by chance. On the other hand, a 
LOD score less than -2.0 is considered evidence to exclude linkage.  
Linkage by homzygosity mapping is an observation of alleles regardless of whether 
they are completely identical and inherited from descent or not while linkage by 
autozygosity mapping searches for identical alleles segregating from the same founder.    
 Exome sequencing is an efficient strategy to selectively sequence the coding 
regions of the genome. Exons are short, functionally important sequences of DNA 
which represent the regions in genes that are translated into protein and the un-
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translated region (UTR) flanking them. UTRs are usually not included in exome studies. 
In the human genome there are about 180,000 exons: these constitute about 1% of the 
human genome, which translates to about 30 megabases (Mb) in length. It is estimated 
that the protein coding regions of the human genome constitute about 85% of the 
disease-causing mutations (Choi et al., 2009). Exome sequencing (Figure 1.2) is only 
able to identify those variants found in the coding region of genes which affect protein 
function. It is not able to identify the structural and non-coding variants associated with 
the disease. This limitation of exome sequencing can be overcome using other methods 
such as whole genome sequencing or target-enrichment strategies.  
Whole genome sequencing (complete genome sequencing) is a process that determines 
the complete DNA sequence of an organism's genome at a single time. Target-
enrichment methods allow one to selectively capture genomic regions of interest from a 
DNA sample prior to sequencing (Bashiardes et al., 2005). 
Using a functional assay is another way to investigate human diseases at a cellular and 
molecular level. Animal models were used during research and investigation of human 
disease for the purpose of better understanding the disease without harming actual 
human being. Whereas a mouse or dog may serve as a mammalian animal model, a 
baboon or macaque may serve as a less inclusive primate animal model. An animal 
model for vertebrates is the zebrafish (Kari et al., 2007, Chakraborty et al., 2009). The 
zebrafish, (Danio rerio) is a tropical freshwater fish that has come to attention recently 
as a genetically tractable vertebrate model system. It is now a common and useful 
model organism for studies of vertebrate development and gene function. There are two 
main reasons to use zebrafish as model system; first, the ability to apply efficient 
invertebrate style genetics to vertebrate-specific questions, and second the optical clarity 
of embryos and larvae, which allow easy visualization of developmental processes 
(Lieschke and Currie, 2007).  Zebrafish genome has been fully sequenced, and it has 
well-understood, easily observable and testable developmental behaviors. Its embryonic 
development is very rapid, and its embryos are relatively large, robust, and transparent, 
and able to develop outside their mother (Dahm and Geisler, 2006). Sophisticated 
mutagenesis and screening strategies on a large scale, and with an economy that is not 
possible in other vertebrate systems, have generated zebrafish models of a wide variety 
of human diseases (Lieschke and Currie, 2007). 
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Figure 1.2: Exome sequencing workflow 
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Studies of kidney development and disease aim to uncover the origins of complexity in 
the kidney and molecular pathogenesis underlying tissue dysfunction. In zebrafish the 
functional larval pronephros consists of only two nephrons with glomeruli fused at the 
embryo midline just ventral to the dorsal aorta as shown in Figure 1.3 (Drummond, 
2005). 
 
 
Figure 1.3: Diagram of the mature zebrafish pronephric kidney in 3 days old larva. 
The pronephric glomerulus is composed of cell types that are typical of higher 
vertebrate kidneys, including fenestrated capillary endothelial cells, podocytes, and 
polarized tubular epithelial cells. Two pronephric tubules connect the glomerulus to the 
pronephric ducts, which run caudally and fuse just before their contact with the outside 
world at the cloaca. The zebrafish pronephric nephrons form a closed system of blood 
filtration, tubular reabsorption, and fluid excretion. The primary function of the fish 
pronephros is for osmoregulation. Without a functional kidney, larvae die of gross 
edema because they have salty blood and yet live in a very dilute environment 
(Drummond, 2005).  
Zebrafish could be used as model for defects in glomerulus formation and nephrotic 
syndromes. Electron microscopy of the zebrafish pronephric glomerulus reveals that 
like mammalian podocytes, zebrafish podocytes form slit diaphragms between their foot 
processes. Zebrafish homologs of podocin and nephrin are specifically expressed in 
podocyte precursor cells as early as 24 hours post fertilization (hpf). These functional 
similarities between mammalian and zebrafish podocytes, coupled with assays for 
glomerular filtration, point to applications of fish as a model for study and treatment of 
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human proteinuria.(Drummond et al., 1998). Several genes that can account for tubule 
cyst formation have been identified in zebrafish (Ibanez-Tallon et al., 2003). Disruption 
of other genes resulted in pronephric cyst formation (Sun et al., 2004), kidney cyst (Otto 
et al., 2003), and glomerular cysts (Sun and Hopkins, 2001). These findings supported 
usage of zebrafish as model for ciliopathy diseases. 
Morpholino oligonucleotides (MOs) are the most common anti-sense “knockdown” 
technique used in zebrafish (Danio rerio) (Bill et al., 2009). MOs are typically 
employed as oligomers of 25 morpholine bases that are targeted via complementary 
base pairing to the RNA of interest. Most Morpholinos are used as tools for reverse 
genetics by knocking down gene function. Gene knockdown is achieved by preventing 
cells from making a targeted protein. Morpholinos can also modify the splicing of pre-
mRNA.(Draper et al., 2001) Knocking down gene expression is a powerful method for 
learning about the function of a particular protein. In zebrafish embryos, MOs have 
become a standard knockdown tool that can modify splicing or block translation, 
depending on the Morpholino's base sequence. Following initial injections into fish 
embryos at the single-cell or few-cell stages, Morpholino effects can be measured up to 
five days later (Bill et al., 2009). A cause for concern in the use of Morpholinos is the 
potential for "off-target" effects. This concern could be solved by coinjecting a rescue 
mRNA when it feasible. mRNA rescue experiments can often restore the wild-type 
phenotype to the embryos and provide evidence for the specificity of a Morpholino. 
 
1.5 Aims of the study 
The hypothesis being tested was that there are many known and unknown genes causing 
kidney diseases resulting from consanguineous marriages in the Saudi population.  
Using patients and families from this population we would identify novel molecular 
causes of human kidney disease. 
Thus, by searching for molecular causes of inherited kidney diseases in Saudi 
population we aimed to: 
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• Identify target genes in genetically heterogeneous inherited kidney diseases such 
as nephrotic syndrome. 
• Determine mutations frequency in well characterized genes to provide a 
molecular genetics diagnosis for known familial nephrotic syndrome. 
• Identify new loci for novel familial disorders and kidney diseases in which 
mutation of well characterized genes have been excluded. 
• Scan candidate genes from novel loci (if present) identified in Saudi families for 
mutations. 
• Utilize a functional model for assessing novel mutations using zebrafish as a 
developmental model. 
In this study, Saudi families affected with nephrotic syndrome (NS),  Bardet-Biedl 
Syndrome (BBS), new autosomal recessive distal renal tubular acidosis and 
nephrocalcinosis (dRTA & NC), and bilateral renal agenesis (BRA) were investigated.
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Chapter 2: MATERIALS AND METHODS 
 
This work was performed mainly at the Saudi Diagnostics Laboratory (SDL) at 
Genetics Department at King Faisal Specialist and Research Centre (KFSH&RC) in 
Riyadh, Saudi Arabia. Zebrafish modeling and Cell Line Transfection experiments were 
carried out at the Institute of Genetics Medicine, Newcastle upon Tyne, England.   
2.1   Family Materials and Control DNA Samples 
In this study we have used DNA and RNA samples obtained, following informed 
consent, from Saudi Arabian patients affected with inherited kidney diseases. Patients 
were identified and diagnosed by the Pediatric Nephrology section and/or Obstetrics-
Gynecology clinic at King Faisal Specialist Hospital and Research Centre, Riyadh, 
Saudi Arabia. Where available, in some families we have obtained samples from 
healthy siblings and parents, in addition to affected cases. 
DNA was extracted from blood, cultured cells, amniotic fluid and chorionic villus 
samples, respectively (Detailed methodologies are given below 2.2).  RNA was 
extracted from cellular material and fresh urine samples where available (See section 
2.3). The total number of individuals recruited for this study was 95, comprising 67 
individuals with Nephrotic Syndrome; 11 individuals with a “New Autosomal 
Recessive Distal Renal Tubular Acidosis and Nephrocalcinosis”(Faqeih et al., 2007), 11 
individuals with Renal Agenesis, and; 6  individuals with ciliopathy syndromes. 
We obtained DNA from 175 Saudi Arabian control DNA samples for estimation of the 
carrier frequency of novel sequence variants detected in the study. These DNA controls 
obtained from healthy blood donors and stored at Genetics Department at King Faisal 
Specialist Hospital and Research Centre for research use. This study has been approved 
by the research advisory council of King Faisal Specialist Hospital, Riyadh, Saudi 
Arabia (RAC#2050 045). 
 Figure 2.1 Outline of the disease gene identification process and some examples of 
methods that can be used in each step of the process. 
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Figure 2.1: Process of sampling, and disease gene identification and functional analysis 
in the study. 
2.2   DNA Extraction 
The PUREGENE DNA isolation kit (Gentra) requires whole blood anticoagulated with 
ethylenediaminetetraacetic acid (EDTA) for extraction of DNA. 3 ml of whole blood 
was first lysed with 9 ml of RBC lysis buffer [containing Tris (hdroxymethyl) 
aminomethane, Sodium Chloride, Magnesium Chloride, and Triton X-100] for 15 min 
to separate red blood cells from white blood cells that contain genomic DNA. After 
centrifugation (Thermo Scientific Sorvall RC BIOS centrifuge) at 3000 rpm for 15 min, 
supernatant was removed leaving behind the visible white blood cells. 3 ml of cell lysis 
buffer [containing Tris, Sodium Chloride, (EDTA), and sodium dodecyl sulfate (SDS)] 
then was added to the pellet and left overnight at room temperature with gentle mixing. 
An anionic detergent (SDS) and DNA stabilizer (EDTA) in the cell lysis buffer will 
isolate DNA by disrupting cell and nuclear membrane. Next day 1 ml of protein 
precipitation solution (containing 3 M Sodium Citrate) was added to the lysate to 
precipitate proteins and other contaminants by salt precipitation.  After centrifugation 
for 20 min at 3000 rpm; supernatant that contain the DNA was added to 5 ml of 100% 
Isopropanol (Fisher A451-4) for DNA recovery. The mix was then centrifuged at 7000 
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rpm for 5 min; the precipitated DNA is visible as a white pellet. The supernatant was 
removed and the pellet was washed with 70% ethanol. After centrifugation the pellet 
was left in the tube to air dry, and then re-suspended in the DNA hydration solution that 
contains a DNA stabilizer (1 mM EDTA, 10 mM Tris·CI pH 7.5). DNA was allowed to 
rehydrate overnight at 37 °C in the water bath (Thermo Scientific; Isotemp water bath) 
The genomic DNA concentration and absorption ratio (260 nm / 280 nm) was measured 
using a NanoDrop 8000 instrument (Thermo Scientific). Optimal purified DNA has an 
A260/A280 ratio between 1.7 and 1.9 and up to 200 kb in size. The DNA was stored at 
4 °C until further use. 
 
2.3   RNA Extraction 
2.3.1 Cell Line RNA Extraction 
TRIzol® Reagent (Invitrogen) is a ready-to-use reagent for the isolation of total RNA 
from cells and tissues. During sample homogenization or lysis, TRIzol® Reagent 
maintains the integrity of the RNA, while disrupting cells and dissolving cell 
components. The addition of chloroform followed by centrifugation separates the 
solution into an aqueous phase and an organic phase. The RNA remains exclusively in 
the aqueous phase. After transfer of the aqueous phase, the RNA is recovered by 
precipitation with isopropyl alcohol. The expected yield for 1 × 106 cells of fibroblasts 
or mammalian cultured cells is 2–7 micrograms (µg). 
Cells were pelleted by centrifugation. 1 ml of TRIzol® Reagent was added to the pellet 
before homogenization. The homogenized samples were incubated at room temperature 
for 5 min. 200 µl of 1-bromo-3-chloropropane (BCP) was added to the mix and left for 
15 min at room temperature. During incubation, the homogenization was mixed 
thoroughly for 5 times. The mix was then centrifuged at 12000 x g for 15 min at 4 °C. 
The supernatant was transferred then to a new tube that contains 500 µl of isopropanol.  
To enhance the precipitation the tube was left at -20 °C for one hour. The tube was then 
centrifuged at 12000 x g for 15 min at 4 °C. The supernatant was removed and the RNA 
pellet was washed once by adding 1 ml of 75% ethanol. Samples were mixed and 
centrifuged at 7500 x g for 5 min at 4 °C. At the end of procedure the RNA was dried 
briefly for 15 min (air dry). The RNA pellet then was dissolved in 50 µl, RNase free 
water and incubated in a water bath at 55 °C for 10 min.   
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RNA concentration and protein ratio (260 nm/280 nm) was measured using NanoDrop 
8000 instrument. The optimal extracted RNA has an A260/A280 ratio ≥1.8. Low RNA 
ratio may results when sample homogenized in an insufficient volume of TRIzol® 
Reagent or may results when incomplete removal of organic phase. The RNA stored at -
80 °C until required for use. Quality of RNA was checked by running 3 µl of purified 
RNA on a 1.0% agarose gel using standard electrophoresis techniques. Purified RNA 
may be visualized under UV fluorescence, where there are typically two discrete bands 
observed in the gel representing 18S and 28S of ribosomal RNA. 
2.3.2 Urine RNA Extraction 
ZR Urine RNA Isolation kit™ (ZYMO RESEARCH) was used to extract RNA from 
urine specimens as described by the manufacture. Briefly, to isolate cells from urine, 30 
ml of fresh urine sample was taken up in a 30 ml syringe. The urine was pushed 
completely through the provided ZRC GF™ Filter to isolate the cells in the filter. The 
remaining urine was removed completely from the filter by pushing through several 
volumes of air. By using a 1 ml syringe, 700 µl RNA Extraction Buffer Plus™ was 
pushed through the filter and the flow-through was collected in an RNase-free 1.5 ml 
tube. By pushing several volumes of air through the filter any residual flow-through 
would be collected. The content in the tube was mixed by vortexing. For RNA isolation, 
700 µl of 100% ethanol was added to the tube containing the flow-through and mixed 
briefly. The mixture was transferred to a Zymo-Spin™ IC Column in a Collection tube 
and centrifuged at 12,000 x g for 2 min and the flow through was discarded. 300 µl 
RNA Wash Buffer was added to the column and centrifuged at 10,000 g for 2 min and 
again the flow-through was discarded.  The column was transferred to an RNase-free 
tube. 10 µl of Nuclease-free water was added directly to column matrix. After 2 min 
waiting the column centrifuged at 10,000 x g for 2 min and eluted RNA was collected. 
The RNA was stored at -80°C until required for use. 
 
2.4   Tissue Culture  
Recent developments in genomics have necessitated a constant supply of DNA 
belonging to specific genotypes. Immortalization by The Epstein–Barr virus (EBV) is 
an effective procedure for inducing long-term growth of human B-lymphocytes and 
these EBV-transformed cells can serve as the most reliable source of DNA. 
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Transformation of peripheral blood lymphocytes by EBV is a laboratory procedure 
developed involving tissue culture. Immortalization of cells takes 6-8 weeks to generate 
large amounts of cells that can be indefinitely grown as a continuing source of genetic 
material.  EBV transformation is for immortalization of human B cells only and one 
limitation of this technique is that there are many genes that not expressed in B 
lymphocytes. 
Whole blood was collected from patients and their relatives in 5 ml Heparin tubes. In a 
15 ml centrifuge tube, 1 ml of Ficoll–Paque solution (<0.12 EU/ml) solution of Ficoll™ 
400 and sodium diatrizoate with a density of 1.077 + 0.001 g/ml. (Amersham 
Biosciences) was added and 2 ml of heparinized blood sample was gently layered onto 
the Ficoll-Paque solution. The tube was centrifuged at 3000 rpm for 20 min. After 
spinning there should be a very definite band of lymphocytes at the interface. Carefully,  
the thin band of lymphocytes was transferred into a new 15 ml centrifuge tube and 
washed with 1X PBS then mixed gently and centrifuged at 3000 rpm for 10 min. 
Another wash step was performed then lymphocytes re-suspended in tissue media of 
Roswell Park Memorial Institute (RPMI 1640) containing 20% Fetal Bovine Serum 
(FBS), 1% antibiotic and 1% L-glutamine, then transferred to a T-25cm² flask 
(Corning).  
0.5 ml of EBV (Epstein Barr Virus) was added into the cell solution. When EBV infects 
B-lymphocytes in vitro, lymphoblastoid cell lines eventually emerge that are capable of 
indefinite growth. Following this, 5 µl of Phytohaemagglutinin (PHA) was added in 
order to stimulating cell growth. Finally, 2 µl of cyclosporine (1 µg/ml, Sigma) was 
added to inhibit proliferation of T cells. The flask was incubated at 37 ˚C in a CO2 
humidified incubator (5% CO2, 98% humidity). The flasks were placed at a 45˚ angle to 
concentrate the cells in the corner of the flask and cap remained loose. Media was 
changed every 3 days to feed the cells. After 7-10 days growth, the cell lines were 
frozen down using media containing 40% of complete media, 55% FBS and 5% 
Dimethyl Sulfoxide (DMSO) until further use. 
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2.5   Polymerase Chain Reaction  
Genomic DNA was amplified by Polymerase Chain Reaction (PCR) to amplify coding 
exons and intron boundaries of genes. Primer 3 software for oligonucleotide primer 
design (Gudbjartsson et al., 2005) was used to design oligonucleotide primers for exons 
and intron boundaries of all genes. To facilitate sequencing all genes by the same M13 
primers all primers were tagged with following M13 primers:  
M13-Forward:  GTAAAACGACGGCCAGT,  
M13-Reverse:  CAGGAAACAGCTATGACC 
PCR was performed in a final volume of 25 µl containing approximately 20 ng of 
genomic DNA, Qiagen master mix kit (Qiagen), including 1X PCR buffer containing 15 
mM MgCl2, 100 µmol/L dNTP, 0.5 µmol/L primer pair, and 1 U/reaction HotStar Taq 
polymerase. In addition, 1X Q-solution was used occasionally to facilitate amplification 
of difficult templates (GC-rich) by modifying the melting behavior of DNA.  
 For thermocycling we used Touchdown PCR. Briefly, touchdown PCR involves 
decreasing the annealing temperature by 1 degree ºC every second cycle to a 
'touchdown' annealing temperature which is then used for 10 cycles. Thermocycling 
consisted of an initial denaturation at 95 ºC for 15 min followed by 10 cycles of 
touchdown PCR. Each cycle consists of denaturation at 95 ºC for 35 sec, annealing at 
65 ºC down to 56 ºC for 35 sec and extension at 72 ºC for 1 min. After these 10 cycles 
another 25 cycles was carried out consisting of denaturation at 95ºC for 30 sec, 
annealing at 58 ºC for 30 sec, and extension at 72 ºC for 50 sec. A final extension step 
of 10 min at 72 ºC is then carried out before holding at 4 ºC. 
In all PCR reactions, a negative control was added to check for DNA contamination, 
also normal control DNA was added to be used as reference in sequencing. All PCR 
products were visualized in a 2% agarose gel (Sigma) to check for PCR contamination 
and PCR amplification. 5 µl of PCR product mixed with 1 µl loading dye was loaded in 
2% agarose gel. The gel was electrophoresed for 30 min at 120 V. Also a 100 bp size 
marker (Qiagen) was loaded in the gel to allow the PCR product size to be confirmed. 
The gel then was checked under UV-transilluminator (BioRAD). 
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2.6   Sequencing of Amplicons 
Direct sequencing of PCR amplicons was used for mutation screening. PCR products 
were treated with the Agencourt® AMPure® PCR purification system that utilizes 
Agenocourt’s solid-phase paramagnetic bead technology for high-throughput 
purification of PCR amplicons. Agencourt AMPure utilizes an optimized buffer to 
selectively bind PCR amplicons 100 bp and larger to paramagnetic beads.  Excess 
oligos, nucleotides, salts, and enzymes then removed using a simple washing procedure. 
Following magnetic beads treatment; products were sequenced using BigDye™ 
Terminator Cycle Sequencing kit (PE Applied Biosystems) as described by the 
manufacturer. Following thermocycling the products were precipitated, washed and re-
suspended in Hi Di formamide. Advantages of using Hi Di formamide instead water are 
stability and no need for heat/cool step. Products electrophoresed on an ABI 3730xl 
capillary sequencer (PE Applied Biosystems). Using Applied Biosystems Genetic 
Analyzers; raw data converted to ABI and EditSeq files formats that exported for 
visualization and analysis of sequence. 
DNA sequencing was performed mainly on one strand or both strands for positive 
mutations for confirmation. For all detected variants, samples and all related family 
members if available were re-PCR and re-sequenced in both directions. Most of 
sequencing was performed by Sequencing Core Facility at Genetics Department at King 
Faisal Specialist Hospital and Research Centre in Riyadh. 
Sequencing data were analyzed using Mutation Surveyor® software Version 3.24 
(SoftGenetics LLC State College) and SeqMan II software 6.1 (DNAStar). Reference 
sequences of genes were downloaded from NCBI website for comparison with 
sequencing results. Database search for novel variants detected was carried out. The 
following websites were searched for reported and novel variants:  
• Ensembl Genome Browser (www.ensembl.org) / 1000 Genomes 
• The Human Gene Mutation Database [HGMD] (www.hgmd.org) 
• Human Genome Variation Society [HGVS] (www.hgvs.org) 
• Exome Variant Server (http://evs.gs.washington.edu/EVS/) 
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2.7   Gene Expression 
2.7.1   Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) was used to 
synthesize first strand cDNA from total RNA. 
The following RNA/primer mixture was combined in 0.2 ml tube:  
3 µg total RNA 3.0 µl 
50 µM oligo (dT)20 1.0 µl 
10 mM dNTP 1.0 µl 
DEPC-treated water 5.0 µl 
Total 10.0 µl 
 
The tube then incubated at 65 °C for 5min then placed on ice for 2 min.  
The cDNA Synthesis mix was prepared in the following order: 
10X RT buffer 2.0 µl 
25 mM MgCl2  4.0 µl 
0.1 M DTT 2.0 µl 
RNaseOUT™ (40 U/ µl) 1.0 µl 
SuperScript™ III RT (200 U/ µl) 1.0 µl 
Total 10.0 µl 
 
On ice the prepared volume (10.0 µl) of cDNA Synthesis mix then added to 
RNA/primer mixture and incubated at 50 °C for 1 hour. The reaction terminated at 85 
°C for 5 min. After brief centrifugation, 1.0 µl RNAse H was added to each tube and 
incubated at 37 °C for 20 min. Addition of RNAse H to increase the sensitivity of the 
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PCR by removing the RNA template from cDNA:RNA hybrid by digestion with 
RNAse H. The cDNA synthesis reaction was stored at -20 °C for further analysis. 
2.7.2   Quantitative Polymerase Chain Reaction (qPCR) 
EXPRESS SYPER®GreenER™ qPCR SuperMixes with premixed ROX Kit (Invitrogen) 
provide components for real time quantitative PCR (qPCR). A 384-well plate was used 
with a maximum reaction volume of 10 µl per well. On ice; a master mix of common 
components for multiple reactions was prepared as follow: 
EXPRESS SYPER®GreenER™ qPCR SuperMixes with premixed ROX 10.0 µl 
10 µM forward primer 0.4 µl 
10 µM reverse primer 0.4 µl 
cDNA (20 folded diluted) 2.0 µl 
DEPC-treated water 7.2 µl 
Total 20.0 µl 
 
Each sample reaction was performed in triplicate. In addition no-template control 
(NTC) reactions were included to test DNA contamination of the enzyme / primer 
mixes. After brief centrifugation, reactions placed in the real-time instrument 
AB7900HT (Applied Biosystems) programmed as follow:  
50 °C for 2 min (UDG incubation) 
95 °C for 2 min 
40 cycles of: 
95 °C for 15 seconds 
60 °C for 1 minute 
2.7.3   Data Analysis of qPCR  
One of the most important steps in relative quantitation experimental design is the 
selection of an appropriate endogenous control. Normalization to an endogenous control 
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(often referred to as a housekeeping gene) allows us to correct results that can be 
skewed by differing amounts of input nucleic acid template. 
The Comparative C 
T 
Method (∆∆ C
T 
Method)  
By measuring the amount of cellular RNA, one is able to determine to what extent that 
particular gene is being expressed. Two different methods of presenting quantitative 
gene expression exist: absolute and relative quantification. Absolute quantification 
calculates the copy number of the gene usually by relating the PCR signal to a standard 
curve. Relative gene expression presents the data of the gene of interest relative to some 
calibrator or internal control gene. A widely used method to present relative gene 
expression is the Comparative C
T 
method, also referred to as the ∆∆C
T 
Method.  It is 
possible to eliminate the use of standard curves and to use the ∆∆C
T 
Method for relative 
quantitation as long as the PCR efficiencies between the target(s) and endogenous 
control(s) are relatively equivalent  (Schmittgen and Livak, 2008).  
Arithmetic Formula:  
The amount of target, normalized to an endogenous reference and relative to a 
calibrator, is given by: 2 
–∆∆CT
.  An excel formula table was used to calculate relative 
quantification of gene expression ∆∆CT. 
 
2.8   Genotyping   
2.8.1   Homozygosity Mapping  
The markers of choice that have emerged for whole-genome linkage scans and 
association studies are single nucleotide polymorphisms (SNPs). Although there are 
multiple sources of genetic variation that occur among individuals, SNPs are the most 
common type of sequence variation and are powerful markers due to their abundance, 
stability, and relative ease of scoring. 
To identify disease loci we carried out a genome wide linkage search using Affymetrix 
GeneChip® Human Mapping 250K Sty Arrays, or Affymetrix Axiom® 2.0 Assay 
Arrays, or Affymetrix SNP 6.0 Arrays, or Affymetrix CytoScan assay platforms 
according to the manufacturer’s protocol (http://www.affymetrix.com). 250 ng genomic 
DNA from each family member was hybridized on the array.  
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All these platforms almost have similar workflow as described in the original article 
(Matsuzaki et al., 2004) :  
Genomic DNA digestion with restriction enzyme → Adaptor Ligation to Digested DNA 
by T4 → Polymerase Chain Reaction (PCR) for Ligated Samples → Fragmentation of 
Purified PCR Products by DNAseI →  The 3′ ends of the fragmented amplicons were 
labeled with biotinlyated by using Terminal Deoxynucleotidyl Transferase  → 
Hybridization → Washing, Staining and Scanning → Data Analysis.    
The main difference between these arrays is the SNP marker density in the genome. 
SNP 6.0 and CytoScan arrays could be used for molecular karyotype analysis as they 
have copy number probes designed to interrogate Copy Number Variations (CNVs) in 
the genome. For CytoScan assay; digestion reaction was set as follow: 
 
Ingredients Concentration X 1.0 
Nuclease Free Water - 11.55 µl 
NE Buffer 2  10X 2.0 µl 
BSA  100X 0.2 µl 
Nsp I  restriction enzyme 10 u/µl 1.0 µl 
   
Total of Master Mix  14.75 µl 
DNA sample 50 ng/µl 5 µl 
Total volume per tube  19.75 µl 
 
The reaction tubes were mixed and spun down for 1 min then incubated in the Thermal 
Cycler for 2 hours at 37 °C then inactivated the enzyme at 65 °C for 20 min. Reaction 
was held at 4 °C.   
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The ligation reaction was set as follow: 
Ingredients Concentration X 1 
Adapter Nsp 1 50 µM 0.75 µl 
T4 DNA Ligase Buffer 10 X 2.50 µl 
T4 DNA Ligase 400U/µl 2.0 µl 
Total - 5.25 µl 
Digested DNA - 19.75 µl 
Ligation mix  5.25 µl 
Total volume per tube  25.0 µl 
 
The reaction tubes were mixed and spin down for 1 min and incubated in the Thermal 
Cycler at 16 °C for 3 hrs. The T4 Ligase was denatured by heating to 70 °C for 20 min. 
The reaction was hold at 4 °C. Reaction tubes were spin down at 2000 rpm for 1 min 
and diluted by adding 75 µl nuclease free water. Four 10 µl aliquots of each sample 
were transferred to the PCR plate and PCR reaction was set as follow: 
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Ingredients Concentration X 1 
Nuclease Free H2O - 39.5 µl 
TITANIUM Taq PCR Buffer 10 X 10.0 µl 
GC-MELT 5mM 20.0 µl 
dNTPs 2.5mM 14.0 µl 
PCR primer 002 100uM 4.5 µl 
TITANIUM Taq DNA 
Polymerase 
50X 2.0 µl 
   
Total of Master Mix  90.0 µl 
DNA sample (ligated product)   10.0 µl 
Total volume per tube  100.0 µl 
 
Thermocycling consisted of an initial denaturation at 94ºC for 3 min followed by 30 
cycles. Each cycle consists of denaturation at 94 ºC for 30 sec, annealing at 60 ºC for 45 
sec and extension at 68 ºC for 15 sec. A final extension step of 7 min at 68 ºC is then 
carried out before holding at 4 ºC. PCR products were checked in 2% agarose gel. 
Majority of product should be between 150 and 2000 bp (Figure 2.2).  
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Figure 2.2: PCR Check:  PCR products run on a 2% TBE gel at 5 V/cm for 45 min. 
Majority of product should be between 150 and 2000 bp. (+) indicates positive control 
DNA, while (-) indicates negative control H2O. 
All 4 PCR products for each sample were pooled by transferring all PCR reactions to 
the appropriately marked 1.5 mL Eppendorf Safe-Lock tube. To purify PCR products, 
720 µl of purification beads was added to each tube and mixed well by inverting several 
times and then incubated at room temperature for 10 min. Tubes then centrifuged for 3 
min at speed (16100 rcf). Tubes were then placed in a magnetic stand and the 
supernatant was pipetted off. 1 ml of Purification Wash Buffer was added to each tube. 
Tubes were mixed vigorously and centrifuged for 3 min at high speed (16100 rcf). By 
placing tubes back to magnetic stand supernatant was pipetted off and 52 µl of elution 
buffer was added to the tubes. Tubes loaded into the foam adapter, and vortexed at 
maximum power for 10 min to resuspend the beads. Tubes were then centrifuged again 
at speed 16100 rcf for 3 min. 47 µl of eluted samples were transferred to an appropriate 
new tube. Purified PCR products were quantified by measuring OD at 260 nm in 
NanoDrop instrument.  
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For fragmentation step, the following reaction was set up: 
Ingredients Concentration X 1 
Nuclease Free H2O - 122.4 µl 
Fragmentation Buffer 10 X 158.4 µl 
Fragmentation Reagent 2U/µl 7.2 µl 
   
Fragmentation Master Mix  10.0 µl 
Purified PCR Product  45.0 µl 
Total volume per tube  55.0 µl 
 
Reaction tubes were incubated at the Thermal Cycler at 37 ºC for 35 min then heated to 
95 ºC for 15 min and hold at 4 ºC forever.  4.0 µl of each fragmented sample was run in 
4% agarose gel to check for fragmentation quality. Average fragment distribution is 
between 25 to 125 bp as in Figure 2.3.  
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Figure 2.3: fragmented samples run on a 4% TBE gel at 5 V/cm for 45 min. Average 
fragment distribution is between 25 to 125 bp.  
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After passing Fragmentation Quality Control, samples were set for labeling reaction as 
follow: 
Ingredients Concentration X 1 
TdT Buffer 5X 14.0 µl 
DNA Labeling Reagent 30 mM 2.0 µl 
TdT  3.5 µl 
   
Labeling Mix  19.5 µl 
Fragmented DNA  51.0 µl 
Total volume per tube  70.5 µl 
 
Reaction tubes were loaded in the Thermal Cycler and incubated at 37 ºC for 4 hrs. The 
reaction inactivated by heating to 95 ºC for 15 min. The reaction was held at 4 ºC. The 
reaction then proceeded to the hybridization step.  
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A hybridization master mix was prepared as followed: 
Ingredients X 1 
Hyb Buffer Part 1 165.0 µl 
Hyb Buffer Part 2 15.0 µl 
Hyb Buffer Part 3 7.0 µl 
Hyb Buffer Part 4 1.0 µl 
Oligo Control Reagent 0100 2.0 µl 
  
Hybridization Mix 190.0 µl 
Labeled  DNA 70.5 µl 
Total volume per tube 160.5 µl  
 
Tubes were loaded onto the thermal cycler and Hybridization program was run as 
follow: 95 ºC for 10 min then hold at 49 ºC. While the reaction tubes incubated at 49 ºC, 
200 µl of each sample was loaded onto each array. Arrays were immediately loaded into 
the hybridization oven. The arrays hybridized for 18 hrs at 50 °C and 60 rpm. Following 
the hybridization, the arrays were washed with 6X SSPE (Phosphate buffer, pH 7.4, 
sodium chloride, EDTA) and 0.01% Tween-20 at 25°C, then more stringently washed 
with 0.6X SSPE and 0.01% Tween-20 at 45 °C. Hybridization signals were generated in 
a three-step signal amplification process: 10 µg/ml streptavidin (Pierce) was added to 
the biotinylated targets hybridized to the oligonucleotide probes, and washed with 6X 
SSPE and 0.01% Tween-20 at 25 °C, followed by the addition of 5 µg/mL biotinylated 
goat anti-streptavidin (Vector Laboratories) to increase the effective number of biotin 
molecules on the target; finally, streptavidin R-phycoerythrin (SAPE) conjugate 
(Molecular Probes) was added and washed extensively with 6X SSPE and 0.01% 
Tween-20 at 30 °C. The Streptavidin, Antibody, and SAPE were added to arrays in 6X 
SSPE, 1X Denhardt's solution, and 0.01% Tween-20 at 25 °C for 10 min. The washing 
and staining procedures were performed using Affymetrix fluidics stations. The arrays 
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were scanned using the Affymetrix Gene Chip® Scanner 3000 7G with the GeneChip® 
Genotyping Analysis Software (GTYPE). The analyzed data was classified by 
chromosome and sorted based on the physical position of the SNPs. We looked for 
regions with informative SNPs that were homozygous for the same allele for the 
affected children and heterozygous for the parents, and heterozygous or homozygous for 
the opposite allele for the unaffected. Homozygosity regions were identified using the 
following software:  CNAG (Version 2.0), Genotyping Console (Version 3.0.1), and 
Chromosome Analysis Suite (ChAS).  CNAG2.0 was developed to enable high-quality 
analysis of copy number alterations and allelic imbalances in cancer genomes, 
congenital disorders, and normal individuals using Affymetrix GeneChip® platforms. 
2.8.2   Linkage and LOD Score Analysis 
Raw data received from Genotyping Core facility was formatted to create manageable 
files that could be used for an initial linkage analysis.  The linkage analysis would be 
performed using easyLINKAGE-Plus, therefore the pedigree and genotype data files 
that we had created from the raw data were appropriately formatted. 
LOD scores were calculated with the easyLINKAGE-Plus software 
(http://www.uniwuerzburg.de/nephrologie/molecular_genetics/molecular_genetics.htm)
ALLEGRO and GENEHUNTER programs were used to calculate a multipoint 
parametric linkage analysis LOD score in autosomal recessive pedigrees. 
 
2.9   Zebrafish Model 
2.9.1   Zebrafish husbandry 
Adult zebrafish were kept and maintained in a zebrafish facility according to standard 
procedures. Transgenic fluorescent reporter fish were used for studying cardiac 
morphology (cmlc2:GFP, green fluorescent protein gene under the control of the cardiac 
myosin light chain 2 gene promoter) (Lange et al., 2008) and renal morphology 
(cldnb:lynGFP, a membrane-localised variant of the green fluorescent protein gene 
under the control of the claudin b gene promoter) (Anzenberger et al., 2006). Other 
zebrafish lines used were AB and Golden. Zygotes were collected from natural 
spawnings and placed in petri dishes of E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 
mM CaCl2, 0.33 mM MgSO4) (Detrich et al., 2011), one dish per clutch. Embryos for 
injection were loaded onto the edge of a glass slide in single file, after discarding dead 
embryos (which appear grey or black under light microscopy). MOs were microinjected 
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under light microscopy into the yolk of 1-8 cell embryos, using a glass micropipette 
(made by a Sutter Instrument Co. P-97 flaming micropipette puller) and an Eppendorf 
FemtoJet pneumatic microinjector. The micropipettes were calibrated by measuring 
droplet size on a reticle so that 2 nl of MO solution was injected into each embryo. 
Successful injection was confirmed by the presence of red solution in the middle of the 
yolk, which diffused slowly outwards into the rest of the embryo. The number of 
microinjected embryos was recorded from the counter on the microinjector display, and 
the number of uninjected embryos retained for comparison was counted manually. 
2.9.2   Preparation of Moepholino (MO) solution for ZF injection: 
Morpholino antisense oligonucleotides are widely used to modify gene expression by 
blocking translation of a targeted protein or by modifying pre-mRNA splicing. 
Morpholinos in the zebrafish serve as a powerful reverse genetics tool by knocking 
down gene function. 
We used microinjection of a morpholino oligo targeted to the translational initiation site 
of BBS5 gene (5-GATCACTGTCTGCGTATATTGTCGA-3); BBS5_ATG oligo 
(300nmol, mw=8465), obtained from Gene Tools. 
150 µL, sterile water was added to lyophilized oligo to make a 2 mM stock solution.  
The solution was aliquoted and stored at -20 °C until ready for use. On the day of the 
injection, the morpholino solution heated at 65 °C for 10 min then snaps cooled on ice 
immediately and spun briefly. This step denatures any secondary structures in the oligo 
and ensures that the solution is completely solubilized. An injection buffer was 
prepared: 45 ul Danieau solution + 5 ul of 0.5% phenol red dye (Sigma-Aldrich Co., 
P0290). The phenol red   serves as a visible marker for the injection of the solution into 
the embryo. 
Finally a working solution prepared by diluting the morpholino solution in the injection 
buffer; A typical working solutions of 0.4 mM to 0.1 mM bbs5 morpholino was 
prepared. The delivered amount of morpholino was estimated from volume of 
morpholino injected. By injecting 1.8 nl of 0.4 mM of morpholino the dose given to the 
embryo is approximately equal to 6 ng.  
 
2.9.3   Preparation of mRNA solution for ZF injection: 
 For gene function studies, we prepared capped RNA for microinjection into zebrafish 
embryos. Capped RNA behaves similarly to eukaryotic mRNAs found in vivo due to 
the presence of the CAP analog.  
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Human BBS5 EST clone (ref. 5272889) inserted into vector pBluescriptR was obtained 
(GeneService) and the clone was sequenced to verify clone length and fidelity.  To 
obtain mutant BBS5 (c.966insT) site directed mutagenesis was employed (using a 
commercial Mutagenesis service (Mutagenex Inc)). Clones (wild type and mutant 
BBS5) contained a T7 site upstream of ATG.  Using a forward primer AE37 (T7 
primer) and reverse primer AE91 (in 3’UTR of BBS5) PCR products of size 1100bp 
from wild type and mutant BBS5 was obtained. These products were cleaned using 
Qiagen PCR clean up kit. The resulted PCR products were used to perform an in vitro 
synthesis reaction of large amounts of capped RNA using the mMessage mMachine 
T7kit (Ambion, Inc., AM1340).  cRNA samples purified by phenol:chloroform 
extraction and isopropanol precipitation. Resulted cRNA was suspended in RNAse free 
H2O and quantified then stored at -80°C until ready for use. Working solutions with 
sterile water and a final concentration of 0.05% phenol red (Sigma-Aldrich Co., P0290) 
was prepared. Phenol red serves as a visible marker for the injection of the solution into 
the embryo. Injecting 1.78nl into embryos to deliver 90pg and 180pg of mRNA requires 
concentration of 50 and 100 ng/µL cRNA respectively. Clones were designed and 
prepared by Dr. John Sayer (Figure 2.9.1 A, B, and C) 
MO injected alone or together with rescue cRNA (Mutant and wild type) as described 
above. 
After microinjection, the embryos were placed in fresh E3 medium, approximately 50 
embryos per petri dish and incubated at 28.5 °C. Mortality counts were performed at 3 
and 24hpf on both injected and uninjected control embryos. The mortality rate in the 0-3 
hour timeframe was used to assess death due to needle trauma; the 3-24 hour timeframe 
was used to assess death due to MO effects. Clutches where the mortality rate in 
uninjected embryos was above 50% at 24 h post-ferilization (hpf) were discarded. 
 
2.9.4   Phenotyping zebrtafish 
Light and fluorescent (GFP filter) microscopy was performed to monitor the embryos at 
24, 48 and 72 hpf using a Leica MZ16FA fluorescent microscope on embryos 
immobilised in 0.1% tricaine in E3. The appearance of each fish at 72 hpf was recorded, 
noting the presence of pericardial effusion, tail length and appearance, body oedema and 
venous stasis in the cardiac venous sinus. Pronephric duct morphology assessment in 
cldnb:lynGFP fish was performed at 48hpf for better visualization. To assess cardiac 
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morphology (D-loop, L-loop or failure of looping and cardiac chamber appearance), 
72hpf cmlc2:GFP embryos were placed on their backs against the edge of a glass slide. 
Fish were phenotyped under light microscopy and classed as following: 
Normal:  if they were indistinguishable from un-injected fish and  
Mild:  if they had small eyes, mild pericardial effusion and mild or no tail defects.  
Moderate:  if they had a large pericardial effusion and moderate tail defects, (obvious 
shortening and large kinks / curls in their tails).  
Severe: if they had no or very short malformed tail, widespread oedema, malformed 
eyes and minimal cardiac muscle contraction.  
These classifications have been  suggested by (Bedell et al., 2011).  
 Images were taken with a Leica DF425C camera and the Leica Application Suite V3 
program. The data was then analysed by counting the number of fish in each group 
exhibiting certain phenotypes. A chi-squared test was performed to discover if a 
difference in the proportion of fish exhibiting certain phenotypes between two groups 
was statistically significant using the Prism GraphPad software.  
 
2.10   Transfection: 
2.10.1    Cell culture 
Routine tissue culture techniques were used to facilitate the growth of the Human 
Embryonic Kidney 293 cells (HEK293) mammalian cell line (Graham et al., 1977). 
These were performed in class II laminar flow hoods with sterile handling techniques. 
Cell lines were cultured in roux of 25 cm2, 75 cm2 or 162cm2 with Dulbecco’s Modified 
Eagle Media (DMEM). 
2.10.2   Methods of Transfection and Factors influencing Transfection  
Transfection is the process of introducing nucleic acids into eukaryotic cells by non-
viral methods.  Using various chemical, lipid or physical methods, this gene transfer 
technology is a powerful tool to study gene function and protein expression in the 
context of a cell. Transcription of the transfected gene can be analyzed 24-48 hours after 
transfection. Transfection is dependent upon multiple parameters which affect 
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efficiency of the reaction. It is important to have a healthy cell culture, preferably of low 
passage number. Cells should be routinely split 24 hours prior to transfection, which 
allows normal cell metabolism to be re-established and increases the take up rate of 
DNA. Contamination with bacteria, mycoplasma and fungi must be avoided. The type 
of vector construct also influences the efficiency of transfection. Linearised plasmid 
DNA allows improved integration into the host genome and may be used for stable 
transfection, whereas transient transfection is most efficient with supercoiled plasmid 
DNA. Best results are obtained with high purity plasmid DNA, and removal of 
endotoxins may be required in sensitive cell lines. Classical transfection methods 
include the calcium–phosphate method and electroporation. In this study transfection 
was carried out using the proprietary reagent Lipofectamine 2000. 
Liposomes are positively charged lipid reagents that interact with the negatively 
charged DNA molecules to form complexes, which are then endocytosed. Compared to 
calcium phosphate this method allows higher efficiency transfection. Cells must often 
be transfected in the absence of serum to achieve high efficiency. Lipofectamine 2000 is 
a new highly efficient liposomal transfection reagent. 
Mutant BBS5 (c.966insT) and wild type plasmids were engineered into pcDNA3.1-NT-
GFP vector (Invitrogen) to test the effect of the mutation on protein expression. A green 
fluorescent protein (GFP) reporter system was introduced in both constructs. Following 
subcloning into pcDNA3.1-NT-GFP clones were fully sequenced to confirm sequence 
fidelity, reading frame and orientation (data not shown). Following successful cloning, 
large scale preparations of plasmid cDNA were obtained using overnight culture in LB 
broth and isolation of DNA using a MaxiPrep kit (Qiagen). Plasmids were engineered 
and prepared by Dr. John Sayer (Figure 2.9.1 D, E, F, and G). 
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Figure 2.4: Constructs used for BBS5 in vitro studies 
A. pBlueScriptR vector is shown containing full length human BBS5 nucleotide sequence. This 
vector DNA was used as a template for the production of cRNA, using the T7 promoter region 
as shown (Blue triangle). 
B. pBlueScriptR vector is shown containing full length human BBS5 with a single nucleotide 
insertion exactly mimicking the novel mutation. This mutant cDNA was used as a template for 
the production of cRNA, using the T7 promoter region as shown (Blue triangle). The frame shift 
causes translation beyond the wild type stop codon, producing a predicted elongated mutant 
protein.  
C. Nucleotide sequence showing single t insertion in the mutant construct (verified by Sanger 
sequencing (data not shown)).  
D. Subcloning ofBBS5 from pBlueScriptR vector into pcDNA3.1NT-GFP was performed.  
Shown is the vector containing full length human BBS5 nucleotide sequence with a N-terminal 
GFP tag (Green). This vector DNA was used for transfection studies. 
E. Subcloning of mutant BBS5 from pBlueScriptR vector into pcDNA3.1NT-GFP was 
performed.  Shown is the vector containing mutant BBS5 nucleotide sequence with a N-
terminal GFP tag (Green). This vector DNA was used for transfection studies. 
F. Amino acid translation of wild-type BBS5. Box identifies residues that would be affected by 
the novel mutation 
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G. Amino acid translation of mutant BBS5, with alternate reading frame and new translated 
amino acids shown in boxed region. 
 
2.10.3   Transfecting Human Embryonic Kidney 293 cells (HEK 293 Cells): 
 Human Embryonic Kidney 293 cells (HEK 293) are a specific cell line originally 
derived from human embryonic kidney cells grown in tissue culture (Graham et al., 
1977). HEK 293 cells grow easily and transfect very readily and have been widely-used 
in cell biology research for many years. They are also used by the biotechnology 
industry to produce therapeutic proteins and viruses for gene therapy. 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen Life Technologies) is a 
commonly used reagent for achieving transient transfection of HEK293 cells with high 
efficiency. Lipofectamine 2000 reagent was used empirically as per the manufacturer’s 
protocol. The day before transfection, HEK 293 cells were trypsinized by removing the 
media and adding 4 ml of 0.05% Trypsin-EDTA (Gibco). After 5 min incubation at 37 
C°, 10 ml of complete growth medium (Dulbecco’s Modified Eagle Medium (DMEM), 
Gibco) was added to 0.5 ml of trypsinized cells.  In 6-well format plate, 0.5 ml of 
trypsinized cells (approximately 6.25 x 105   cells) and 1.5 ml of DMEM media were 
added to each well on top of a sterilized cover slip. The plate was incubated at 37 °C for 
24 hrs. Cell density was 50-80% confluent on the day of transfection, to allow efficient 
transfection. On the day of transfection, the plate was checked and the media was 
replaced with 1.5 ml of complete growth media. Typically the 6 well plate of HEK293 
cells was divided into two groups, three wells for transfection with wild type plasmid 
and remaining three for mutant plasmid.  
For each well of cells to be transfected, 2.5 µg of plasmid DNA was diluted in 500 µl of 
Opti-MEM® Reduced Serum Media without serum. For each well of cells, 5 µl of 
Lipofectamine™ 2000 was added to the above diluted Opti-MEM®: DNA solution and 
mixed gently. The mix was left at room temperature for 30 min to form DNA- 
Lipofectamine™ 2000 Reagent complexes. After incubation, 500 µl of the mix was 
added directly to each well containing cells and mixed gently by rocking the plate back 
and forth. The plate then was incubated at 37 °C for 24 hrs in a CO2 incubator. 
2.10.4   Immunofluorescence  
For fixation, 40 grams of para-formaldehyde (Sigma) was dissolved in 1X PBS (Sigma) 
up to 1 Liter to make 4% of para-formaldehyde (4% PFA). Media was removed from 
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the plate and cells were fixed with 2 ml of 4% PFA at room temperature for 10 min. 
Cells then were washed twice with 500 µl 1X PBS for 5 min each. Cells 
permeabilization was achieved with 0.5% Ttriton-X100 in PBS solution for 10 min at 
room temperature. Cells were then washed twice with 1X PBS for 5 min each. Prior to 
immunofluorescence staining, cells were blocked with 5% BSA in PBS for 30 min to 
block non-specific binding of immunoglobulin. 1.0 ml of monoclonal anti mouse 
acetylated tubulin (Sigma) diluted in block solution at 1 in 1000 was added to each well 
for 1 hour at room temperature. Cells were washed with PBS three times for 5 min each. 
Secondary antibody Alexa Fluor 549 donkey anti mouse (Invitrogen) diluted 1 in 200 in 
block solution was added to cells at room temperature for 1 hour. Cells were washed 
with PBS three times for 5 min each. Coverslips were mounted on microscopic slides 
with vectashield (Vector Laboratories H-1000 with DAPI (DNA stain)) and sealed with 
nail polish. Staining protocol was also carried out using a pericentrin primary antibody 
(Abcam) and secondarily detected using an anti-rabbit Cy3 antibody.  
For fluorescence visualization, digital images of the green, red, blue and overlay 
fluorescent pattern were captured using confocal laser scanning microscopy (Nikon and 
Olympus). 
 
2.11   Bioinformatics: 
Bioinformatics is the application of computer science and information technology to the 
field of biology and medicine.  
The following software packages were used in the study: 
2.11.1 easyLINKAGE-Plus for Linkage Analysis 
easyLINKAGE was designed to make the use of linkage programs user-friendly and to 
enable those analyses on Microsoft Windows based operating systems. The software 
was written in a PERL/Tk-based program. The programe was generated in 2005 
(Lindner and Hoffmann, 2005, Hoffmann and Lindner, 2005) to combine automated 
setup and performance of linkage analyses and simulation under an easy to handle 
graphical user interface for Microsoft Windows 2000/XP and standard UNIX systems. 
An Improved easyLinkage program (easyLINKAGE Plus) is enabling linkage analyses 
for large-scale SNP data in addition to those of microsatellites. A major benefit of 
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easyLINKAGE is the generation of structured text outputs and graphical plots of LOD 
scores, P values, and many other parameters. The implementation of SNP projects 
derived from the Affymetrix 10k/50k/100k/250k/500k/axiom and Illumina chips is 
another major step ahead. Those projects can be analyzed with Allegro (single-
/multipoint analyses), GeneHunter/-Plus, Merlin, FastLink, SimWalk and SuperLink. 
For SNP projects only two files are necessary: one file that contains all genotypes, other 
file with the pedigree information in linkage format. Only files that start with “p” and 
end with “pro” will be recognized as pedigree information files.  
Information in our pedigree files were arranged according to the Table 2.1 below in a 
Notepad txt files. The name of pedigree file was saved as (pESRF_ADfamily.pro) to be 
recognized as a pedigree information file. 
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Family 
ID 
Individual 
# 
Father Mother Gender  
1=Male 
2=Female 
Affection status, 
1=unaffected 
2=affected 
DNA 
availability 
0= No 
2= Yes 
1 1 7 8 1 2 2 
1 2 7 8 2 2 2 
1 3 7 8 2 2 2 
1 4 7 8 2 2 2 
1 5 7 8 2 2 2 
1 6 9 2 2 2 2 
1 7 0 0 1 2 0 
1 8 0 0 2 1 0 
1 9 0 0 1 1 0 
1 10 7 8 1 1 2 
1 11 7 8 1 1 2 
Table 2.1: Arrangment of pedigree data in Notepad txt files for run in easyLINKAGE 
software. 
 
The file that contains genotypes was first exported to an Excel file to assign each 
individual an identifier code for the pedigree.  If there was no call for a SNP, this was 
coded as 00. The data for each individual were then combined to produce a single 
genotype data file. The file then paste in a Notepad txt file and saved as Snapshot files 
(ESRF_ADfamily.snp).  Both files (pedigree and genotype) were then uploaded in 
easyLINKAGE-Plus software and Allegro program was used to perform parametric 
linkage analysis in autosomal recessive and dominant models as shown in Figure 2.4. 
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Figure 2.5: Parameters used to run Allegro program to perform linkage analysis in 
easyLINKAGE-Plus software. 
Allegro is a computer program for multipoint genetic linkage analysis and related 
calculations (Gudbjartsson et al., 2005). Allegro multipoint linkage analysis is based on 
the Lander-Green Hidden Markov model (HMM). 
It is the program that used to calculate parametric LOD score in inherited kidney disease 
families in our study. The biggest advantages of Allegro over other programs are the 
allele sharing models that it provides and a much shorter execution time. In addition to 
parametric LOD scores, Allegro calculates allele sharing LOD scores (Kong and Cox, 
1997) and non-parametric (NPL) scores. The linkage analysis of Allegro involves three 
steps. Firstly, determination of single point probabilities of individual inheritance 
vectors, secondly multipoint calculation, where genotype information on neighboring 
markers is taken into account, and thirdly score calculation. The computational engine 
of Allegro is based on the Fourier transforms to calculate convolutions (Kruglyak and 
Lander, 1998). Although Allegro is not limited in terms of the number of markers, using 
large quantities of SNPs can lead to a wrong haplotype assignment. 
GeneHunter is another program implemented in easyLINKAGE. In 1996, Kruglyak et 
al. introduced GeneHunter (Kruglyak et al., 1996) and since then it has undergone many 
improvements. It does perform multipoint analysis of pedigree data that include: LOD-
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score computation, non-parametric linkage analysis, information-content mapping, and 
haplotype reconstruction. It is similar to Allegro in using the Lander-Green Hidden 
Markov model of extracting complete multipoint linkage data from incomplete marker 
information. The program was recompiled for the use in Microsoft Windows. 
GeneHunter program is limited to run in nuclear pedigrees or small multigenerational 
pedigrees (less than 16 individuals). In addition Allegro and other programs result in 
faster analysis speeds than GeneHunter. In our study we used GeneHunter to calculate 
LOD score and to confirm results obtained by Allegro. 
 
2.11.2 Homozygosity Mapping Software 
The following software programs were used to analyze homozygosity in autosomal 
recessive families.  CNAG (Version 2.0):  Copy Number Analyzer for Affymetrix 
GeneChip Mapping 100K arrays (CNAG) version 2.0 was developed (Nannya et al., 
2005) to enable high-quality analysis of copy number alterations and allelic imbalances 
in cancer genomes, congenital disorders, and normal individuals using Affymetrix 
GeneChip® platforms. It employs a robust algorithm to correct between chip variations 
introduced by the differences in experimental conditions, enabling high quality copy 
number analysis. When the constitutive DNA is available, it also allows for allele-based 
copy number estimation to sensitively detect allelic imbalances. Copy number calls are 
automated according to the copy number calls based on the hidden Markov model 
analysis and the LOH inference is also enabled even when constitutional DNA is not 
available. This algorithm improves signal-to-noise (S/N) ratios by reducing variation in 
the raw signal ratios and optimizes the selection of the reference. In addition, 
availability of accurate genotyping information further enables LOH inference and 
allele-based copy. 
The CNAG software was used initially as a tool to detect loss of heterozygosity (LOH) 
regions in the families studied. The software is user friendly but was not designed 
mainly for homozygosity mapping and therefore many homozygosity regions were 
missed. The software is free and can be downloaded from the following website: 
http://www.genome.umin.jp/CNAGtop2.html  
Genotyping Console (Version 3.0.1): was the second software to be used for 
detecting homozygosity regions in families. The software provided by Affymetrix® is 
the first commercially available software that integrates SNP genotyping, copy number 
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polymorphism (CNP) genotyping, and rare copy number variation (CNV) identification 
in one data analysis application. It generates genotyping calls, copy number calls for 
CNV regions and individual probe sets, loss of heterozygosity (LOH) data, cluster 
graphs, and quality control metrics. The software was used for analysis of 500K Array 
Sets and SNP 6.0 Array. 
The Affymetrix® Chromosome Analysis Suite 1.2 (ChAS) Software was 
designed specifically for cytogenetic researchers with an easy-to-use graphical interface. 
The software is the newest and most used software in this study. It has many advantages 
over other software packages. In addition to its ease of use, the software can provide full 
view of Chromosomal aberrations that may include copy number gain or loss, 
mosaicism, in addition to loss of heterozygosity (LOH). ChAS provides several options 
for viewing and studying the loaded CYCHP or CNCHP data as graphic displays or 
tables. Unfortunately, the computer algorithm for ChAS is not provided by the 
company. 
2.11.3   Sequence Alignment Software 
Mutation Surveyor® software Version 3.24 from softgentics and Lasergene’s SeqMan 
II version 6.0 software were used for sequence alignment and analysis.  Lasergene’s 
SeqMan II offers quick and accurate sequence assembly and analysis of Sanger 
sequencing data. Sequencing results can be copied and blast in other browser for 
sequence search. Mutation Surveyor® is DNA Sequencing analysis software capable of 
performing variant analysis of up to 2000 Sanger sequencing files (.ab1) generated by 
Applied Biosystems Genetic Analyzers electrophoresis system in 15 minutes. Utilizing 
patented anti-correlation technology Mutation Surveyor delivers excellent accuracy, 
sensitivity, low false positive and negative rates in the analysis of DNA variants. 
 
2.11.4   Web-based Genetics Tools 
The following websites were used for displaying genes, gene mapping, gene findings, 
gene predictions, reference sequences, mRNA and expressed sequence tag alignments, 
simple nucleotide polymorphisms, expression and regulatory data, and pairwise and 
multiple-species comparative genomics data in addition to clinical information. 
• The University of California Santa Cruz (UCSC) Genome Browser 
(genome.ucsc.edu): The UCSC Genome Browser presents a diverse collection of 
annotation tracks including mRNA alignments, mappings of DNA repeat 
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elements, gene predictions, gene-expression data, and disease-association data. 
The Genome Browser was used for gene predictions in a region, gene expression 
in tissues, designing primers through ExonPrimer, to detect change 
conservations through vertebrate. BLAT (the BLAST-Like Alignment Tool) was 
used to map sequence to the genome.  It was developed to identify similarities 
between DNA sequences and protein sequences and to assist in the annotation of 
the human genome sequence. 
• The National Center for Biotechnology Information (www.ncbi.nlm.nih.gov): 
Through this site, the NCBI provides access to Genbank and to the Entrez 
databases, as well as to many tools for sequence analysis and data mining. 
Locuslink is also at NCBI, and for non-redundant and curated sequence data 
covering the fly, human, mouse, rat and zebrafish genomes. The NCBI website 
was used for downloading reference sequences (Gene), to determine candidate 
genes in locus interval (Map Viewer), References citation (PubMed), to have 
information of human genes and genetic disorders (Online Mendelian 
Inheritance in Man (OMIM)), and Database of Short Genetic Variations 
(dbSNP) that contains population-specific frequency and genotype data, and 
mapping information for both neutral variations and clinical mutations. 
• Ensembl Genome Browser (www.ensembl.org): The Ensembl project produces 
genome databases for vertebrates and other eukaryotic. It is a joint project 
between EMBL - EBI and the Wellcome Trust Sanger Institute to develop a 
software system which produces and maintains automatic annotation on selected 
eukaryotic genomes. Ensembl was used to display gene sequence, transcripts 
(cDNA), and exons. Also used to detect variations at nucleotide and structural 
levels. 
• The GeneCards Human Gene Database (www.genecards.org) 
• Genetics Home Reference (ghr.nlm.nih.gov) 
• UniProt (www.uniprot.org) 
• Tissue-specific Gene Expression and Regulation [TiGER] 
(http://bioinfo.wilmer.jhu.edu/tiger) 
• GeneDistiller 2 (www.genedistiller.org) 
• GenAtlas (www.genatlas.org) 
• GeneTests (www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests) 
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For searching and assessing reported and novel mutations detected in the study the 
following websites were visited: 
• The Human Gene Mutation Database [HGMD] (www.hgmd.org) 
• Human Genome Variation Society [HGVS] (www.hgvs.org) 
• PolyPhen-2 prediction of functional effects of human nsSNPs 
(http://genetics.bwh.harvard.edu/pph2/): The score range in PolyPhen-2 is fall 
between 0 and 1. Where 0 is benign change and 1 is probably damaging.  
• SIFT (http://sift.jcvi.org): SIFT score, ranges from 0 to 1. The amino acid 
substitution is predicted damaging if the score is ≤ 0.05, and tolerated if the 
score is > 0.05. 
• SNPs3D (www.snps3d.org): SNPs3D scoring follows the higher the entropy is, 
the more tolerant a position is to a mutation. i.e. scores less than zero are more 
damaging than above zero.  
 
2.11.5   Statistics (GraphPad Prism) software 
Chi-square is a statistical test commonly used to compare observed data with data we 
would expect to obtain according to a specific hypothesis. The chi-square test is always 
testing what we call the null hypothesis, which states that there is no significant 
difference between the expected and observed result.  
A chi-squared test was performed to discover if a difference in the proportion of fish 
exhibiting certain phenotypes between two groups was statistically significant using the 
GraphPad Prism software.  
 
All data were stored at server’s computers of KFSH&RC and IGM and stored in 
personal laptop. Copies of all data were stored in external hard drive. Data was shared 
between KFSH&RC and IGM through RAS logon at IGM and through Dropbox 
website (www.dropbox.com). 
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Chapter 3: RESULT 
3.1 Nephrotic Syndrome 
3.1.1 Introduction 
Nephrotic Syndrome (NS) is a renal disease characterized by heavy proteinuria, 
hypoalbuminemia, edema and hyperlipidemia (Franceschini et al., 2006). Urinary losses 
of macromolecules such as albumin reflect a dysfunction of the highly permselective 
glomerular filtration barrier (GFB) (Mundel and Shankland, 2002). The GFB structure 
consists of podocyte foot-process, glomerular basement membrane (GBM), endothelial 
fenestration and the slit-diaphragm (SD). The SD, which represents the main size 
selective filter barrier in the kidney, is thought to be a modified adherens junction and a 
growing number of proteins have been identified to have a crucial role in this structure 
(Mundel and Shankland, 2002).  
The identification of mutations leading to defects in proteins highly expressed in the 
podocyte and slit diaphragm (Figure 3.1.1) has helped to unravel the basis of GFB 
physiology and pathophysiology (Machuca et al., 2009). Kidney biopsies in NS patients 
may show non-specific changes such as minimal change, as well as focal segmental 
glomerulosclerosis (FSGS) and diffuse mesangial sclerosis (DMS) (Godefroid and 
Dahan, 2010). A molecular genetic diagnosis is important for making treatment 
decisions including suitability for renal transplantation and to enable screening other 
family members at risk of disease.  
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Figure 3.1.1: Molecular overview of the slit-diaphragm and podocyte cell–matrix 
interactions (Machuca et al., 2009). 
Nephrotic syndromes may be given a series of descriptive labels dependent upon their 
age of presentation. Congenital NS (CNS), manifests in utero or during the first 3 
months of life (Hinkes et al., 2007); infantile NS, has an onset between 3 months and 1 
year of age (Hinkes et al., 2007) and  childhood steroid resistant nephrotic syndrome 
(SRNS) may be defined as no urinary remission within 4 weeks of prednisone  therapy 
60 mg/m2/day (Brodehl et al., 1982). In recent years, the identification of genes coding 
for podocyte and slit diaphragm proteins by positional cloning in NS patients helped our 
understanding of molecular basis of inherited NS. To date defects in over ten genes 
have been recognized; NPHS1 (Kestila et al., 1998), NPHS2 (Boute et al., 2000), 
PLCE1 (Hinkes et al., 2006), WT1 (Jeanpierre et al., 1998), LAMB2 (Zenker et al., 
2004), PTPRO (Ozaltin et al., 2012), ACTN4 (Kaplan et al., 2000), TRPC6 (Winn et al., 
2005), CD2AP (Kim et al., 2003), INF2 (Brown et al., 2010), and MYO1E (Mele et al., 
2011). 
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NPHS1 gene (Nephrin): 
Nephrin is the major component of SD which is a 1241-residue transmembrane 
adhesion protein of the immunoglobulin superfamily. NPHS1 is the coding gene for 
Nephrin.  Kestila et al. (Kestila et al., 1998) mapped the CNF gene to chromosome 
19q13.1 and subsequently cloned the NPHS1 gene, which contains 29 exons and has a 
size of 26 kb. Mutations in NPHS1 cause the congenital nephrotic syndrome (CNS) of 
Finnish type that characterized by autosomal recessive inheritance. Two mutations, Fin-
major and Fin-minor account for more than 90% of mutations in Finland.  To date there 
are 173 mutations in the NPHS1 gene reported to cause NS [HGMD]. Compared with 
many other genetic disorders, NPHS1 shows relatively little phenotypic variation. 
NPHS2 gene (Podocin): 
Podocin is a hairpin-like protein at slit diaphragm which lines the podocytes and assists 
in maintaining the barrier at the GBM. Podocin is a 383-residu and a member of the 
stomatin family, which is one of the most important membrane proteins and is 
exclusively expressed in the podocytes at the foot processes in the place of anchorage of 
the slit diaphragm. Podocin interacts with nephrin and CD2AP, and is part of a protein 
complex within podocytes that includes Neph1 and Neph2 proteins. 
NPHS2 gene on chromosome 1q25 consists of 8 exons and codes for podocin. 
Mutations in NPHS2 cause autosomal recessive NS. Mutations in NPHS2 accounts for 
42% of familial and 10% of sporadic cases of childhood-onset Steroid Resistant 
Nephrotic Syndrome (SRNS) and have also been found in 39% of patients with CNS 
(2). There are 116 mutations reported so far in the NPHS2 gene. 
PLCE1 gene (phospholipase C epsilon) 
Phosphatidylinositol-4,5-bisphosphate phosphodiesterase epsilon-1 is an enzyme that in 
humans is encoded by the PLCE1 gene. PLCE1 belongs to the phospholipase family 
that catalyzes the hydrolysis of polyphosphoinositides such as phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) to generate the second messengers Ins(1,4,5)P3 and 
diacylglycerol. These products initiate a cascade of intracellular responses that result in 
cell growth and differentiation and gene expression. The PLCE1 gene located on 
Chromosome 10q23 and consists of 32 exons coding for 2302 amino acids. 
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PLCE1 gene mutations have been recently described in patients with early onset 
nephrotic syndrome (NS) and diffuse mesangial sclerosis (DMS) (Boyer et al., 2010). In 
addition, two cases of PLCE1 mutations associated with focal segmental 
glomerulosclerosis (FSGS). To date there are 28 mutations reported in the gene 
according to HGMD database.  
CD2AP gene (CD2-Associated Protein): 
CD2 associated protein seems to act as an adapter protein between membrane proteins 
and the actin cytoskeleton. It is may anchor the podocyte slit diaphragm to the actin 
cytoskeleton in renal glomerolus. Also it may play a role in receptor clustering and 
cytoskeletal polarity in the junction between T-cell and antigen-presenting cell.  
CD2AP gene located in chromosome 6p12 and consists of 18 exons coding for 639 
amino acids. Defect in CD2AP gene modify the interaction with CD2 in lymphocytes 
and alter the composition of the renal slit diaphragm. Mutations in the CD2AP results in 
presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced 
glomerular filtration rate and edema. Only six mutations reported on this gene. 
LAMB2 gene (Laminin subunit beta-2): 
LAMB2 encodes the basement membrane protein laminin beta2. Laminin is thought to 
mediate the attachment, migration and organization of cells into tissues during 
embryonic development by interacting with other extracellular matrix components. 
LAMB2 gene located in chromosome 3p21 consisting of 32 exons coding for 1798 
amino acids. Mutations of LAMB2 are the cause of Pierson syndrome that is 
characterized by nephrotic syndrome with neonatal onset, diffuse mesangial sclerosis 
and eye abnormalities.  Mutations in LAMB2 also cause congenital nephrotic syndrome 
that may be associated with ocular abnormalities. Non truncating LAMB2 mutations 
may display variable phenotypes ranging from a milder variant of Pierson syndrome to 
isolated congenital nephrotic syndrome. Fifty five mutations were reported to cause 
diseases in LAMB2 gene so far.  
MYO1E gene (myosin IE): 
This gene encodes a member of the nonmuscle class I myosins which are a subgroup of 
the unconventional myosin protein family. The unconventional myosin proteins 
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function as actin-based molecular motors and serve in intracellular movements. MYO1E 
gene is located on Chromosome 15 with 28 coding exons. Mutations in this gene are the 
cause of focal segmental glomerulosclerosis-6 (Mele et al., 2011). To date there are only 
two mutations reported in the MYO1E gene (A159P and Y695X). 
PTPRO gene (protein tyrosine phosphatase, receptor type, O): 
PTPRO gene encodes a member of the R3 subtype family of receptor-type protein 
tyrosine phosphatases. The function of PTPRO is to possess tyrosine phosphatase 
activity. It is localized mainly in the glomerulus of kidney also detected in brain, lung 
and placenta. The PTPRO gene located on Chromosome 12 and consisted of 26 coding 
exons. Recently, (Ozaltin et al., 2012) reported two splicing mutations that cause 
nephrotic syndrome, childhood-onset. No other mutations reported in the gene up to 
date. 
Recently, NEIL1 (Nei Endonuclease VIII-like 1) which encodes a base-excision DNA 
repair enzyme was postulated as a candidate gene for NS in a single consanguineous 
family (Sanna-Cherchi et al., 2011). Its role in NS remains uncertain. 
Despite increasing genetic evidence supporting the fact that underlying mutations lead 
to NS, the majority of NS occurs sporadically; The incidence of familial cases is 
estimated to be just 3 to 5% (Obeidova et al., 2006). In this study we screened for 
mutations in 9 genes implicated in inherited NS in a Saudi Arabian population with 
either CNS, infantile NS or childhood SRNS. Such a study has never been conducted 
for this part of the world. The Saudi Arabian population has a tribal structure and the 
overall rate of consanguineous marriage is reported to be around 58%, with regional 
variations (el-Hazmi et al., 1995). In such a population, the identification of mutations 
in known recessive disease genes is an important consideration and we were interested 
in our ability to detect a molecular genetic cause of NS. Identification of a molecular 
genetic cause of NS allows both a definitive diagnosis and improved clinical 
management of the patient and at risk relatives.  It is noteworthy that the Saudi 
population is at high risk of renal failure, with 133 incident cases per million population 
per year that require renal replacement therapy (2011). 
We identified 67 cases, representing 53 families with CNS, infantile NS or childhood 
SRNS and undertook mutational analysis in known / candidate NS genes. We found a 
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high rate of mutations in this cohort, solving 47% of cases. Direct sequencing identified 
novel and likely pathogenic genetic variants in NPHS1, NPHS2, MYO1E and PLCE1, 
increasing the known spectrum of mutations in these genes. 
3.1.2 Methods 
3.1.2.1   Study Cohort 
Following informed consent, DNA was extracted from peripheral blood cells using the 
Gentra Systems PUREGENE DNA Isolation kit. A total of 67 samples from 53 
different families were obtained. Altogether, 29 samples were obtained from 15 families 
with evidence of familial nephrotic syndrome and 38 samples were obtained from 
families with a single affected individual with NS. Clinical phenotypes included 
patients with CNS, infantile NS and childhood SRNS. Consanguineous marriages were 
noted; where 36 families were consanguineous and five families were not. 
Consanguinity status was unknown in 12 families. 
3.1.2.2   Mutation Analysis 
Mutational screening was undertaken of known genes implicated in nephrotic 
syndrome; NPHS1, NPHS2, LAMB2, PLCE1, CD2AP, MYO1E, WT1, PTPRO and 
NEIL1. Direct sequencing of all coding exons and exon-intron boundaries was 
performed. Oligonucleotide primers for PCR amplification of genomic DNA were 
designed using Primer3 software (http://frodo.wi.mit.edu/) and synthesized by Metabion 
International AG (Germany). Primer sequences are listed in Appendix A. PCR was 
performed in a final volume of 25µl. PCR products were treated with the Agencourt® 
AMPure® PCR purification system. PCR products were sequenced using BigDye™ 
Terminator Cycle Sequencing kit (PE Applied Biosystems) as described by the 
manufacturer. Sequences were analyzed using Mutation Surveyor® software Version 
3.24 (SoftGenetics) and SeqMan II software 6.1 (DNAStar). 
Computational analyses of novel missense mutations were performed with PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/), SNPS3D 
(http://www.snps3d.org/) and mutationtaster (http://www.mutationtaster.org/). To assess 
splicing effects we used the GeneSplicer software 
(http://www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml). In addition to 
database searches, a control DNA panel from 175 individuals from a Saudi Arabian 
population was used to screen for all novel sequence variants. 
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3.1.3 Results 
Sixty seven individual cases affected with congenital NS, infantile NS, childhood SRNS 
representing 53 families from the Arabian Peninsula were screened for mutations in the 
following genes: NPHS1, NPHS2, LAMB2, PLCE1, MYO1E, WT1, PTPRO, NEIL1 and 
CD2AP. We identified mutations known NS genes in 11 out of 15 (73%) families where 
there was reported to be more than 1 affected member with NS, suggesting an inherited 
cause. A molecular genetic diagnosis was obtained in 37% (14 of 38) of families with a 
single affected member with NS. All families in whom we detected mutations had a 
history of consanguinity, most commonly first cousin marriages. Overall, in this 
population, by screening 9 genes implicated in inherited NS we established a likely 
molecular genetic cause in 47% of families (Figure 3.1.2 and Table 3.1.1).  
 
Figure 3.1.2: Percentage of cases with mutations in genes causing NS in Saudi 
population 
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Table 3.1.1: Saudi Arabian nephrotic syndrome cases identified with mutations in disease associated genes 
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Gene 
Homozygous Nucleotide 
Change 
Segregatio
n from 
parents 
Amino Acid 
change 
PolyPhen-2 SIFT SNPS3D 
Allele frequency 
in Saudi 
population 
Expected 
pathogenicity 
NPHS1 c.1627+2T>G Yes 
Predicted 
Splicing defect 
N/A N/A N/A 0 Pathogenic 
NPHS2 c.115C>T N/A Q39X N/A N/A N/A 0 Pathogenic 
NPHS2 c.413G>C N/A R138P 
Probably 
damaging 
(1.00) 
Damaging (0) 
Deleterious  
(-1.28) 
0 Pathogenic 
PLCE1 c.3058C>T Yes Q1020X N/A N/A N/A 0 Pathogenic 
MYO1E c.141C>G Yes Y47X N/A N/A N/A 0 Pathogenic 
MYO1E c.356C>T N/A T119I 
Probably 
damaging (1.00) 
Damaging (0) 
Deleterious  
(-2.65) 
0 Pathogenic 
 
Table 3.1.2: Novel genetic variants detected in NPHS1, NPHS2, PLCE1 and MYO1E and in silico analysis of pathogenicity
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Figure 3.1.3: Sequencing chromatograms of pathogenic (in red) and benign (in green) 
variants detected in Saudi Arabian NS cases.  Sequence chromatogram is shown with 
nucleotides shown, with reference sequence shown below. Reading frame is indicated 
by black bars and amino acid translations are given. Exons are marked with capital 
letters while introns marked with small letters. 
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No mutations were found in WT1 following screening of exons 8 and 9, NEIL1 or 
PTPRO by screening all coding exons. In this Saudi Arabian cohort, mutations in the 
NS genes NPHS2, NPHS1 and PLCE1 account for 21%, 11% and 8% of cases, 
respectively of NS (Figure 3.1.2).  Mutations in NPHS2 represent over two-fifths of 
genetically proven NS in this population. 
Previously published data from a world-wide cohort suggested that ~50% of CNS is 
caused by mutations in NPHS1 (Schoeb et al., 2010). In our cohort, mutations in 
NPHS1 accounted for 4 out of 7 cases (57%) of CNS which had a confirmed molecular 
genetic diagnosis. 
Of the novel homozygous sequence variants in coding regions (Table 3.1.2 and Figure 
3.1.3), we identified 3 novel nonsense mutations, a donor splice site mutation with a 
high likelihood of aberrant splicing and 2 missense mutations. In silico predictions 
suggested that these missense changes are pathogenic (Table 3.1.2).  
A detailed analysis of the results for each gene is given below. 
NPHS1: In this gene we found 6 families carrying known or predicted pathogenic 
mutations. 5 of the mutations were found in the homozygous state, and one (S22) was a 
compound heterozygous mutation involving two previously reported variants P368L 
and R460Q (Beltcheva et al., 2001) (Table 3.1.1). Here, segregation of the mutation 
from each parent was confirmed (data not shown). None of our cohort had Finmajor 
(nt121delCT, L41fsX91) or Finminor (c.3325C>T, R1109X) mutations (Kestila et al., 
1998). The affected patient from family S3 had a homozygous frame shift mutation in 
NPHS1 combined with a novel heterozygous NPHS2 (c.761G>T; p.C254F) allele 
(Table 3.1.1 and 3.1.3). A p.P264R missense change found in NPHS1 in 2 families 
(Table 3.1.4). This allele has previously been identified as contributing to a compound 
heterozygous mutation in NPHS1 in cases of severe CNS (Koziell et al., 2002, Caridi et 
al., 2009). It has also been noted in cases of tri-alellic inheritance of steroid resistant 
FSGS (Lowik et al., 2008). Tri-allelism (sometimes called oligogenicity) refers to the 
finding of 2 recessively inherited mutations at one loci plus a third mutated loci in a 
different gene. It has been frequently described in patients with Bardet Biedl Syndrome 
(BBS) (see Chapter 4).  The P264R variant has a minor allele frequency of 1% 
(rs34982899, dbSNP 1000 Genomes) and its pathogenicity is not proven. Indeed it has 
recently been classified as a polymorphism (Machuca et al., 2010).  One novel 
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homozygous sequence variants was detected in the NPHS1 gene (S37 Table 3.1.1 and 
Table 3.1.2). This sequence variant is predicted to be a splice site mutation affecting the 
5’-splice donor site (c.1627+2T>G) predicting exon skipping of exon 12. A novel 
heterozygous NPHS1 variant c.528T>C (p.S176S) is in a highly conserved region, and 
may affect splicing at acceptor site, given that the 528T nucleotide is the second 
nucleotide within exon 5 (Table 3.1.3). This variant was found in a heterozygous state 
in two patients from the same family (F22) in combination with a heterozygous 
missense change in LAMB2 (c.1982G>A; p.R561Q) (Table 3.1.3). 
Another novel heterozygous NPHS1 variant c.840+6G>A was found in 7 families, 2 of 
whom also had a homozygous mutation p.Q1020X in PLCE1 gene (Table 3.1.1 and 
3.1.3). This NPHS1 c.840+6G>A variant was also found in 1.15% of our normal 
controls, suggesting it is unlikely to be pathogenic in isolation (Table 3.1.3).  
Of the six families with homozygous or compound heterozygous NPHS1 mutations, 
four presented with CNS, whilst the others had milder phenotypes, consistent with 
previous reports (Heeringa et al., 2008). 
NPHS2: Among our NS cohort there were 11 families with NPHS2 mutations 
(Table 3.1.1). All mutations in affected individuals were in a homozygous state 
consistent with known parental consanguinity. Mutations detected in NPHS2 accounted 
for 44 % of all the mutations detected in our cohort.  
Two novel homozygous NPHS2 mutations were detected: a nonsense mutation 
c.115C>T (p.Q39X) which is the most premature truncating mutation reported so far in 
NPHS2 and a missense mutation c.413G>C (p.R138P) in patients with SRNS.  Of note, 
this arginine residue at position 138 (R138) of podocin has been the residue mutated in 
other cohorts, specifically (R138Q) and (R138X) (Boute et al., 2000). Both mutations 
R138Q and R138X were reported in SRNS patients. Indeed R138Q has been described 
as a founder mutation in European populations (Boute et al., 2000). Huber and et al. 
demonstrated that this mutation causes a failure to recruit nephrin into lipid rafts (Huber 
et al., 2003), providing important insights into the pathogenesis of this NPHS2 
mutation.  
A novel heterozygous NPHS2 variant C254F was detected in a patient homozygous for 
a c.515delCCA mutation in NPHS1 gene (Table 3.1.1 and 3.1.3). The variant C254F 
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was not predicted to be definitely pathogenic by in silico models (Table 3.1.3) but 
neither was it found in our normal controls. This suggests that C254F could be a 
modifier allele. 
Whilst screening our control population for novel NPHS2 variants, we observed a 
NPHS2 variant P20L (data not shown) in 2.32% of Saudi Arabian controls. This variant 
is of unknown functional significance (Caridi et al., 2009) and is rare in control 
European populations (Ruf et al., 2004a) and was not associated with a NS disease 
phenotype, suggesting that this change should be considered as a rare polymorphism. 
PLCE1: A novel homozygous mutation in PLCE1 (Q1020X) was detected in 4 
families in our cohort, with a broad range of phenotypes (Table 3.1.1). All affected 
individuals had the identical mutation, and segregation was confirmed in 2 of the 
families (F5 and F15, data not shown). This truncating mutation is predicted to have a 
severe effect on the PLCE1 protein with loss of the PLC catalytic domain, the protein 
kinase C conserved region and the Ras association domain (Hinkes et al., 2006). 
Interestingly, each of the Q1020X mutations in exon 7 of PLCE1 gene was associated 
with the variant (c.4665+52G>C) in intron 18 (Table 3.1.3).  
Affected and unaffected daughters in a family of African ancestry with SRNS (F17) 
were found to be homozygous for a rare variant (K2173R) in PLCE1 (Table 3.1.4). We 
did not found this variant in our Saudi Arabian control cohort. The affected F17 
member was also heterozygous for novel variants c.840+6G>A in NPHS1 gene and 
R644H in LAMB2 gene (Table 3.1.3). 
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Table 3.1.3: Novel genetic variants of unknown significance and polymorphisms detected in NPHS1, NPHS2, LAMB2, NEIL1 and PLCE1. 
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Gene Family ID 
Nucleotide 
Change 
Amino Acid 
change                
Homozygous or 
Heterozygous 
SNP ID 
Allele frequency in Saudi 
population 
NPHS1 S39 c.791C>G P264R Homozygous rs34982899 N/A 
NPHS1 S34, F22 c.791C>G P264R Heterozygous rs34982899 N/A 
NPHS2 F13 c.709G>C E237Q Heterozygous rs146906190 N/A 
LAMB2 S18, S29  c.5293G>A A1765T  Heterozygous rs74951356 N/A 
LAMB2 S20, S26 c.2099G>A G700E Heterozygous rs142860588 N/A 
LAMB2 S39 c.3443G>A R1148H Heterozygous rs138774635 0.82% 
PLCE1 F17 c.6518A>G K2173R Homozygous rs111929795 0% 
CD2AP F5, S14, S16 c.902A>T K301M Heterozygous rs141778404 2.79% 
 
Table 3.1.4: Nonpathogenic sequence variants / polymorphisms identified in known nephrotic syndrome genes 
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MYO1E: We detected novel homozygous MYO1E mutations in 3 families (Table 
3.1.1). Two families presented with SRNS and minimal change glomerulonephritis on 
renal biopsy. The affected patients both had a Y47X nonsense mutation, segregating 
from each parent (data not shown).  The affected patient in family S17 presented with 
SRNS and FSGS on renal biopsy and was found to have a T119I homozygous mutation 
(Table 3.1.1 and Figure 3.1.3). The Threonine residue at position 119 is conserved 
throughout vertebrates (including zebrafish) and in the myosin-1d homolog of the 
amoeba Dictyostelium discoideum. The Y47X is a severe truncating mutation, with a 
predicted loss of all functional domains of the MYO1E protein, including the motor-
head domain, the calmodulin binding IQ domain and the tail domain (Mele et al., 2011).  
CD2AP: A single patient from family F23 in our NS cohort was found to have 2 
known heterozygous variants in CD2AP (Table 3.1.1). The first F220L is a novel 
variant of unknown significance (rs139926926), in a residue conserved to Danio rerio 
and was not detected in 350 healthy Saudi Arabian alleles. This variant was combined 
with T374A, a likely pathogenic mutation (Gigante et al., 2009). The heterozygous 
T374A mutation in CD2AP was previously reported in a 2 year old child presenting 
with SRNS and histological features of FSGS, and the missense change disrupts a 
proline rich domain important for protein-protein interactions (Gigante et al., 2009). 
In addition, the CD2AP variant K301M was found as a heterozygous allele in 3 of our 
patients; one was associated with homozygous Q1020X mutation in PLCE1 gene (F5), 
other two (S14 & S16) were detected alone (Table 3.1.4). Although K301M has been 
reported previously as a pathogenic mutation (Gigante et al., 2009), we also found this 
variant in 2.79% of our normal controls suggesting that this variant is a polymorphism.  
LAMB2:  We found novel heterozygous LAMB2 sequence variants in 5 families from 
our cohort (Table 3.1.3). The affected patient in family S18 had a L465P heterozygous 
variant in LAMB2 gene together with a A1765T polymorphism in LAMB2 (Schoeb et 
al., 2010) (Table 3.1.3 & 3.1.4). The L465P missense change is novel, and was absent 
from control samples, but predicted to be benign using in silico testing (Table 3.1.3).  In 
another family (F22), two affected patients (brothers) with FSGS had a single 
heterozygous R561Q variant in LAMB2. This novel variation of unknown severity was 
present in 0.27% of healthy controls and was in combination with a novel heterozygous 
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NPHS1 S176S variant, predicted to have some deleterious impact upon splicing (Table 
3.1.3).  
Additional novel (and likely polymorphic) variants were detected in the LAMB2 gene 
(Table 3.1.3, Figure 3.1.3). A heterozygous L1258V missense variant was detected in 
two families and also detected in 0.55% of our normal controls. The variant R644H was 
detected in one allele of our patients and in 0.82% of normal controls. 
Family S39 had a known heterozygous variant in LAMB2 (c.3443G>A; p.R1148H) in 
association with a heterozygous P264R NPHS1 polymorphism (Table 3.1.4). This 
R1148H LAMB2 variant was found also in 0.82% of our normal controls (Table 3.1.4).   
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3.1.4 Discussion 
This study is the first to describe the molecular basis of NS in a Saudi Arabian 
population. Despite finding a high rate of mutations in known NS genes within our 
cohort (47%), these findings suggest there are other novel genetic causes of NS yet to 
be discovered. The genetic heterogeneity underlying NS, even in this highly 
consanguineous population, is evident. It is noteworthy that all patients with identified 
mutations in NS associated genes were from consanguineous marriages and most of the 
pathogenic mutations identified were in the homozygous state. There were two families 
(S22 and F23) where we identified compound heterozygous mutations in NPHS1 and 
CD2AP, respectively. Thus, reliance on screening genes in homozygous regions alone 
in known consanguineous families may miss compound heterozygous changes in 
relevant genes. Our experience is not unique. Using a homozygosity mapping approach 
in 12 families from different backgrounds with CNS, Schoeb et al. solved just 5 families 
by detecting homozygous mutations in NPHS1 (Schoeb et al., 2010). A more systematic 
search, including all known NS genes, is therefore important for achieving a high 
mutation detection rate. A strategy of targeted gene sequencing for patients manifesting 
NS in the first year of life in a world-wide study has previously been reported, and 
noted that two-thirds of patients could be explained by mutations in 1 of 4 genes 
(NPHS1, NPHS2, WT1 or LAMB2) (Hinkes et al., 2007). In the modern era of whole 
exome sequencing and targeted gene capture and sequencing, these approaches will 
allow mutations in known NS genes and novel NS genes to be detected with great 
efficiency. 
In our study, which included families with CNS, infantile NS and childhood SRNS, 
following molecular analysis of 9 known NS genes, mutations were detected in around 
47% of cases, which is comparable to the mutation detection rate in SRNS by other 
groups (Santin et al., 2011). Cohorts of more restricted phenotypes have identified 
mutations ~80% of cases (non-Finnish CNS) by a systematic screen of implicated genes 
(Machuca et al., 2010). Our mutation detection rate was, as one might predict, higher in 
patients where there was evidence of familial disease (more than 1 affected member) 
(73%) than in single individuals with NS (37%). Sporadic SRNS is likely to account for 
a greater proportion of NS, where just one individual is affected and where there is no 
family history of NS. Out of 36 consanguineous families we were able to detect likely 
causative mutations in 24 families and no mutations were found in other 12 families.  
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In five non-consanguineous families, causative mutation was found only in one family. 
No mutations were detected in remaining 12 families with unknown consanguinity 
status.    
Mutations in NPHS2 gene are the most frequent identified genetic cause of NS in our 
Saudi Arabian cohort, accounting for 44% of all pathogenic mutations detected, in 
comparison to ~40% of a European cohort (Hinkes et al., 2007), and ~30% in a large 
Turkish study (Berdeli et al., 2007). Common NPHS2 mutations in our cohort included 
missense mutations V260E and V180M. All cases with mutations in NPHS2 presented 
with childhood SRNS except one family (F3) that had CNS in association with a 
NPHS2 R168H mutation. All mutations detected in NPHS2 were homozygous, 
consistent with parental consanguinity in these cases.  
NPHS1 mutations were detected, as expected, mainly in patients presenting with CNS 
patients. Three cases presented with childhood SRNS.  
In PLCE1 gene we found one mutation common to four families with NS patients. Each 
of these families were descendants from large Saudi Arabian tribes. In Saudi Arabia, 8 
tribes account for around 10% of the country’s population. The association of the 
Q1020X in PLCE1 with the intronic variant (c.4665+52G>C) in PLCE1 in each of 
these cases may indicate a founder effect (Table 3.1.3).  
The original description of MYO1E mutations identified just 2 consanguineous families 
with missense mutations A159P and nonsense mutation Y695X, originating from Italy 
and Turkey respectively (Mele et al., 2011). There have been no additional reports of 
MYO1E mutations to date. Here, by identifying two novel MYO1E mutations in an 
Arabic consanguineous population, we confirm the pathogenicity of MYO1E in NS and 
expand the spectrum of mutations. 
Most of the mutations previously reported in the CD2AP gene have been heterozygous 
changes, except in one case with biopsy proven FSGS where a homozygous mutation 
was found (Lowik et al., 2008).  In our cohort we identified a single patient from a 
consanguineous family harboring a compound heterozygous mutation (F220L/T374A) 
in the CD2AP gene. In a previously published cohort of 35 families with SRNS in 
whom NPHS1, NPHS2, and PLCE1 mutations had been previously excluded, no 
CD2AP mutations were identified, confirming their rarity (Benoit et al., 2010).  
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We found one case (S3), presenting as CNS, where a previously reported homozygous 
mutation (c.515delCCA) in NPHS1 (Lenkkeri et al., 1999) was associated with a 
heterozygous missense change (c.761G>T; C254F) in NPHS2. This emphasizes the 
need to screen multiple NS associated genes, even within a consanguineous pedigree, to 
determine modifier gene effects. The presence of triallelism in NS has been noted 
before (Koziell et al., 2002, Caridi et al., 2003) (Schultheiss et al., 2004) and additional 
alleles in NS genes may modify the renal phenotype and the clinical presentation and 
course. Weber et al. described a child with CNS in whom a combination of a 
heterozygous de novo splice mutation in NPHS1 and a homozygous NPHS2 R138Q 
mutation was detected (Weber et al., 2004).  In contrast, it is noteworthy that in Bardet 
Biedl syndrome (BBS), an inherited ciliopathy where oligogenicity has frequently been 
previously reported (Badano et al., 2003, Pereiro et al., 2011), a Saudi cohort failed to 
exhibit these phenomena (Abu-Safieh et al., 2012).  
We were extremely careful not to define all the variants we have detected as pathogenic 
mutations, although many of them were found in less than 1% of our normal controls. 
With each new variant, we carefully checked for the presence of additional mutations 
(in the same and other NS associated genes) and confirmed the variant co-segregated, 
where parental samples were available, with clinical status within the family. As an 
example, the P264R variant we observed in NPHS1 (Table 3.1.4) has previously been 
implicated as pathogenic in cases of severe CNS (Koziell et al., 2002) however in a 
more recent paper it has been classified as a polymorphism (Machuca et al., 2010). 
Often novel (heterozygous) sequence variants were also detected in our ethnically 
matched control population (Table 3.1.3). We also note that the high rate of 
consanguineous marriage may make it difficult to estimate pathogenicity of novel 
mutations without segregation and extended family analysis. 
Carrier frequency of NS in Saudi population could be established using Hardy–
Weinberg equilibrium (HWE) providing the prevalence of NS in the population is 
known. Determination of allele frequency and heterozygous carrier frequency in a 
population for which the prevalence of disease is known is the most important medical 
application of the HWE. The HWE holds only for large population in which there is 
random mating. Consanguinity in Saudi population is around 55% and this is may alter 
allele frequency in the population by increasing proportion of homozygous in the next 
generation.  
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Based on data obtained, allele frequency of NS in Saudi population is a challenge due to 
consanguinity and unknown prevalence of the disease in the population. 
The molecular genetic diagnosis of NS remains a vital aid to the clinical management of 
families with NS. It allows for the appropriate long term management to be undertaken, 
genetic counseling to be undertaken and where necessary, screening of siblings and 
other at risk family members. Decisions regarding immunosuppression and 
transplantation are aided by a molecular genetic diagnosis. It is well recognized that 
children with causative mutations in NS genes do not respond well to treatment with 
corticosteroids and other immunosuppressants (Hinkes et al., 2007). 
In conclusion, in a Saudi Arabian cohort, 47% of families with NS were explained by 
mutations on 5 known nephrotic syndrome genes (NPHS1, NPHS2, PLCE1, MYO1E 
and CD2AP). NPHS2 gene mutations were the most common molecular genetic cause 
of NS in this cohort. Unsolved patients from consanguineous families suggest additional 
novel genetic causes of NS are likely. The genetic heterogeneity of NS, suggests that 
screening strategies should continue to include multiple NS genes, including rare and 
recently discovered genetic causes, to allow a high yield of molecular genetic 
diagnoses. This will then lead to improvements in both precise diagnosis and clinical 
management.
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Chapter 3: RESULTS 
3.2 Bardet-Biedle Syndrome and Modelling of a Novel BBS5 Mutation 
3.2.1   Introduction 
Bardet–Biedl syndrome (BBS; OMIM 209900) is a ciliopathic disorder that affects 
multiple organs and body systems. It is characterized by polycystic kidney, 
hypercholesterolemia, hypogonadism, mental retardation, obesity, polydactyly, renal 
failure, retinitis pigmentosa, rod-con dystrophy, and syndactyly (Moore et al., 2005).  
Beales and et al proposed a scheme for diagnosing BBS (Beales et al., 1999); They 
suggested four primary features or three primary features and two secondary features 
are required for a clinical diagnosis of Bardet–Biedl syndrome as shown in Table 3.2.1.  
BBS is inherited in an autosomal recessive fashion. To date; at least 16 BBS genes have 
been identified (BBS1, BBS2, ARL6, BBS4, BBS5, MKKS, BBS7, TTC8, BBS9, BBS10, 
TRIM32, BBS12, MKS1, CEP290, WDPCP and SDCCAG8).  The frequency, function 
and locus of each gene are shown in Table 3.2.2.  
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Primary features Secondary features 
Four features are required to be 
present: 
Or three primary plus two secondary 
features are required: 
Rod-cone dystrophy Speech disorder/delay 
Polydactyly Strabismus/cataracts/astigmatism 
Obesity Brachydactyly/syndactyly 
Learning disabilities Developmental delay 
Hypogonadism in males Polyuria/polydipsia (nephrogenic 
diabetes insipidus) 
Renal anomalies Ataxia/poor coordination/imbalance 
 Mild spasticity (especially lower limbs) 
 Diabetes mellitus 
 Dental crowding/ hypodontia/small 
roots/high arched palate 
 Left ventricular hypertrophy/congenital 
heart disease 
 Hepatic fibrosis 
 
Table 3.2.1:  Diagnostics criteria of BBS: 
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Gene Frequency Locus Function Refernces 
BBS1 23% 11q13 
BBSome 
protein 
(Mykytyn et al., 2002)  
BBS2 8% 16q21 
BBSome 
protein 
(Nishimura et al., 2001)  
BBS3/ARL6 0.40% 3p12-p13 GTPase (Chiang et al., 2004) 
BBS4 2% 
15q22.3-
q23 
BBSome 
protein 
(Mykytyn et al., 2002) 
BBS5 0.40% 2q31 
BBSome 
protein 
(Li et al., 2004) 
BBS6/MKKS 6% 20p12 
Part of 
chaperonin 
complex 
(Kim et al., 2005) 
BBS7 2% 4q27 
BBSome 
protein 
(Badano et al., 2003) 
BBS8/TTC8 1% 14q32.1 
BBSome 
protein 
(Ansley et al., 2003) 
BBS9/B1 6% 7p14 
BBSome 
protein 
(Nishimura et al., 2005) 
BBS10 20% 12q21.2 
Part of 
chaperonin 
complex 
(Stoetzel et al., 2006) 
BBS11/TRIM32 0.10% 
9q31-
q34.1 
E3 ubiquitin 
ligase 
(Chiang et al., 2006) 
BBS12 5% 4q27 
Part of 
chaperonin 
complex 
(Stoetzel et al., 2007)  
BBS13/ MKS1 4.50% 17q23 
Centriole 
migration 
(Leitch et al., 2008) 
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BBS14/CEP290
/NPHP6 
1% 12q21.3 
Basal body: 
RPGR 
interaction 
(Leitch et al., 2008) 
BBS15/ 
WDPCP 
1% 2p15 
Basal body: 
localisation 
of septins 
and 
ciliogenesis 
(Kim et al., 2010)  
BBS16/SDCCA
G8 
1% 1q43 
Basal body: 
interacts 
with OFD1 
(Otto et al., 2010) 
Table 3.2.2:  The frequency, function and locus of BBS genes 
 
Although BBS inherited in autosomal recessive pattern, there is evidence of non 
Mendelian mode of inheritance named oligogenic inheritance or triallelic inheritance 
(Katsanis et al., 2001).  Oligogenic inheritance is a term that describes 2 recessively 
inherited mutations at one loci plus a third mutated loci in a different gene. Trialleleic 
inheritance has been observed. This phenomenon was observed in two ciliopathy 
diseases, BBS (Katsanis et al., 2001) and nephronophthisis (Hoefele et al., 2007).  
However, in a number of families, trans mutant alleles interact with the primary causal 
locus to modulate the penetrance and/or the expressivity of the phenotype.  
The proteins encoded by these genes are involved in the maintenance and function of 
cilia. Identification of BBS8 led to linking BBS to ciliary dysfunction where situs 
inversus (a defect of left-right axis determination) was diagnosed. It was found that all 
BBS proteins studied to date localize primarily to centrosomes, basal bodies, or cilia 
(Zaghloul and Katsanis, 2009). BBS proteins are required for the localization of G 
protein-coupled receptors to primary cilia on central neurons. Recent studies suggest 
that the BBS complex can associate with the RAB8 GDP/GTP exchange factor to 
promote trafficking of vesicles to the cilium (Nachury et al., 2007). In addition studies 
using C. elegans have shown that bbs8 may be involved in the regulation of the RFX 
transcription factor, which regulates expression of ciliary protein–encoding genes 
(Ansley et al., 2003). These findings suggest an important role for BBS proteins in 
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ciliary function, and these proteins have been associated with ciliogenesis and 
intraflagellar transport (IFT), the motor-dependent trafficking of cargo along the cilium 
(Zaghloul and Katsanis, 2009). 
 In Europe and North America, BBS has a prevalence of 1 in 140,000 to 1 in 160,000 
newborns (Beales et al., 1997) 
The prevalence of BBS in Arabs varies from one country to another. It is estimated to 
be 1 in 13,500 newborn among Bedouins of Kuwait (Farag and Teebi, 1989), 1 in 
30,000 in Oman (Rajab et al., 2005) and 1 in 156,000 individuals in Tunisia (M'Hamdi 
et al., 2011) . The incidence of BBS is estimated by the Centre for Arab Genomic 
Studies to be 6-10 per 100 000 live birth in Arab population (CTGA Database). 
Recently there have been a few reports describing clinical and molecular BBS in Saudi 
Arabia (Abu Safieh et al., 2010, Cherian and Al-Sanna'a, 2009).  
The BBS5 gene was identified and mapped by Li (Li et al., 2004) to chromosome 2q31. 
Nachury et al found that BBS5 is 1 of 7 BBS proteins (BBSome) that form the stable 
core of a protein complex required for ciliogenesis (Nachury et al., 2007). It was 
suggested that BBS5 mediated binding to phospholipids, predominantly 
phosphatidylinositol 3-phosphate. 
Pathogenic mutations in BBS5 gene were identified in several patients with BBS. There 
are 17 reported mutations to date (Table 3.2.3) according to HGMD 
(http://www.hgmd.org). These mutations distributed among many ethnic groups.  
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Nucleotide 
change 
Amino acid 
change 
Mutation type Phenotype Reference 
c.1A>T p.M1L Missense 
Bardet-Biedl 
syndrome 
Muller (2010) 
Hum Genet 127, 
583 
c.2T>A p.M1K Missense 
Bardet-Biedl 
syndrome 
Harville (2010) J 
Med Genet 47, 
262 
c.149T>G p.L50R Missense 
Bardet-Biedl 
syndrome 
Chen (2011) 
Invest 
Ophthalmol Vis 
Sci 52, 5317 
c.158C>T p.T53I Missense 
Bardet-Biedl 
syndrome 
Abu-Safieh 
(2012) Eur J 
Hum Genet 20, 
420 
c.166A>G p.R56G Missense 
Bardet-Biedl 
syndrome 
Muller (2010) 
Hum Genet 127, 
583 
c.214G>A p.G72S Missense 
Bardet-Biedl 
syndrome 
Hjortshoj (2008) 
Am J Med Genet 
A 146A, 517 
c.547A>G p.T183A Missense 
Bardet-Biedl 
syndrome 
Hjortshoj (2008) 
Am J Med Genet 
A 146A, 517 
c.551A>G p.N184S Missense 
Phenotype 
modifier 
Li (2004) Cell 
117, 541 
Zaghloul (2010) 
Proc Natl Acad 
Sci U S A 107: 
10602 
[Functional 
characterisation] 
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Song (2011) 
Invest 
Ophthalmol Vis 
Sci 52: 9053 
[Additional 
phenotype] 
 
p.R207H 
  
Missense 
  
Phenotype 
modifier 
  
Li (2004) Cell 
117, 541 
Zaghloul (2010) 
Proc Natl Acad 
Sci U S A 107: 
10602 
[Functional 
characterisation] 
c.620G>A 
c.889G>A p.D297N Missense 
Bardet-Biedl 
syndrome 
Feuillan (2011) J 
Clin Endocrinol 
Metab 96, E528 
c.522+3A>G 
IVS6 ds A-G 
+3 
Splice site 
Bardet-Biedl 
syndrome 
Li (2004) Cell 
117, 541 
c.619-1G>C 
IVS7 as G-C -
1 
Splice site 
Bardet-Biedl 
syndrome  
Feuillan (2011) J 
Clin Endocrinol 
Metab 96, E528 
c.123delA   Deletion   
Smaoui (2006) 
Invest 
Ophthalmol Vis 
Sci 47, 3487 
c.54dupC   Insertion 
Bardet-Biedl 
syndrome 
Feuillan (2011) J 
Clin Endocrinol 
Metab 96, E528 
263_271delT
ACGAGGCCi
nsGCTCTTA 
  
Insertion/Delet
ion 
Bardet-Biedl 
syndrome 
Li (2004) Cell 
117, 541 
Table 3.2.3: HGMD reported mutations of BBS5 gene. 
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Many investigators have shown that the zebrafish provides experimentally tractable and 
physiologically relevant models of important aspects of ciliary dysfunction(Zaghloul et 
al., 2010, Badano et al., 2006, Chiang et al., 2006, Leitch et al., 2008, Ross et al., 2005). 
It is proven that human mRNA for ciliopathy genes may be utilized to rescue both 
morphant and mutant zebrafish phenotypes efficiently, providing a robust platform for 
interpretation of the pathological relevance of identified mutated alleles (Zaghloul et al., 
2010, Chiang et al., 2006, Leitch et al., 2008, Parfitt et al., 2009). Rescue experiments 
in zebrafish for the AHI1 ciliopathy gene was demonstrated recently by our 
group(Simms et al., 2012). 
 Suppression of some BBS proteins in zebrafish causes gastrulation defects that include 
shortened and curvature body axes, longer somites, broad and kinked notochords, 
cardiac abnormalities (including situs inversus) and pronephric duct dilatation (Stoetzel 
et al., 2006, Stoetzel et al., 2007, Leitch et al., 2008, Ross et al., 2005, Gerdes et al., 
2007). 
Here, we report a consanguineous Saudi Arabian family with clinical features of BBS, 
together with a novel mutation in BBS5 gene. For first time, we have developed a 
zebrafish model of BBS5 knockdown and mimicked the human mutation in this organ 
system. Using cell culture systems we also verify the pathogencity of the mutation by 
demonstrating mislocalisation of mutated BBS5 protein in renal epithelial cells. 
 
3.2.2   Results 
3.2.2.1   Clinical Phenotype: 
A first degree consanguineous family from Saudi Arabia was given a diagnosis of BBS. 
The family consisted of 3 affected children, unaffected child and parents (Figure 3.2.1).  
The affected children all had post axial polydactly of the hands and feet (primary 
feature 1). Clinical examination of their eyes suggested a mild eye phenotype, with 
some decreased visual acuity with occasional rotator eye movements but with preserved 
retina. The affected children were all of short stature and obese (primary feature 2) with 
hyperphagia. They had variable degrees of developmental delay with learning 
disabilities (primary feature 3) and speech delay (secondary feature). They have 
variable degree of kidney phenotype (primary feature 4).  
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They all had subclinical hypothyroidism. The affected male and one of the affected 
females had a small Ventricular Septal defect (VSD) (secondary feature) (Table 3.2.4). 
Thus, each of the affected individuals had enough primary and secondary features to 
establish a clinical diagnosis of BBS. 
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 Gender Age polydactyly obesity cognitive 
impairment 
Renal 
insufficiency 
retinal 
dystrophy 
CHD Others 
Affected-1 Female 9 + + + - - - Hypothyroidism / 
squint / decreased 
visual acuity  
Affected-2 Female 7 + + + + - + Hypothyroidism 
Affected-3 Male 3 + + - + - + Hypothyroidism 
 
Table 3.2.4: Clinical characteristics of the patients of BBS family
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Figure 3.2.1: Family pedigree of the family with BBS5 mutation. Squares indicate male 
family members, circles female family members; solid symbols indicate affected 
persons, circles and squares with dots indicate likely carriers, and double horizontal bars 
consanguinity. Roman numbers underneath circles and squares indicate the sibling 
number. 
3.2.2.2   Genome wide SNP Genotyping: 
 To search for homozygous regions, all members of the BBS family were genotyped 
with an Affymetrix GeneChip probe array containing around 238000 biallelic SNPs. 
The SNP genotype call rate was ≥ 96% (Data not shown). 
All three affected children shared regions of homozygosity in the genome.  The 
chromosome 2 region of homozygosity contained the BBS5 gene as shown in Figure 
3.2.2. 
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Figure 3.2.2: A screen grab of ChAS2 software for chromosome 2 showing 
homozygosity in BBS5 gene in all three affected with BBS. 
  
3.2.2.3   BBS5 gene analysis and Mutation Screening: 
 As candidate gene, BBS5 was screened by direct sequencing of the entire coding 
sequence and consensus splice sites of the gene. Oligonucleotide primers are listed in 
the appendix. In exon 12 of the BBS5 gene we found a novel mutation c.966insT 
(p.A323CfsX55) predicted to cause a frameshift that cause truncation 55 amino acids 
downstream (Figure 3.2.3A). The mutation resulted in a predicted elongated peptide 
that has 379 amino acids instead of 342 in the wild type (Figure 3.2.3B). The three 
affected siblings were (as expected) homozygous for the mutation, whilst both parents 
and unaffected son were heterozygous for the mutation. The mutation was not found 
following screening of 96 DNA samples obtained from normal controls of an ethnically 
matched population. Mutation Taster software predicted a disease causing mutation 
with a high score for this alteration. 
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Figure 3.2.3: (A): Sequencing chromatogram of exon 12 of BBS5 gene showing 
insertion of T nucleotide in both alleles of affected son and in one allele of the mother. 
(B): Showing differences between wild type BBS5 protein (green) and mutant BBS5 
(red).  
3.2.2.4   Knockdown of BBS5 in Zebrafish: 
 In order to establish a developmental model for BBS5, we explored genetic knockdown 
in an animal model. Using zebrafish (ZF) embryos, morpholino antisense 
oligonucleotides (MO) were designed to modify gene expression of BBS5 (see materials 
and methods chapter, section 2.9.2). In general, MOs were used to block translation of a 
targeted protein or to target a predicted intron-exon boundary, thus modifying pre-
mRNA splicing.  
Using microinjection techniques in single cell stage embryos, 6ng of the morpholino 
oligo (MO) targeted to the translational initiation site of BBS5 gene was injected into 
zebrafish embryos. This amount of morpholino injected was chosen after performing 
titration experiments, because high dose of morpholino (12ng) lead to death of all 
embryos and low dose (3ng) showed no effect (data not shown). Six hours post 
morpholino injection; embryos were inspected under a light microscope to remove 
death embryos (as a results of poor egg quality). 10 hours embryos were counted and 
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dead embryos were removed.   By 48 hour post fertilization (hpf), morphant embryos 
displayed a typical ciliopathy phenotype with body axis curvature, cardiac 
abnormalities (including situs inversus) and pronephric duct dilatation as shown in 
Figure 3.2.4. Phenotypes were classified as mild, moderate and severe using criteria 
(described in the materials and methods chapter; section 2.9.4) based on morphology 
and body axis changes seen at set time point during development (Leitch et al., 2008, 
Zaghloul et al., 2010, Huang et al., 2011). 
Injection of BBS5 MO (ATG blocking) alone showed phenotype in approximately 20% 
of fish (n=194). The main phenotypes seen were severe and moderate boxy axis 
curvature and cardiac anomalies (Figure 3.2.4). 
Figure 3.2.4: Zebrafish displayed a ciliopathy phenotype at 72 hpf following injection 
with BBS5 morpholino. Arrow shows 3 ears instead of 2 in the zebrafish as an 
indication of BBS phenotype in zebrafish. 
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In order to mimic the novel human BBS5 mutation co-injection of MO with mutated 
BBS5 mRNA (c.966insT) (see Figure 2.4 B) showed dysmorphic phenotype in 33% of 
fish embryos (n=78) while the co-injection of MO with wild type BBS5 mRNA to 
rescue the phenotype, showed the phenotype in approximately 5% of fish (n=103) 
(Figure 3.2.5).  These results confirm the pathogenicity of the (c.966insT) BBS5 
mutation that led to BBS phenotype in the patients. Using the GraphPad Prism software, 
Chi-square analysis showed significant differences in the proportion of fish exhibiting 
phenotypes between groups.  
Chi-square analysis was used to compare the effects of treatment upon phenotype of the 
fish as shown in Table (3.2.5). 
In order to compare the groups; three contingency tables were designed. In the first 
table a comparison of the treatment of fish with BBS5 ATG MO alone and MO + wild 
type rescue mRNA showed a significant difference in the phenotype of fish (p = 0.009).  
In the second table, a comparison of the treatment of fish with MO alone and MO + 
mutant mRNA was performed. There is no significant difference between these two 
categories (p = 0.2283), indicating pathogenicity of the mutant mRNA. The third table 
compares the treatment of fish with MO + wild type rescue mRNA and MO + mutant 
mRNA. This group showed significance difference between these two categories (p = 
0.0002) again implicating that the mutant BBS5 mRNA produced a disease phenotype 
in this model system. 
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Figure 3.2.5: Analysis of morphant phenotypes and rescue with co-injection with wild-
type or mutant BBS5 RNA. 
 
 Treatment 
Wild Type 
Phenotype (n) 
Affected 
Phenotype (n) 
P value 
Significan
ce 
BBS5 MO vs. 82 18 0.009 Yes 
BBS5 MO + WT rescue 
mRNA 
94 6     
          
BBS5 MO vs. 82 18 0.2283 No 
BBS5 MO + MUT  mRNA 75 25     
          
BBS5 MO + WT rescue 
mRNA vs. 
94 6 0.0002 Yes 
BBS5 MO + MUT mRNA 75 25     
 
Table 3.2.5: Chi-square analysis of comparing the effects of treatment upon phenotype 
of the fish 
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3.2.2.5   Transfection of HEK293 with BBS5: 
Wild type and mutant BBS5 were transfected in HEK293 to assess the pathogenicity of 
the mutation detected (c.966insT) at cellular level (see Figure 2.4 D & E) . It is reported 
that BBS proteins localize to the basal body of ciliated cells (Fan et al., 2004) and BBS 
is caused by defect at the basal body of ciliated cells (Ansley et al., 2003). 
To detect the  localization of BBS5 protein and to determine the effect of mutation, we 
transfected a construct encoding a green fluorescent protein(GFP)-tagged version of the 
protein into HEK293 cell line. Localization of  GFP-tagged WT BBS5 protein (green) 
in HEK293 cells shows presence at the basal body, as indicated by colocalization with 
acetylated tubulin and pericentrin in red as shown in Figure 3.2.6. Transfection of the 
mutant BBS5 mRNA (containing the c.966insT mutation) in BBS5 had an observable 
effect on  the localisation of BBS5 (Figure 3.2.6). The cellualar localisation of the 
mutated BBS5 appeared to be more intracellular and difuse and the colocalation of 
BBS5 with pericentrin was lost (Figure 3.2.6). 
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Figure 3.2.6: Comparison of wild type and mutant BBS5 localization in HEK293 cells. 
(A) Wild type (WT) BBS5-GFP colocalizes with pericentrin at centrosomes. (B) WT 
BBS5-GFP colocalizes with pericentrin at the centrosomes in a cell undergoing mitosis. 
(C & D) Mutant (Mut) BBS5-GFP is distributed diffusely throughout the cell and fails 
to colocalize with the centrosomal marker pericentrin. 
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3.2.3 Discussion 
The identification of mutations causing BBS is challenging because of genetic 
heterogenity of BBS. There are mutliple genes implicated and evidence of oligogencitiy 
is strong. The oligogencity in reported with BBS however was not observed in a cohort 
of BBS pateints from Saudi Arabia (Abu-Safieh et al., 2012). 
Homozygosity mapping remains a robust approach that is highly suited for genetically 
heterogeneous autosomal recessive disorders in populations in which consanguinity is 
prevalent. Using genchip platforms of single nucleotide polymorphisms (SNP) helped 
in advancing homozygosity mapping and made it easier by saving time and resources. 
By homozygosity mapping we targetted a region containing BBS5,  rather than 
screening all 16 genes causing BBS.  Phenotype-genotype correlation is very poor in 
BBS and this is evident in our case. In the original BBS5 gene discovery paper (Nachury 
et al., 2007) there was no clinical phenotype properly reported. Although this study 
identified a mutation in BBS5, the phenotype resemble reported phenotypes in others 
from same population who had mutations in BBS1, BBS3, and BBS4 (Abu Safieh et al., 
2010). This is expected because all BBS proteins localized primarily to the basal body 
of mammalian cells. BBS proteins regulate proteasome function in addition to the 
transport of inversin from the basal body into the cytoplasm(Zaghloul and Katsanis, 
2009).   
All three of the affected patients had hypothyroidism and it is not clear if this is related 
directly to the BBS5 mutation. Congenital hypothyroidism is a condition that affects 
infants from birth and results from a partial or complete loss of thyroid function. Most 
cases of congenital hypothyroidism are sporadic. It is estimated that 15 to 20 percent of 
cases are inherited in an autosomal recessive fashion. Mutations in the DUOX2, 
SLC5A5, TG, TPO, and TSHB genes prevent or reduce the production of thyroid 
hormones, even though the thyroid gland is present (http://ghr.nlm.nih.gov). Performing 
homozygosity mapping by decent in all three affected patients showed no homozygosity 
in the region of these genes, which may indicate other causes of hypothyroidism in this 
family. It would be worth sequencing all congenital hypothyroidism genes to rule out a 
compound heterozygous mutation in the family. 
BBS5 mutations are a minor contributor to BBS as only 2% of families from various 
ethnic backgrounds harbor BBS5 mutations (Li et al., 2004). Of 17 reported pathogenic 
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mutations in BBS5 gene, four of them reported in Arabs (Hjortshoj et al., 2008, Chen et 
al., 2011). The type of mutation identified (c.966insT) is unique because this frameshift 
resulted in peptide elongation and such mutation never been reported in BBS genes to 
date. Unfortunately, due to only genomic DNA being available for this family, our 
options to investigate this elongated BBS5 protein by using mRNA and Western blot 
studies are limited. 
A molecular diagnostic test covering all 16 known BBS genes is important to confirm 
clinical diagnosis although it will not affect treatment modalities. The predictive power 
of each genotype will remain limited until the genetic basis of the phenotypic variability 
is understood (Zaghloul and Katsanis, 2009). At present, molecular diagnosis using 
whole exome sequencing or ciliopathy genes array is amenable at low cost rate in 
comparison to Sanger sequencing of all 16 BBS genes. These technologies offer 
extensive information that may complicate diagnosis of the disease at time being.  
Although this is not the first time of modeling BBS5 mutation in zebrafish, others (Yen 
et al., 2006) have not described the phenotype of morphant in detail. By using zebrafish 
to investigate the function of the mutated BBS5 gene in BBS syndrome, we have helped 
to characterize the function of this protein in embryogenesis. The advantages of  using 
zebrafish for modeling human disease include the use of a vertebrate that shares many 
developmental processes and anatomical features with humans and the assaying of a 
physiologically relevant phenotype of known significance to the syndrome in humans 
(Zaghloul et al., 2010). In order to determine whether the BBS5 mutation had a 
dominant negative affect, further experiments would be required. It would be 
interesting, for example, to see the effect of injecting mutant BBS5 mRNA alone, to see 
whether this overrides (in a dominant negative manner) the wild type BBS5 mRNA. It 
would also be interesting to determine the expression pattern of BBS5 in zebrafish 
embryos to try and explain the multi system effects that were seen in the BBS5 MO 
injected fish.  
At cellular level genes that are mutated in ciliopathies, can affect ciliary signalling in 
different ways: through changes in cilia structure; in targeting signaling molecules 
appropriately; or at the level of the sensory and/or signaling molecules (Bettencourt-
Dias et al., 2011) . It is known that BBS5 localized to basal bodies just beneath the cilia 
(Li et al., 2004).    The BBSome, associates with the GDP/GTP exchange factor Rab8, 
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which allows for vesicle trafficking to the base of the cilium (Nachury et al., 2007). We 
were limited in not having cell line of affected individuals to use BBS5 antibodies to 
help in localizing wild type and mutant BBS5 proteins in the cell by 
immunohistochemistry. 
Mislocalization of mutated BBS5 protein was confirmed by transfecting HEK293 cell 
line. Mislocalization also observed in the the dominant-negative mutation L327P in 
BBS4 gene in post mitotic IMCD3 cells (Zaghloul et al., 2010). There are no known 
ciliary or centrsomal targetting motifs within BBS5, however our data suggests that 
such a motif may be within the C-terminus of the protein beyond amino acid 322. 
Further experiments mutating each residue in turn (322-341 amino acid residues of 
BBS5) at the C-terminus would help identify such a motif. An alternative strategy 
would be to engineer a series of 3’-terminal tagged mutants, with a varying severity of 
truncation  to identify the precise region of any putative localisation signal. 
In conclusion we describe a family with clinical features of BBS, together with a novel 
mutation in BBS5. Modeling this disease in zebrafish mimics the human disease, and 
pathogencity of the novel BBS5 mutation is demonstrated by mislocalisation in renal 
epithelial cells. 
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Chapter 3: RESULTS 
3.3 A New Syndrome of Autosomal Recessive Distal Renal Acidosis 
associated with Nephrocalcinosis 
3.3.1   Introduction 
The kidney maintains systemic acid-base homeostasis through proximal tubular 
reabsorption of filtered bicarbonate (HCO3−), and excretion of the protons (H+) by the 
alpha intercalated cells of the collecting duct. Impairment of either process produces a 
phenotype known as renal tubular acidosis (RTA)(Alper, 2010). RTA is a clinical 
syndrome secondary to this accumulation of acid in the body. A clue to diagnosis is a 
failure of the kidneys to appropriately acidify the urine. There are four types of RTA, 
and these may have different clinical syndromes and different inherited and acquired 
causes (Katzir et al., 2008). These are outlined briefly below. 
Type 1 distal RTA (dRTA) is characterized by a failure of acid secretion by the alpha 
intercalated cells of the cortical collecting duct of the distal nephron. 
Type 2 proximal RTA (pRTA) is caused by a failure of the proximal tubular cells to 
reabsorb filtered bicarbonate from the urine, leading to urinary bicarbonate wasting and 
subsequent acidemia.  
Type 3 RTA is a combined proximal and distal RTA in which a reduction in proximal 
tubular reclamation of filtered bicarbonate is combined with a disturbance in distal 
tubular mechanism of maximally acidifying the urine. 
Type 4 RTA is associated with a mild (normal anion gap) metabolic acidosis due to 
either to a deficiency of aldosterone, or to a tubular resistance to its effects. Table 3.3.1 
summarizes the clinical features of type 1, 2, and 4 (type 3 is usually excluded from 
modern classifications). 
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Type Location Metabolic Acidosis Potassium disturbance Nephrocalcinosis Pathophysiology 
Type 1 Distal tubule Yes (severe) Hypokalemia Common 
Failure of H+ secretion by the α 
intercalated cells 
Type 2 Proximal tubule yes  Hypokalemia uncommon 
Failed HCO3− reabsorption from the 
urine by the proximal tubular cells 
Type 4 Adrenal Mild when present Hyperkalemia uncommon 
Deficiency of aldosterone, or a 
resistance to its effects, i.e. 
hypoaldosteronism/pseudohypoaldoster
onism (commonly found in diabetes 
mellitus patients) 
 
Table 3.3.1: Renal Tubular Acidosis types and clinical features 
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Causes of RTA generally can be classified as inherited or acquired RTA. Acquired 
forms of RTA can develop quite commonly and may be secondary to autoimmune 
diseases (e.g. Sjogren’s syndrome, systemic lupus erythematosus (SLE), and 
thyroiditis), and drugs or toxins (e.g. amphotericin B, toluene inhalation). 
Inherited causes of both proximal and distal RTA have been reported. Proximal RTA is 
often seemed with disorders that result in a generalized proximal tubular dysfunction, 
such as cystinosis. dRTA is rarer and there are three main types: (a) autosomal 
dominant dRTA (the commonest form), (b) autosomal recessive dRTA with 
sensorineural deafness, (c) and autosomal recessive dRTA without or with mild 
sensorineural deafness (Laing et al., 2005).  Genetic causes of RTA include the 
following genes: SCL4A1(Devonald et al., 2003), ATP6V1B1(Karet et al., 1999b), 
ATP6V0A4 (Karet et al., 1999a), SLC4A4 (Igarashi et al., 1999), and CA2 (Sly et al., 
1983). Mutations in these genes may cause a spectrum of proximal and distal RTA. 
Table 3.3.2 represents a summary of the inherited renal tubular acidoses. 
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Type of RTA Inheritance Age at Presentation Gene(s) Protein 
Distal (Type 1) Dominant Older/adult SCL4A1 AE1 
  
Recessive Childhood SCL4A1 AE1 
  
Recessive with early onset 
hearing loss 
Infancy/childhood ATP6V1B1 B1 subunit of H+-ATPase 
  
Recessive with later onset 
hearing loss 
Infancy/childhood ATP6V0A4 a4 subunit of  H+-ATPase 
Proximal (Type 2) 
Recessive with ocular 
abnormalities 
Infancy SLC4A4 NBC1 
Combined proximal and 
distal (Type 3) 
Recessive with osteopetrosis Infancy/childhood CA2 CA II 
 
Table 3.3.2: Summary of the Inherited Renal Tubular Acidoses 
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Both dominant and recessive dRTA commonly result in bone diseases and 
nephrocalcinosis (NC). 
Nephrocalcinosis (deposition of calcium in the kidney) is an aetiologically 
heterogeneous disorder associated with an increase in the calcium content of the 
kidneys with underlying complex pathology. It is often seen in premature infants as a 
complication of various renal disorders or metabolic disturbances or as a consequence 
of loop diuretics. Nephrocalcinosis is related to, but not the same as, kidney stones 
(nephrolithiasis). In general any disorder that leads to high levels of calcium in the 
blood or urine may lead to nephrocalcinosis. Inherited conditions that can cause 
nephrocalcinosis include: Bartter’s syndrome (Cumming and Ohlsson, 1984), other 
genetic causes of hypercalciria including mutations of CLDN16 (Simon et al., 1999) and 
CLDN19 (Konrad et al., 2006) genes, familial hypomagnesemia (Praga et al., 1995), 
primary hyperoxaluria (Morris et al., 1982), and inherited renal tubular acidosis.  
 
A new autosomal recessive syndrome with the constellation of distal renal tubular 
acidosis, small kidneys, nephrocalcinosis, neurobehavioral impairment, short stature, 
and distinctive facial features was recently described in a first degree cousin marriage in 
Saudi family(Faqeih et al., 2007). It was suggested that the syndrome is likely to be of 
autosomal recessive inheritance based on similarly affected siblings from both sexes 
associated with parental consanguinity.  We initiated a molecular study to identify the 
gene variants that may be underlying the syndrome.   
 
3.3.2   Results 
3.3.2.1   Family Data 
This large family consisted of parents who are phenotypically normal. The parents were 
first cousins from Saudi Arabia with four affected and seven unaffected siblings (2 of 
whom are not included in this study) (Figure 3.3.1).  
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Figure 3.3.1: Family pedigree of the family (F2) with new autosomal recessive dRTA 
and NC. Squares indicate male family members, circles female family members; solid 
symbols indicate affected persons, circles and squares with dots indicate likely carriers, 
and double horizontal bars indicate consanguinity. Roman numbers underneath circles 
and squares indicate the sibling number. Arrows indicate individuals with available 
DNA. 
In addition, one pregnancy ended at term with a male baby (IV: 7) with severe hydrops 
and renal failure who died at 1 week of life (further data is not available). There were no 
similar clinical cases reported on either side of the family (following questioning of 
known close relatives). Clinical presentations were described fully in the original paper 
(Faqeih et al., 2007). The major central nervous system (CNS) and renal abnormalities 
found in the affected patients are summarized in Table 3.3.3. 
Clinical/laboratory finding Patient 1 Patient 2 Patient 3 Patient 4 
Short stature yes yes yes yes 
CNS abnormalities         
Ventriculomegally yes yes yes yes 
Abnormal myelination yes yes yes yes 
Renal abnormalities         
Small kidneys yes yes yes yes 
Proteinuria yes yes yes yes 
Cortical hyper-echogenicity yes yes yes yes 
Medullary nephrocalcinosis yes yes yes no 
Poor cortico-medullary differentiation yes yes yes yes 
Metabolic acidosis and RTA yes yes yes yes 
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Table 3.3.3: Summary of major CNS and renal abnormalities in the family F2 
 
The family was screened first by direct sequencing for CA2 and ATP6V1B1 genes, both 
genes represent candidate genetic causes of renal tubular acidosis and CA2 mutation 
(c.232+1G>A) is common in Saudi population. Sequencing revealed no mutations in 
either of these genes. Other genes that cause RTA including SLC4A1 and ATP6V0A4 
were screened lately and no mutations were detected.  
 
3.3.2.2   Homozygosity Mapping 
Following a hypothesis of inheritance by descent and to identify a novel gene locus as 
the cause of this new syndrome, we carried out a genome wide linkage search using 
Affymetrix GeneChip® Human Mapping 250K Sty Arrays according to the 
manufacturer’s protocol (http://www.affymetrix.com). We looked for regions with 
informative SNPs that were homozygous for the same allele for the affected children 
and heterozygous for the parents, and heterozygous or homozygous for the opposite 
allele for the unaffected individuals. A region of homozygosity in chromosome 2 was 
identified in four affected using CNAG (Version 2.0) software. To rule out large 
chromosomal abnormalities and to confirm our findings suggesting a region of 
homozygosity in chromosome 2 we used CytoScan arrays on all family members as 
described in the methods and materials chapter. From this scan the primary data was 
analyzed using Chromosome Analysis Suite (ChAS) software. These results did not 
detect any chromosomal abnormalities and the region of homozygosity was confirmed 
at the same region of chromosome 2 between genes TSGA10 and ST6GAL2 at physical 
map position Chr2: 99688169-107503563. Figure 3.3.2 (A&B) represents the region of 
homozygosity using two different analysis algorithms, CNAG2 versus ChAS2.   
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Figure 3.3.2:  Homozygosity mapping using two comparable approaches  
(A): This is a screen grab of CNAG2 software for chromosome 2.   The arrow indicates 
shared homozygosity regions (shown in violet) on chromosome 2 between all 4 affected 
patients of the family using 250K chip array. Affected family members are marked IV: 
3, 4, 8, 9 respectively. 
(B): A screen grab of ChAS2 software for chromosome 2. Family members are 
annotated as in A. The arrow between 2 lines indicates shared homozygosity region in 
chromosome 2 between all 4 affected patients of the family using CytoScan chip array. 
Pink color indicates genes. Cytogenetic map is shown graphically map below. 
 
3.3.2.3   Linkage Analysis and LOD Score Calculation 
To confirm the region of homozygosity identified on chromosome 2 in parametric 
values, a LOD score was calculated with the easyLINKAGE-Plus software using the 
raw Axiom SNP data in all four affected, parents and 5 unaffected individuals (n=11). 
In order to perform this, the numbers of SNP calls for each patient were first reduced by 
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the software program based on  (i) informative SNPs (heterozygous SNPs are 
informative for linkage analysis therefore SNPs that are always homozygous for one 
allele in all typed samples were removed (equal to 285114 SNPs)), (ii) Mendelian error 
rates (e.g. genotyping errors due to non -specificity of experimental assay, inappropriate 
allele calling, or simply random assay instability; these errors were excluded (46 
SNPs)), and (iii) genotype call rate (e.g. any SNP with a genotyping call rate of less 
than 80% was excluded (0 SNPs)). The net number of SNPs used to calculate the LOD 
score were 268293 SNPs per sample. Using a disease allele frequency of 0.001 the 
GENEHUNTER program was used to calculate a multipoint parametric linkage analysis 
LOD score in an autosomal recessive pedigree model. The program was run at 1 marker 
every 0.1000 cM.  The highest LOD score obtained was 3.37 at the same region of 
homozygosity, located within the chromosome 2 locus (Figure 3.3.3). LOD score 
results showed peaks at other loci (chromosomes: 6 and 11). The highest LOD score at 
chromosome 6 was 2.9 and 2.77 at chromosome 11. Haplotypes results of all three 
chromosomes 2, 6, and 11 are presented in Table (3.3.4). 
 
Table 3.3.4: Haplotypes of regions of chromosomes 2, 6 and 11 with high LOD score in 
the F2 family. Red color indicates genotypes in all 4 affected, yellow in parents, and 
green in 5 unaffected siblings. 
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Figure 3.3.3:  Graphical plots of LOD scores result from easyLINKAGE Plus software 
of the family F2 with new autosomal dRTA and NC. The y axis indicates the LOD 
score value, whilst the x axis shows chromosomes 2, 6 and 11.  
  
Homozygosity was not detected in chromosome 11 using the homozygosity mapping 
approaches and this is may be explained by SNP density and small homozygosity 
region. Chromosome 6 haplotype may indicate compound heterozygous mutation in the 
family. 
 
Because both homozygosity mapping and LOD score analysis approaches determined 
same region on chromosome 2 that had highest LOD score obtained 3.37 we focused 
initially on chromosome 2 locus. 
The Chromosome 2 region falls between the SNPs (rs4851019) and (rs920217) 
respectively. The physical map for the region is Chr2: 102636083-105363180 using 
UCSC genome browser hg18 assembly. The region contains 20 known coding and 
hypothetical genes (Figure 3.3.4). 
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Figure 3.3.4: Screenshot of UCSC genome browser hg18 of chromosome 2 showing the 
region of homozygosity mapping and linkage analysis results. All coding and 
hypothetical genes in the region are shown. 
 
3.3.2.4   Candidate Gene Sequencing 
Using these annotated genes within the Chromosome 2 putative locus as “candidate 
genes” we attempted to detect the mutated gene by exon PCR, followed by direct 
sequencing.  
All genes in the region, known coding and hypothetical genes (Table 3.3.5) according to 
UCSC genome browser hg18 assembly were screened by direct sequencing of PCR 
products. All four affected patients, their parents, and one unaffected member of the 
family together with a normal DNA control (from an ethnically matched control) were 
sequenced for all 20 genes (a total of 148 amplicons per sample).  
Primer-3 software for oligonucleotide primer design was used to design exons and 
intron boundaries of genes. Oligonucleotide primers are listed Appendix A. These 
oligonucleotide primers were amplified by PCR. DNA sequencing was performed on 
one strand. Sequencing data was analyzed using SeqMan II software 6.1 (DNAStar).  
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Screening all of the annotated genes in the region introduced a new interval between the 
SLC9A4 gene and the BC038566 hypothetical gene, where one of the affected 
individuals was heterozygous for SNPs in both genes. The new physical map position 
Chr2: 103,236,166 - 106,015,68 is shown in Table 3.3.5. However, no mutations were 
detected within the coding sequence of the 20 genes (known and hypothetical) screened 
(data not shown). In addition, promoters regions of SLC9A2 and POU3F3 genes were 
sequenced given these were strong candidates for a renal phenotype. However these 
regions were negative for mutations (data not shown). 
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Gene Physical position Status of Gene 
Sequencing results 
on affected 
Tissues of expression MGI knockout mouse results 
SLC9A4 103,089,762-103,150,431 Coding Gene Heterozygous     
SLC9A2 103,236,166-103,327,809 Coding Gene Homozygous 
Colon, Testis, Kidney, 
Brain 
Gastric acid secretion is impaired in 
homozygous mutant mice 
MFSD9 103,333,666-103,353,337 Coding Gene Homozygous     
TMEM182 103,378,490-103,434,138 Coding Gene Homozygous Heart, Bone Marrow   
AK054856 103,353,394-103,432,398 mRNA Sequence Homozygous     
AK296254 104,995,308-105,024,790 mRNA Sequence Homozygous     
LOC150568 105,050,805-105,129,215 non-coding RNA Homozygous     
AX746619 105,363,095-105,372,213 non-coding RNA Homozygous     
AK096621 105,363,098-105,374,177 mRNA Sequence Homozygous     
AK096498 105,421,977-105,467,916 mRNA Sequence Homozygous     
POU3F3 105,471,969-105,473,471 Coding Gene Homozygous Kidney, Brain 
Homozygous mutation of this gene 
results in death within 36 hours after 
birth 
AK095498 105,481,955-105,488,840 mRNA Sequence Homozygous     
MRPS9 105,654,483-105,716,418 Coding Gene Homozygous Kidney, Brain   
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Gene Physical position Status of Gene 
Sequencing results 
on affected 
Tissues of expression MGI knockout mouse results 
GPR45 105,858,200-105,859,924 Coding Gene Homozygous     
LOC644617 105,880,847-105,882,690 mRNA Sequence Homozygous     
TGFBRAP1 105,883,540-105,946,148 Coding Gene Homozygous Thymus, Kidney, Brain   
C2ORF49 105,954,013-105,961,984 Coding Gene Homozygous Bone, Kidney, Brain   
FHL2 105,977,283-106,015,681 Coding Gene Homozygous Heart, Kidney, Brain 
Mice homozygous for a targeted null 
mutation exhibit no discernable 
phenotype; mice are viable and fertile 
with normal cardiac development and 
physiology 
BC038566 106,209,554-106,227,016 mRNA Sequence Heterozygous     
NCK2B 106,471,502-106,509,632 Coding Gene Heterozygous     
 
Table 3.3.5: Summary of genes sequenced, results of sequencing, tissue of gene expression, and knockout mouse model. 
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Higher density mapping Affymetrix GeneChip® Human Mapping 6.0K was employed 
to detect other smaller regions of homozygosity, in part because of the spurious peaks 
obtained from the LOD score results. Running this raw data through Genotyping 
Console (Version 3.0.1) software confirmed that, the region on chromosome 2 was the 
only region to share homozygosity between the 4 affected siblings. Figure 3.3.5 shows 
homozygosity results of SNP 6.0 arrays for all affected siblings. These results 
confirmed that extra LOD scores peaks in the genome were likely to be false positives 
and that the region of chromosome 2 remained the putative locus. 
 
Figure 3.3.5: A Screenshot of Genotyping Console (Version 3.0.1) software for 
chromosome 2 using SNP 6.0 arrays. Homozygosity region of all 4 affected family 
members falls between two vertical black lines. No other homozygosity regions were 
detected in the genome. 
 
3.3.2.5   miRNA Sequencing 
Because no pathogenic mutations were detected in coding exons and exon-introns 
boundaries in the genes screened within the Chromosome 2 locus, we decided to 
sequence all miRNA in the new interval of homozygosity (Chr-2:103,236,166 - 
106,015,681). MicroRNA (miRNA) is a short ribonucleic acid (RNA) molecule found 
in eukaryotic cells. A microRNA molecule has very few nucleotides (an average of 22) 
compared with other RNAs. 
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miRNAs are post-transcriptional regulators that bind to complementary sequences on 
target messenger RNA transcripts (mRNAs), usually resulting in translational 
repression or target degradation and gene silencing. Using UCSC Genome Browser on 
Human Feb. 2009 (GRCh37/hg19) Assembly we found 16 miRNAs regulatory sites 
(Figure 3.3.6).  
 
 
 
Figure 3.3.6: Screenshot of UCSC genome browser hg19 of chromosome 2 showing the 
miRNA (green) in the region of homozygosity. UCSC genes (top) and RefSeq genes 
(bottom) are in blue. 
 
Primers were designed using Primer 3 software. Oligonucleotide primers are listed in 
Appendix A. These primers were amplified by PCR and direct sequencing was carried 
out. By sequencing all 16 miRNA no sequence variants were detected (Data not 
shown). Sequencing TGFBRAP1: miRNA-181:1; resulted in all 4 affected to be 
negative for rs70953504 (28bp deletion) while parents and other siblings vary between 
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homozygous and heterozygous for the SNP (Figure 3.3.7). The SNP was found in 1 out 
of six ethnically matched controls. 
 
Figure 3.3.7: Sequencing chromatogram of rs70953504 of TGFBRAP1: miRNA-181:1 
showing deletion of 28 nucleotides in both alleles of unaffected son. Both affected were 
negative for the deletion and mother had deletion in one allele (heterozygous). 
 
3.3.2.6   Gene Expression 
Assuming the mutation may be located in promoters regions or non-coding regions of 
genes, gene expression profiling for all known genes in the homozygous region of 
chromosome 2 was carried out. We performed real time quantitative PCR in order to 
attempt to measure gene expression.  
Whole blood samples from two affected individuals (IV-6 and IV-8), the father (III-2), 
and one unaffected (IV-5) were obtained following informed consent. Transformation 
of peripheral blood lymphocytes by EBV was performed using standard tissue culture 
techniques. After tissue growth, RNA was extracted from lymphoblast cultures then 
reverse transcribed to cDNA. The cDNA was then used in real time quantitative PCR 
(qPCR). Expression oligonucleotide primers for the following genes were designed 
using Primer3 software: SLC9A2, MFSD9, TMEM182, POU3F3, MRPS9 and 
TGFBRAP1.  GAPDH1 oligonucleotide primers were used as an endogenous control. 
Oligonucleotide primers are listed in Appendix A. Relative gene expression ∆∆CT 
identified no differences between gene expressions of affected versus others.  
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Because gene expression is tissue specific we considered preferentially expression of 
these genes and some of them may not expressed lymphocytes. The phenotype of 
disease within this family involves kidneys and brain. In order to assess renal 
expression, we obtained urine samples from the family; as some cells (proximal tubular 
cells and others) pass into the urine under normal physiological conditions(Sutherland 
and Bain, 1972). 
Urine samples from three affected individuals (IV-4, IV-6, and IV-8), Father (III-2), 
two unaffected individuals (IV-1 and IV-5) and urine sample from an ethnically 
matched normal control were obtained. The yield of RNA was little (around 0.3 µg) 
therefore we were able to test for three genes only: SLC9A2, POU3F3, and MRPS9. 
GAPDH expression was used as an internal control.  SLC9A2, POU3F3, and MRPS9 
are known to be expressed in kidney and brain tissues 
(http://bioinfo.wilmer.jhu.edu/tiger). We were limited to replicate the experiment results 
only once to confirm our findings. Results for genes expression are shown in Table 
3.3.6. There was no difference in expression of candidate gene SLC9A2 and POU3F3 in 
urine from father and affected, using GAPDH as an internal reference control. MRPS9 
results indicated increased expression but these results could not be replicated in the 
same affected sample nor be confirmed in other affected siblings.  
 
 
Table 3.3.6: Primary results of gene expression of MRPS9 gene in urine sample. The 
III-2 specimen (Father) and two specimens A and B from the affected (IV-4) were 
analyzed. Each specimen was amplified in triplicate (Labeled Sample1, 2, 3 
respectively) for MRPS9 and GAPDH genes. Induct results indicated that the expression 
of the gene in the affected is higher by 7.11 and 5.99 folds than normal. 
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Because no mutations were detected in chromosome 2 region, we looked at other 
regions with high LOD score (chromosomes 6 and 11). The region in chromosome 11 
contained one gene (OPCML gene) where no mutations were detected in the family. 
The region in chromosome 6 contained five candidate genes and sequencing these genes 
still in progress.  
3.3.3   Discussion 
We have had the opportunity to investigate at a molecular genetic level a possible new 
autosomal recessive disease described in the Saudi population. Our molecular genetics 
work confirmed a likely autosomal recessive inheritance of the disease by 
homozygosity mapping, and subsequently we explored both linkage analysis, and 
candidate gene screening. Homozygosity mapping and linkage analysis methods 
confirmed a putative novel locus of the disease in the family on Chromosome 2 by 
virtue of the family size and the number of affected individuals. LOD score results 
showed peaks at other loci (Chromosomes: 6 and 11). There are many factors can affect 
linkage analysis. These include disease allele penetrance, marker allele frequency, 
genotyping errors, and linkage heterogeneity. However, higher positive LOD scores and 
a larger number of them are expected around true rather than around false peaks (Hoh 
and Ott, 2000).  In addition, using high density SNP arrays for homozygosity mapping, 
none of the additional regions (outside of Chromosome 2) were revealed by using 
detailed homozygosity mapping. The physical map of the putative novel locus is Chr-
2:103,236,166 - 106,015,681, and the cytogenetic map reference 2q12.1. No renal 
phenotype has been associated with any gene mutations in this region, according to 
OMIM. Knockout mice of three genes in the region (SLC9A2, POU3F3, and FHL2) 
have shown variable phenotypes (Table 3.3.5) as described by the Mouse Genome 
Informatics (MGI). None of these phenotypes however, are similar to affected 
individuals of the family F2.  
Despite screening all known and hypothetical genes in the region by exon PCR, we 
were unable to determine mutated gene. On the other hand, exon PCR confirmed the 
region of homozygosity where all four affected shared the same genotypes at the region. 
Candidate gene screening covered only entire cDNA regions, and introns and promoter 
regions were not included. Development of Next Generation Sequencing (NGS) has 
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revealed the importance of deep intron mutations. There are a few reports describing 
lethality of intron mutations (Webb et al., 2012, Abu Safieh et al., 2010).  
The promoter regions of SLC9A2 and POU3F3 genes were fully sequenced and they 
were also negative for mutations or disease causing variants. The promoter regions of 
other candidate genes have not been studied yet.  
In addition sequencing of all the 16 miRNAs in the region revealed no pathogenic 
mutations. Results for rs70953504 in all affected confirmed once again the region of 
homozygosity. Profiling miRNA expression in the affected siblings could be achieved 
using commercially available miRNA RT-PCR kits. This is may help in detecting 
reduced miRNA expression as a mechanism of disease in this family.     
 The POU3F3 promoter region, a strong candidate gene based on murine model data 
(Castro et al., 2006), is a GC rich region (Sumiyama et al., 1996), and methylation 
studies of the region have not been performed. Methylation of DNA is a biochemical 
process that is important for normal development in eukaryotic species.  It occurs at 
cytosines residues within the sequence context of CpG islands (Bird, 1986). It is known 
that genes are not active at all times and DNA methylation is one of several 
mechanisms that cell use to control gene expression. Given the critical role of DNA 
methylation in gene expression and cell differentiation, it seems that errors in 
methylation could give rise to a number of lethal diseases such as Rett syndrome, which 
is caused by mutations in the gene encoding methyl-CpG-binding protein-2 (MECP2) 
(Amir et al., 1999) and Fragile-X syndrome where CGG repeat expansion at the 5′-
untranslated region and aberrant de novo methylation of the CpG island upstream of the 
gene can cause the disease (Kremer et al., 1991, Oberle et al., 1991).  Testing for gene 
expression of some of the candidate genes through real time qPCR was performed, but 
no clear results of abnormal gene expression were obtained. Gene expression is tissue 
specific and we were uncertain of expression of genes in B lymphocytes. The RNA was 
extracted from lymphoblast and the effect of EBV in genes tested unknown. From a 
technical point of view, real time qPCR has to be reproducible and a result has to be 
consistent. This was a difficult task with the limited amount of RNA extracted from the 
urine samples obtained in this study. The primary purpose of the gene expression 
experiment was to lead to a possibly defective gene, rather than identify the molecular 
cause. Gene expression usually used to prove consequences of molecular defect or in a 
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reverse manner to highlight the effect of the gene to help in identifying the molecular 
cause. 
Sequencing whole mRNAs of all genes in the region may help in identifying causative 
gene that lead to the disease in the family. Next generation sequencing (NGS) is another 
approach that could help in detecting mutated gene(s).  
In order to proceed with NGS, there are three options, Firstly sequencing the whole 
genome, secondly performing exome sequencing, which sequences the coding regions 
of the genome selectively, or thirdly targeted region sequencing (target region capture) 
by enriching specific region by microarray or solution hybridization based on probes 
designed according to the bases sequence of interested genomic regions. The region of 
homozygosity in Chromosome 2 is around 3 Mb and the third option would be the 
preferred option to try and solve genetically this family, because this is a focused and 
in-depth investigation on genetic variants in the region. Exome sequencing would not 
cover completely all coding exons in the genome and we already sequenced all known 
coding exons in the region but still valid options for other loci. 
 Given that NGS typically result in many changes of unknown significance, sequence 
variants will need confirmation. In such circumstances we can reduce such effort by 
sequencing a pooled sample of all four affected, and a pooled sample of both parents. 
Sequence variants can also be limited to the region of homozygosity already established 
in this study.  
In conclusion, using homozygosity mapping, we have been able to localize a small 
region on Chromosome 2 that represents a putative novel locus for a syndrome that 
results in dRTA and nephrocalcinosis in a large family of Saudi Arabian origin. Efforts 
to unravel the molecular cause of the disease in chromosome 2, 6, and 11 are in 
progress.  
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Chapter 3: RESULTS  
3.4 Bilateral Renal Agenesis 
3.4.1   Introduction 
Renal Agenesis (RA) or Potter’s syndrome is a congenital absence of one (unilateral) or 
both (bilateral) kidneys.  The kidneys develop between the 5th and 14th week of fetal 
development, and by the 14th week they are normally producing urine (Harewood et al., 
2010). Bilateral Renal Agenesis (BRA) belongs to a group of prenatally lethal renal 
diseases, including severe bilateral renal dysplasia, and severe obstructive uropathy. 
The incidence of BRA is approximately 1/10000 births (Sanna-Cherchi et al., 2007). 
Unilateral renal agenesis (URA) is more common 1/1000-2000 (Yalavarthy and Parikh, 
2003, Pohl et al., 2002) and is usually clinically silent.  BRA is often detected on fetal 
ultrasound because there will be a lack of amniotic fluid (oligohydramnios).  The 
common association between oligohydramnios and BRA often leads babies to have 
additional birth defects, including abnormalities of the urinary system, genitals, limbs, 
heart, and lungs. Approximately 40% of fetuses with bilateral renal agenesis will be 
stillborn, and if born alive, the baby will usually live only a few hours (Kelalis et al., 
1985). Currently, the precise causes of renal agenesis are not known. Studies have 
shown that unilateral and bilateral renal agenesis may be genetically related (Kerecuk et 
al., 2008). Several lines of evidence suggest a genetic contribution to the development 
of BRA and renal adysplasia. First, the incidence of BRA is increased in fetuses who 
have first degree relatives with congenital renal anomalies (Roodhooft et al., 1984, 
Bankier et al., 1985), Second, renal anomalies are associated with some autosomal 
recessive and dominantly inherited disorders. According to Winter-Barraitser 
Dysmorphology Database (London Medical Databases, London) there are 148 different 
syndrome entities associated with renal agenesis (Harewood et al., 2010). Third, animal 
genetic models have implicated many genes important for renal development (Bates, 
2000). Furthermore, human renal agenesis has been characterized as a multifactorial 
disorder with an apparent genetic contribution  (Yalavarthy and Parikh, 2003). Table 
3.4.1 (Modified from (Sanna-Cherchi et al., 2007)) lists principal genes targeted in mice 
leading to renal agenesis, hypoplasia, and dysplasia. 
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Gene 
Human 
homolog Kidney phenotype Reference 
Nuclear proteins/Transcription factors   
Foxd1 FOXD1 
Small, fused, undifferentiated 
kidneys Hatini et al., 1996 
Eya1 EYA1 Absent kidneys Johnson et al., 1999 
Emx2 EMX2 Absent kidneys Miyamoto et al., 1997 
Hoxa11/Hox
d11 
HOXA11/HOX
D11 Small or absent kidneys Davis et al.,1995 
Lhx1 LHX1 Absent kidneys 
Shawlot and 
Behringer, 1995 
Pax2 PAX2 Small or absent kidneys Torres et al., 195 
Sall1 SALL1 Absent kidneys 
Nishinakamura et 
al.,2001 
Pbx1 PBX1 Small or absent kidneys Schnabel et al., 2003 
Wt1 WT1 Absent kidneys Kreidberg et al., 1993 
Secreted factors/Other     
Bmp4 BMP4 
Altered ureteric bud (UB) 
branching Miyazaki et al.2000 
Bmp7 BMP7 Disrupted nephrogenesis Dudley et al., 1995 
Wnt4 WNT4 Undifferentiated kidneys Stark et al., 1994 
Gdnf GDNF 
Absent kidneys, severe 
dysgenesis Sanchez et al., 1996 
Receptors       
Ret RET 
Absent kidneys, severe 
dysgenesis 
Schuchardt et al., 
1994 
Fgfr1/Fgfr2 FGFR1/FGFR2 Absent kidneys Poladia et al., 2006 
Agtr2 AGTR2 
Multiple urinary tract 
malformations Nishimura et al.,1999 
Table 3.4.1: Genes targeted in mice leading to renal agenesis, hypoplasia, dysplasia 
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For the isolated, non-syndromic renal agenesis/hypoplasia and dysplasia, segregation 
studies have been performed (Sanna-Cherchi et al., 2007). Mutations in genes such as 
TCF2 (Bingham et al., 2000), PAX2 (Sanyanusin et al., 1995), EYA1 (Abdelhak et al., 
1997), SIX1 (Ruf et al., 2004b), SALL1(Kohlhase et al., 1998), RET (Skinner et al., 
2008), BMP4 and SIX2 (Weber et al., 2008) have been shown to be associated with 
renal agenesis or pediatric congenital anomalies of the kidney and urinary tract 
(CAKUT), which is a larger category of renal diseases including renal agenesis. Due to 
its complexity and association with other phenotypes, many genes are likely to play a 
role in renal agenesis. 
Medications and therapy for RA in addition to prevention by molecular testing could be 
improved by understanding its molecular genetics basis. 
Here we report identification of a putative novel gene causing BRA in a Saudi Arabian 
family. 
3.4.2 Results 
3.4.2.1   Family Data 
Two consanguineous families were recruited for the study. The first family (RA-FAM1) 
belongs to a large tribe in Saudi Arabia and consisted of two branches, labeled A and B 
(Figure 3.4.1). Branch A of the RA-FAM1 had visited Obstetrics and Gynecology 
(OB/GYN) clinic at KFSH&RC since 1991 presenting with a series of stillborn fetuses. 
Following ethical approval we were involved with this family from 2008. At that time 
we were able, following informed consent, to obtain DNA from family members RA-
FAM1_III:5 (unaffected mother) and RA-FAM1_IV:8 (a stillbirth fetus). In 2009 the 
DNA was obtained RA-FAM1_IV:9 (stillborn fetus). The DNA from RA-FAM1_III:4 
(unaffected father) and RA-FAM1_IV:6 and RA-FAM1_IV:7 (two healthy siblings) 
was also obtained, following informed consent. 
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Figure 3.4.1: Family pedigree of the family (RA-FAM1) with bilateral renal agenesis. 
Squares indicate male family members, circles female family members; solid symbols 
indicate affected persons, slashes deceased fetuses and double horizontal bars 
consanguinity. Roman numbers underneath circles and squares indicate the sibling 
number. Arrows indicate individuals where DNA is available. Individuals (III:4, III:5, 
IV:6, IV:7, IV:8 and IV:9) represent branch A of the family (circle in blue); whilst 
(III:10 and IV:4) represent branch B (circle in red). 
Branch B (the mother RA-FAM1_III:10 and stillbirth fetus RA-FAM1_IV:4, Figure 
3.4.1) of the family where referred to OB/GYN clinic at KFSH&RC in 2003. In 2010 
we obtained permission to use DNA from the mother (III:10) and a fibroblast culture 
from dead fetus (IV:4).  
A second family (RA-FAM2) was referred to OB/GYN clinic at KFSH&RC in 
December 2011 after initiation the study with the RA-FAM1. We were able to obtain 
DNA only from the affected dead fetus with bilateral renal agenesis and both parents. 
No healthy siblings available (Figure 3.4.2). 
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Figure 3.4.2: Pedigree of RA-FAM2. Arrows indicate individuals where DNA is 
available. SB indicates still birth fetuses.    
 
3.4.2.2   Clinical Presentation 
Branch A of the family RA-FAM1 lost a total of seven pregnancies with an antenatal 
ultrasound diagnosis of BRA together with absence of the bladder in association with 
oligohydramnios. Branch B of RA-FAM1 lost three pregnancies due to 
oligohydramnios with different features in each pregnancy. The stillborn fetuses had 
additional abnormalities including cleft palate, abnormal limbs, and small chest. 
Parents in both branches were healthy, and healthy siblings were present in both 
branches of the RA-FAM1 (Figure 3.4.1). The pedigree and clinical presentation are 
suggestive of autosomal recessive inheritance.  
RA-FAM2 lost three pregnancies in another regional hospital. RA-FAM2 was referred 
to our hospital when they presented with severe oligohydramnios in a fourth pregnancy.  
The antenatal ultrasound diagnosis revealed BRA with the absence of a bladder. Fetal 
blood sample together with the parent’s blood was collected for extraction. Both parents 
are healthy. Again, the presentation of disease and the pattern of inheritance suggest an 
autosomal recessive disorder (Figure 3.4.2). 
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3.4.2.3   Homozygosity mapping using 250K Arrays 
In order to try and define a novel disease locus for bilateral renal agenesis in these two 
families (RA-FAM1 and RA-FAM2) we initially performed homozygosity mapping, 
using DNA from branch A of RA-FAM1. We used Affymetrix GeneChip® Human 
Mapping 250K Sty Arrays to identify regions of homozygosity between the two 
affected family members (IV:8 and IV:9). Using CNAG2 software we were able to 
identify five regions of homozygosity; two regions on Chromosome 1((q21.3-q24.2) 
and (q32.2-q41) respectively), one region on Chromosomes 5 (q31.1-q33.1), and two 
regions on Chromosome 17 ((p13.2-p12) and (q11.2-q12) respectively (Figure 3.4.3).  
 
 
Figure 3.4.3: CNAG2 software analysis showing regions of homozygosity detected in 
branch A of RA-FAM1 using 250K chip. Arrows indicate regions of homozygosity in 
both affected. 
 
These regions failed to contain genes that were known to be involved in renal agenesis 
in humans or mice.  
Three possible candidate genes for renal agenesis were identified within these regions. 
These include fibroblast growth factor 1 (FGF1) (Jaye et al., 1986) and GDNF family 
receptor alpha 3 (GFRA3) (Baloh et al., 1998) on Chromosome 5 and transforming 
growth factor beta 2 (TGFB2) (Schlunegger and Grutter, 1992) on Chromosome 1. 
Direct sequencing (using exon PCR and Sanger sequencing, oligonucleotide primers 
sequences given in Appendix A) of these genes however, revealed no pathogenic 
mutations (Data not shown).  
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3.4.2.4   Homozygosity Mapping and Linkage Analysis using SNP 6.0K Arrays 
After obtaining DNA samples from branch B of family RA-FAM-1, we carried out 
additional homozygosity mapping using a higher density strategy. We employed 
Affymetrix GeneChip® Human Mapping 6.0K chip arrays in family members (affected 
members IV:8, IV:9, and IV:4 and unaffected members III:4, III:5, III:10, IV:6, and 
IV:7 ) in order to detect shared regions of homozygosity in all affected members. We 
also used data from 6.0K SNPs genotyping for the calculation of LOD score by linkage 
analysis. 
Homozygosity mapping in family RA-FAM1 revealed just one distinctive region shared 
by all three affected and abolished most of the homozygosity regions detected by 250K 
arrays. The region of homozygosity on Chromosome 1 had previously been detected 
using the more limited 250K arrays for two of the affected (IV:8 and IV:9) see Figure 
3.4.3. The confirmed region of homozygosity was located on the long arm of 
Chromosome 1 (q32.2-q41). The physical map position of the region is chr1: 
204,586,303-223,963,718 (Figure 3.4.4). 
 
 
Figure 3.4.4: A screenshot of Genotyping Console (version 3.0.1) software for 
chromosome 1 using SNP 6.0 arrays. Black arrows indicate shared homozygosity 
blocks in all three affected. Red block arrow indicates the cytogenetic locus. 
 
Chapter 3______________________________________________________Results 4 
 
118 
 
Linkage analysis was performed in order to confirm the locus of homozygosity by 
parametric analysis. Data from the 6.0K SNP genotyping arrays was handled and run 
using the easyLINKAGE-Plus software (see Materials and methods). Data from 7 
members of family RA-FAM1 (IV:4, IV:8, IV:9, IV:6, IV:7, III:4, III:5) was used for 
the analysis. The ALLEGRO program was run using a disease allele frequency of 0.001 
to calculate a multipoint parametric linkage analysis LOD score in an autosomal 
recessive pedigree model. The highest LOD score obtained equal to 2.65 on 
Chromosome 1 (Figure 3.4.5). The net SNPs number used for LOD score calculation 
was 10527 SNPs after removal of non-informative and Mendelian errors SNPs. The 
linkage interval falls between rs7542334 and rs12025220 that is equal to physical map 
position Chr1: 193,239,154 - 219,634,630. 
 
 
Figure 3.4.5: Graphical plots of LOD scores result from easyLINKAGE Plus software 
for the family with renal agenesis. The y axis indicates the LOD score value, whilst the 
x axis shows Chromosomes 1 through 22.  The arrow indicates the highest LOD score 
on Chromosome 1.   
 
Although the LOD score is not equal to 3 the value which indicates linkage, the score is 
high enough in the context of the number of affected (3) and the pedigree where the 
genetic background of one affected is not equal to that of the other two. Moreover, the 
large block of homozygosity in the same region support the linkage between the locus 
and disease causing gene. 
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3.4.2.5   Candidate gene screening 
The region of homozygosity and linkage analysis identified in family RA-FAM1 on 
Chromosome 1 was large and contained numerous genes. Screening all genes in the 
region (using exon PCR and Sanger sequencing) would be very costly and time 
consuming. In such a situation, there are several approaches that could be helpful. 
Firstly, using a next generation sequencing (NGS) approach could be employed to 
screen all genes in the region. Secondly a more selective screening of certain genes in 
the region could be carried out, based on their known or predicted function, 
transcription, and phenotype, aided by software such as GeneDistiller2 software 
(www.genedistiller.org). Another approach would be to combine data from families 
with a similar phenotype (e.g. family RA-FAM2). 
Initially, we adopted a selective screening of candidate genes. Using GeneDistiller2, 
searching for genes with a known involvement of renal/urinary system phenotype; ten 
genes in the Chromosome 1 region were proposed to be candidates. These genes were 
ADORA1, REN, KISS1, ESRRG, RASSF5, CD55, CR2, CR1L, FLVCR1, and TGFB2 
gene. The later (TGFB2) had already been sequenced, given its known role in renal 
development (see section 3.4.2.3). Of the remaining 9 genes, we directly sequenced the 
following genes REN, CR2, FLVCR1 and ESRRG. These genes looked like appropriate 
candidates, based on their known function and expression data. Defects in REN gene are 
a cause of renal tubular dysgenesis (RTD) [OMIM: 267430]. RTD is an autosomal 
recessive severe disorder of renal tubular development characterized by persistent fetal 
anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset 
oligohydramnios (the Potter phenotype) (Gribouval et al., 2005). Genetic variations in 
CR2 gene are associated with susceptibility to systemic lupus erythematosus type 9 
(SLEB9) (Wu et al., 2007). The FLVCR1 gene encodes a member of the major 
facilitator superfamily of transporter proteins. Defects in FLVCR1 are the cause of 
posterior column ataxia with retinitis pigmentosa (PCARP) (Rajadhyaksha et al., 2010).  
Estrogen-related receptor gamma (ESRRG) is an orphan receptor that acts as 
transcription activator in the absence of bound ligand. It is expressed at high level in 
fetal kidney and brain (Greschik et al., 2002). Direct sequencing of REN, CR2, FLVCR1 
and ESRRG genes did not identify any pathogenic mutations (data not shown). Because 
of emerging data on the ciliopathy gene CENPF, we also sequenced this gene in its 
entirety, as it falls in the Chromosome 1 region of homozygosity in family RA-FAM1 
but no mutation was detected.  
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In summary a total of 93 amplicons per sample were amplified and sequenced by 
screening REN, CR2, FLVCR1, ESRRG and CENPF genes. The region of homozygosity 
was confirmed in all the affected patients when screened for these genes. 
 
3.4.2.6   Homozygosity mapping using CytoScan arrays 
Given the lack of success in the candidate gene approach, another approach would be to 
utilize NGS (exome sequencing) to screen for all genes in the putative Chr1 locus. 
However, at this time we received DNA samples from family RA-FAM2, also with 
bilateral agenesis. Using DNA samples from family RA-FAM2 plus all three affected 
from family RA_FAM1, we carried out homozygosity mapping using CytoScan arrays. 
The CytoScan arrays were used to compare regions of homozygosity in all four affected 
(IV:8, IV:9 and IV:4 from family RA-FAM1 and IV:4 from family RA-FAM2 ) and to 
check for any  molecular karyotype abnormalities.  Data analysis by ChAS software 
reported no chromosomal aneuploidy in affected fetuses. The single affected in family 
RA-FAM2 (IV:4, Figure 3.4.2) shared with other three affected in family RA-FAM1 
(IV:8, IV:9, IV:4) the region of homozygosity previously identified on Chromosome 1 
(Figure 3.4.6). The shared region of homozygosity from family RA-FAM1 was reduced 
by combining data from the family RA-FAM2 affected member. This new region of 
homozygosity on Chromosome 1 contained only eight genes. These are: MIR205, 
CAMK1G, LAMB3, G0S2, HSD11B1, TRAF3IP3, C1orf74, and IRF6. 
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Figure 3.4.6: A screen grab of ChAS2 software for chromosome 1 for four affected in 
both families. Arrows indicate shared homozygosity region in chromosome 1 between 
all 4 affected patients of the two families using CytoScan chip array. Pink color 
indicates genes. Cytogenetic map is shown graphically map on right side. 
 
3.4.2.7   Exon PCR Sequencing 
Using these annotated genes (MIR205, CAMK1G, LAMB3, G0S2, HSD11B1, 
TRAF3IP3, C1orf74, and IRF6) within homozygosity region on Chr1 as “candidate 
genes” we attempted to detect the mutated gene by exon PCR, followed by direct 
Sanger sequencing. 
Primers for all eight genes were designed using Primer-3 software for oligonucleotide 
primer design (Primer sequences are given in Appendix A). The entire cDNA of all 
genes was amplified using DNA from III:4 of family RA-FAM1 (father), together with 
one affected and unaffected individual from family RA-FAM1 branch A (IV:8 and 
IV:6), and mother and affected from branch B of family RA-FAM1 (III:10 and IV:4) in 
addition to mother and affected (III:2 and IV:4) in family RA-FAM2. One ethnically 
matched normal control was included in addition. A total of 72 amplicons per sample 
were sequenced. Analysis of sequencing chromatograms from all genes using SeqMan 
and Mutation Surveyor® software resulted in the detection of a novel homozygous 
missense mutation in calcium/calmodulin-dependent protein kinase IG (CAMK1G) gene 
in affected members of family RA-FAM1. At nucleotide 619 (NM_020439.2) of the 
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cDNA of CAMK1G gene the wild type Guanine replaced by mutant Adenine 
(c.619G>A) predicting an amino acid change from Valine to Isoleucine at position 207 
(NP_065172.1) of the protein (p.V207I) as shown in Figure 3.4.7. The mutation was 
detected in two branches of family 1 and segregated in autosomal receive fashion where 
parents were heterozygous and all three affected were homozygous for the missense 
change. Unaffected siblings were heterozygous for the sequence variant. The mutation 
was confirmed by sequencing both directions in all family members. Unfortunately, no 
mutations were detected in family RA-FAM2. Although all affected in both families 
showed homozygosity, checking SNP haplotype results in chromosome 1 region where 
CAMK1G gene located revealed no allele sharing between both families (Table 3.4.2). 
We determined the frequency of the change c.619G>A in 190 ethnically matched 
normal controls from our population. This variant was not detected, suggesting that this 
gene may be a novel cause of renal agenesis. 
 
Figure 3.4.7: Sequencing chromatogram showing part of exon-7 of CAMK1G gene. 
Vertical line indicates position of nucleotide change. Arrows indicate homozygous 
change in 3 affected. Heterozygous parents and unaffected sibling denote R [G/A].    
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Table 3.4.2: SNP haplotype results for both families (RA-FAM1 and RA-FAM2) for the 
region in chromosome 1 that contained CAMK1G gene. All four affected from both 
families were highlighted by yellow. Genotypes in red indicate differences between two 
families.  
 
3.4.2.8   in silico analysis 
Because the change identified in family RA-FAM1 was novel and the fact that no 
pathogenic mutations have been reported before in the CAMK1G gene (according to 
HGMD (www.hgmd.org)) we performed bioinformatics analysis to verify the 
pathogenicity of the change.  
There are many software packages that can help in assessing the pathogenicity of new 
sequence variants. We used several programs including PolyPhen-2, SIFT, SNPs3D and 
Mutation Taster. The results summary of these in silico analyses are given in Table 
3.4.3. 
Using in silico analyses, all four programs used for the mutation analysis concurred that 
the amino acid change would be predicted to be a disease causing mutation. The amino 
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acid change from Valine to Isoleucine at position 207 was assessed for its possible 
effect on the structure and function of the CAMK1G protein. Conservation of wild type 
amino acid Valine among different species was tested using Mutation Taster program. 
The results showed the conservation of the amino acid Valine among 10 species as 
shown in Figure 3.4.8. Mutant protein features also assessed by Mutation Taster 
program where indicated that the protein has had protein kinase domain between amino 
acids 23 and 227 which is lost by the mutation. Also a helix structure between amino 
acid 198 and 214 is predicted to be lost because the changed amino acid falls in this 
region (Figure 3.4.8). 
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Gene UniProt # 
Nucleotide 
Change 
Amino 
Acid 
change               
PolyPhen2 
(Score) 
SIFT SNPS3D 
Mutation Taster  
(prediction value) 
Allele frequency in 
Saudi population 
Pathogenicity 
CAMK1G Q96NX5 c.619G>A p.V207I 
Probably 
damaging 
(1.00)
1
 
Damaging 
(0.04)
2
 
(-0.7)
3
 
Disease causing 
(0.999)
4
 
0 Yes 
 
Table 3.4.3: Summarized results of in silico analysis of CAMK1G variant c.619G>A. 
 
                                                 
1
 PolyPhen2 results range from 0-1, with highest score indicating the probability of damage of the mutation. 
2
 SIFT scores range from 0 to 1, where amino acid substitutions are scored and are deemed to be damaging if the score is ≤ 0.05, and tolerated if the score is > 0.05. 
3
 SNPs3D scoring follows the higher the score entropy is, the more tolerant a position is to a mutation. 
4
 Mutation Taster scores mutations from 0 to 1, where a value close to 1 indicates a high 'security' of the prediction.   
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Figure 3.4.8: A screen grab from Mutation Taster program showing conservation of the 
amino acid Valine at position 207 in CAMK1G gene among different species.  
 
At the protein structure level the protein homology/analogy recognition engine (Phyre2) 
program was used to check a comparison in structure and three dimensions 
configuration between wild type CAMK1G protein and mutant CAMK1G (p.V207I). 
Wild type and mutant proteins sequence of CAMK1G gene were uploaded. At three 
dimensions (3D) model of the two sequences resulted in a different configuration 
between wild type and mutant protein (p.V207I) as illustrated in Figure 3.4.9. In 
addition a helix structure between amino acids 198 and 214 was disrupted as predicted 
by Phyre2 program (Figure 3.4.10) in consistent with Mutation Taster prediction 
(Figure 3.4.8).  
 
Figure 3.4.9: 3D protein configuration of wild type CAMK1G (A) and mutant 
CAMK1G (B). 
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Figure 3.4.10: Part of protein structure of CAMK1G gene AA175-AA220. Arrow 
indicates amino acid change from Valine to Isoleucine in wild type (A) and in mutant 
(B). Green indicates helix. 
 
Information about CAMK1G gene interactions is scarce. CAMK1G interactions were 
searched for using the SNPsD3 website (http://www.snps3d.org). This identified groups 
of genes where interactions may be relevant. The first group consisted of known disease 
genes that included HMGCR (HMG-CoA reductase is the rate-limiting enzyme for 
cholesterol synthesis), LAMB3 (epidermolysis bullosa junctional Herlitz type disease), 
HSD11B1 (cortisone reductase deficiency [CRD]), and IRF6 (cause van der Woude 
syndrome and popliteal pterygium syndrome). The second group of genes predicted or 
known to interact with CAMK1G are those one with an unknown phenotype and 
included SLC16A1, HDAC4, CAMK1, CAMKK2, HDAC5, NEK2, and G0S2 as 
illustrated in Figure 3.4.11. 
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Figure 3.4.11: Illustration of CAMK1G gene interactions. Blue rectangles indicate 
known disease genes. Green rounded rectangles indicate genes of unknown phenotype. 
 
3.4.3   Discussion 
Using a large consanguineous family with renal agenesis and renal dysplasia we have 
identified a putative novel gene. A search for the disease causing gene used three 
integrated techniques, homozygosity mapping, linkage analysis and candidate gene 
screening. This led to the identification of CAMK1G gene as putative causative gene of 
bilateral renal agenesis in a single family.  This gene encodes a protein similar to 
calcium/calmodulin dependent protein kinase, however, its exact function is not known.  
A novel missense mutation c.619G>A (p.V207I) in the CAMK1G gene was found in a 
consanguineous family with three stillborn affected by BRA. The distinctive 
homozygosity region between all affected, a high LOD score, and confirmed 
homozygosity in all genes screened in the region in addition to finding a lethal mutation 
segregating in all family members supported our hypothesis of a novel disease locus on 
Chromosome 1 and highly rule out other loci. The region of homozygosity on 
Chromosome 1 was apparently reduced by the addition of data from an unrelated 
affected fetus from family RA-FAM2. However, this may have only been coincidental, 
as we were unable to detect the causative mutation in family RA-FAM2. In family RA-
FAM1 linkage analysis resulted in a LOD score less than 3 (LOD score ≥ 3 indicate 
linkage). This is expected because of the number of affected and genomic background 
of the three affected is not similar (grandmother of IV: 4 different than grandmother of 
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III: 13 and III: 14). We did not find a mutation in CAMK1G in family RA-FAM2. This 
may be because this family does not map to the disease locus, and contributed to the 
homozygosity mapping by chance especially no linkage analysis was performed for this 
family. Renal agenesis is likely to be heterogeneous disease and may be caused by a 
defect in many genes that code for cell structure or signaling pathways.    
Because of the frequent stillbirth rate of BRA infants, genes causing this severe disease 
have not been carefully studied in humans. The putative gene we have detected belongs 
to CAMK Ser/Thr protein kinase family and subfamily of CaMK by similarity 
(http://genome.ucsc.edu). The exact function of the gene is unknown and further studies 
will hopefully reveal the importance of the gene. In mice, renal agenesis is commonly 
found in animals lacking the genes for the tyrosine kinase receptor Ret, its co-receptor 
Gfra1, or the Gfra1 ligand Gdnf (Schuchardt et al., 1994, Pichel et al., 1996, Cacalano 
et al., 1998).  
However, in humans, the genes responsible for kidney development have remained 
elusive. Genes interacting with CAMK1G gene include IRF6 gene which can lead to the 
autosomal dominant van der Woude syndrome (VWS) (Kondo et al., 2002). The IRF6 
and CAMK1G genes are located nearby in terms of physical position at same 
homozygous region of Chromosome 1. De Medeiros and et al reported a novel mutation 
in IRF6 resulting in VWS-PPS spectrum disorder with renal aplasia (de Medeiros et al., 
2008). The main phenotype of VWS is cleft palate and this is seen in some of stillborn 
fetuses in family RA-FAM1. These data could support the hypothesis of interaction 
between these two genes in addition to other genes in the region such as HSD11B1 and 
LAMB3. 
Bioinformatics analyses are widely used for new sequence variants. Many molecular 
genetics approaches are enhance by bioinformatics analysis. Here, we used 
homozygosity mapping and linkage analysis software packages to aid us to identify a 
putative novel locus. Following the identification of sequence variant, mutation 
prediction software programs helped in identifying the change as pathogenic. Protein 
fold recognition software (Phyre2) also predicted a defect in mutant protein. 
The use of a gGene interactions predcition program helped in giving a very preliminary 
idea about the possible functions of the gene. It is important to note that all these in 
silico models are modest support for pathogenicity of any sequence variant and 
experimental confirmation will be required to determine in vivo effects. 
Chapter 3______________________________________________________Results 4 
 
130 
 
Further studies are required to determine CAMK1G gene function and the localization 
of the encoded protein.  
Gene expression may help in identifying the effect of the mutation on mRNA 
expression in developing renal tissues. Western blot analysis would be required to 
determine the effect of the missense mutation on peptide translation although this is not 
a truncating mutation. Localization of the protein in renal epithelial cells (for example) 
could be studied to better understanding of the function of the protein. Cells transfection 
with wild type and mutant CAMK1G may give some clues as to protein mislocalisation. 
Animal models are another approach that would highlight the effect of knockout gene 
and its phenotype. Interestingly, mice homozygous for a knock-out allele of CAMK1G 
exhibited impaired dendritogenesis (http://www.informatics.jax.org/). 
 
In conclusion, we described a putative new gene underlying bilateral renal agenesis in a 
consanguineous Saudi Arabian family. Further detailed analyses on the gene and its 
encoded protein will need to be conducted to confirm our findings at experimental level
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Chapter 4 
CONCLUDING DISCUSSION 
 
The human genome has around 22,000 genes and around 180,000 coding exons. There 
are at present 3500 known simple disease causing genes. There are 1800 genes with an 
unknown molecular basis, and 1900 further genes suspected to be Mendelian 
inheritance genes. This is points to the fact that there are more genes yet to be 
discovered and mechanisms of genes function yet to be investigated. It seems that our 
understanding of the genome is still at the beginning of reading letters and making basic 
sense of words. 
Our study demonstrates recent challenges in the field of genetics. Each chapter had its 
own challenge, from the mutation detection rate in monogenic genes causing nephrotic 
syndrome to variants of unknown significance in novel genes as in our families with 
renal agenesis. 
Because autosomal recessive (AR) diseases have strong genotype-phenotype 
correlations, the diagnostic approach of AR disease is a very powerful tool to manage 
and detect monogenic kidney disease. Our study investigating genes causing NS in the 
Saudi population was aimed to detect the frequency of mutations in known genes 
causing the disease. Seventeen mutations in 5 genes covered 47% of patients with NS. 
On the other hand, the 53% of patients who were negative for mutations in known NS 
genes are a potentially valuable cohort for the identification of new genes causing NS. 
A functional assay for investigating the novel BBS5 mutation employed an animal 
model, the zebrafish.  The morphant phenotype that was noted in the animal model as 
consequence of BBS5 knockdown resembled the human disease. Animal models are 
useful to generate a picture of the disease phenotype but still limited in explaining 
interaction mechanisms within the cell. On the other hand, in vitro cell line experiments 
can reveal molecular mechanisms but do not show the whole picture compared to that of 
a living organism. Functional assays should be an integral part of the investigation in all 
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genetics studies for better understanding of human genome interactions and 
mechanisms of disease. 
For the potentially novel cause of autosomal recessive distal tubular acidosis and 
nephrocalcinosis, we identified a putative locus. Finding the causative gene in this 
family remains a challenge. It is now clear that mutations within coding exons are not 
the only cause of human genetic diseases. Variants within regulatory elements such as 
promoters and enhancers, in addition to variants in introns may play a role in their 
pathogenicity. New generation sequencing (NGS) may overcome Sanger sequencing’s 
limitations and help to reveal the importance of variants outside coding regions. Other 
landmarks in the genome such as repetitive segments and methylated regions should be 
investigated as well, as they may contribute to our understanding of the genome.  
Proving the functional importance of a potentially novel missense mutation in a family 
with bilateral renal agenesis remains challenging.  This is now the case with many 
variants of unknown significance resulting from exome sequencing technology. The 
technology has added much genomic information that we are still unable to put it in 
context of genome function. Not only that, this new technology has diverted our 
attention of understanding gene function in vivo to bioinformatics software in order to 
handle huge data and predict the effect of defective genes. Trends of using in silico gene 
prediction software instead of in vivo experimentation is now expanding and this may 
affect our imagination to develop new in vivo assays that would help in our 
understanding of the genome.  
In spite of all the challenges mentioned before, this study establishes a solid basis for 
understanding some of the inherited kidney diseases in Saudi Arabia. The new findings 
include novel mutations in nephrotic syndrome genes and BBS genes. The study also 
identified a putative novel locus in a new autosomal recessive distal tubular acidosis and 
nephrocalcinosis syndrome, and a potential novel gene causing bilateral renal agenesis. 
These studies add valuable information to the scientific community and support other 
research to investigate more in renal disease in Saudi Arabia.
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Appendix A 
List of oligonucleotide primer sequences used in the thesis 
Chapter 3.1 Nephrotic Syndrome 
NPHS1       
NPHS1-
Fw_ex1&2 Ggacccagagaaagccagac 
NPHS1-
Rv_ex1&2 GGGGAGCCGGAAGTCAG 
NPHS1-
Fw_ex3&4 GATCAGAGCCTGAGACCCTC 
NPHS1-
Rv_ex3&4 TCAGGAACACACACCCTTCC 
NPHS1-Fw_ex5 TCCCCAGAATCTATCTTGCG NPHS1-Rv_ex5 GGTTCCCATGGGGAAAATTAG 
NPHS1-Fw_ex6-
7 GACTCCCCAAATTTCAGATG 
NPHS1-Rv_ex6-
7 AGCTCAGGACTGGCTCCC 
NPHS1-Fw_ex8 ACAGTGGGGTCTGGGAGC NPHS1-Rv_ex8 CCAGTAGGCATAATTTGGGG 
NPHS1-Fw_ex9 GGGCTGGTCTGTGAGAAATC NPHS1-Rv_ex9 CCCTTCCCTATCCACGAGTC 
NPHS1-
Fw_ex10-11 TAGCACGATGGATAGGGGTG 
NPHS1-
Rv_ex10-11 TGCCCAAGATTCTGAAGGAG 
NPHS1-Fw_ex12 CCAGTGGGCAGGGTAGG NPHS1-Rv_ex12 acctggctctgtccctcc 
NPHS1-
Fw_ex13-14 ggtggACGCAGACCAGG 
NPHS1-
Rv_ex13-14 AGACCCAAGGAGTAGTTTAGGG 
NPHS1-
Fw_ex15-16 Cctgtgcctgatctccaatc 
NPHS1-
Rv_ex15-16 GAGACTCCACAATGGGCAAG 
NPHS1-Fw_ex17 AAGACATCCCTCCCACCTG NPHS1-Rv_ex17 caagAAACCACAACCCCTTG 
NPHS1-
Fw_ex18-19 
GGGCAGTGATGGATCTGG 
NPHS1-
Rv_ex18-19 GACTCAGGGAGGGGAAGTG 
NPHS1-Fw_ex20 CAAGCATAAGTGGTTGGGTG NPHS1-Rv_ex20 ATCAGGGATGTGGGAATGG 
NPHS1-
Fw_ex21-22 GGGAAAACCTGGACAGAATC 
NPHS1-
Rv_ex21-22 ttcaccatactaccctacaCATCC 
NPHS1-Fw_ex23 
CATGAATCTAATAGGCTTAAGAA
GAGG NPHS1-Rv_ex23 CAAGCAGAGGAGGTAGGGTC 
NPHS1-
Fw_ex24-26 TTCTCGGGGAGACCCAC 
NPHS1-
Rv_ex24-26 CTAACGGCAGGGCTTCAG 
NPHS1-
Fw_ex27-28 AGGTTGATCATTGCCCTTCC 
NPHS1-
Rv_ex27-28 ATAGGAGGTAGGCTCCCAGC 
NPHS1-Fw_ex29 TTCTGGGAAGTTAAGCAGGG NPHS1-Rv_ex29 TGGGTTTTATGGAGCTCACC 
NPHS2       
NPHS2-Fw_ex1 ACACAGCTGTCGGGGTTC NPHS2-rv_ex1 CTCTGGCTTCAGTGGGTCTC 
NPHS2-Fw_ex2 
GGACCAACAGATGCTAGTCAGT
G NPHS2-rv_ex2 ggtgtgGCCAGTGAGAGG 
NPHS2-Fw_ex3 TATGCCAAGGCCTTTTGAAG NPHS2-rv_ex3 CATGGGTTGAAGAAATTGGC 
NPHS2-Fw_ex4 AAAGGTGAAACCCAAACAGC NPHS2-rv_ex4 tcattttgtcCACGGTAGGTAG 
NPHS2-Fw_ex5 ACCCCACATAGGAAAGGAGC NPHS2-rv_ex5 GGGATGGAACTGGCCATAG 
NPHS2-Fw_ex6 AGGGTTTAGGCATGCTCTCC NPHS2-rv_ex6 
TGGCTGTAAGATATTAGGTGATT
TG 
NPHS2-Fw_ex7 TTTGGCCCCTAAATCATGG NPHS2-rv_ex7 GGACAGTAAGGAAGCAAAGGG 
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NPHS2-Fw_ex8-
1 Gatgctcagtgcttgtctgc NPHS2-rv_ex8-1 TGTTGACCAAAGCTGTTTCC 
NPHS2-Fw_ex8-
2 CATGGAATGCACGAAGTCAC NPHS2-rv_ex8-2 TCTCCCTCAGATTTTAAGCCAC 
PLCE1       
PLCE1-Fw_ex1 AAGTTGCAGAGTGCAATCCC PLCE1-rv_ex1 AATCTGGCATGATTTTCTCCC 
PLCE1-Fw_ex1-2 TGGAAGCAACTTGCCAAAG PLCE1-rv_ex1-2 
CAAAAGTATTTATCATTCAAGGT
GTC 
PLCE1-Fw_ex1-3 AATTGTGTACCACTACCTGGGG PLCE1-rv_ex1-3 AATTGTGTACCACTACCTGGGG 
PLCE1-Fw_ex2 TTGCACTTGGAGCATCTGAG PLCE1-rv_ex2 
GTGAACTTAATTTTCCATCAGGA
G 
PLCE1-Fw_ex3 TATCTGTTGCAGGGGACACC PLCE1-rv_ex3 GGGGAGGTATGCTTGAAAATC 
PLCE1-Fw_ex4 cccagccAGGACCTACAG PLCE1-rv_ex4 CTGGCTTGGGTAAAGGTGAG 
PLCE1-Fw_ex5 AATTTAGGCTCCTTGCTGTAAAC PLCE1-rv_ex5 GACAGGGCCTGATGAGACAG 
PLCE1-Fw_ex6 GCCAAGTATGTTATCCAGGC PLCE1-rv_ex6 
AAGTAGGAAACAACTCATCAACA
GG 
PLCE1-Fw_ex7-1 CAGTGAAAATGTCTTTGGGTTG PLCE1-rv_ex7-1 AGATCCAAGACCCCTTCCG 
PLCE1-Fw_ex7-2 CTCCCCAGCCAGCAGTAAAG PLCE1-rv_ex7-2 tcacccagtgtgtgctcttg 
PLCE1-Fw_ex8 
CATTAATATATTTACTTCCCCATT
GC PLCE1-rv_ex8 TCACCATACAGCGGTCCTG 
PLCE1-Fw_ex9 GCAGTATTGAAGGTGGGTAGG PLCE1-rv_ex9 AATGTTTGCAATGCTTAAATCAC 
PLCE1-Fw_ex10 GGTTTGTATTTGGTTCTGAGGG PLCE1-rv_ex10 ATATGCCCTTCCACACAACTG 
PLCE1-Fw_ex11-
12 AATTGGAGCAAGTCTGGTGG 
PLCE1-rv_ex11-
12 AGCACACTATGTGGGACAGG 
PLCE1-Fw_ex13 ACTTTGCAAAAGATGCTGGC PLCE1-rv_ex13 TCCCAGATTTAAAGGCTTTGG 
PLCE1-Fw_ex14-
15 GATGTGGTGGTTTCTTTCCC 
PLCE1-rv_ex14-
15 GCTCTTCAAAGGAGTCTGGG 
PLCE1-Fw_ex16 TTCGAGGCTTTATCTCCAGG PLCE1-rv_ex16 aacagagcgagaacccg 
PLCE1-Fw_ex17 CTACCCTGCCTTCTGACCAC PLCE1-rv_ex17 GACAATTGCAAAACAAGGGC 
PLCE1-Fw_ex18 GCAGGGGACAGCTTCTTTC PLCE1-rv_ex18 GGTCTATGGAATGAAAAGCCC 
PLCE1-Fw_ex19 ACGATTGTGTTAAACATCAGGG PLCE1-rv_ex19 ATTACTGGTCTTTGGCGCTC 
PLCE1-Fw_ex20 GCTCTTAAGTGAAGCATTGGG PLCE1-rv_ex20 ACAGGGAGCAAGTGGAATC 
PLCE1-Fw_ex21 Aaaagagctttgggaatccag PLCE1-rv_ex21 TGAGAGTGTTCACAATGCCC 
PLCE1-Fw_ex22 ATGTTGAGTTGCCTTGCTTG PLCE1-rv_ex22 
AGGGAAGTGCTTAGACAGTAAA
ATATC 
PLCE1-Fw_ex23 TGCTATGACTGTTTACTGGGATG PLCE1-rv_ex23 CAGTCTGGAATCTTGCCCC 
PLCE1-Fw_ex24 
TAAGGTGATACTTAAGCGACAA
AG PLCE1-rv_ex24 CCAGTTCGTTTTCAGGAAGG 
PLCE1-Fw_ex25 AAGCAGTGAGGTGCAGAGG PLCE1-rv_ex25 aaattctggcatccatcacc 
PLCE1-Fw_ex26 TTCCAGGAGCATCTTCTTTTC PLCE1-rv_ex26 AAGCCCACCTTCAGTGTAGC 
PLCE1-Fw_ex27 
GCACCTCTGTATCAAATAGAGCT
TAG PLCE1-rv_ex27 
ACACACAGGCATTTATACACACA
C 
PLCE1-Fw_ex28 TGAACACCATGAAAGTTGATTTG PLCE1-rv_ex28 TTCAGGGAGGTTGTGAGTGG 
PLCE1-Fw_ex29 CATCACCAAGATACAAGCTCAG PLCE1-rv_ex29 GAACTTCACTCATAAAATGAGCC 
PLCE1-Fw_ex30 GAATGAATGCAAATGTTGGAG PLCE1-rv_ex30 TCCTAAATTTCACCAGCTTCC 
PLCE1-Fw_ex31 GTCATGTGACAGAGGAACCTG PLCE1-rv_ex31 
AAAAGACATTGTACTAATTATGC
CTTC 
PLCE1-Fw_ex32 TGGCTGGAAAACTCTGAACC PLCE1-rv_ex32 atggcccctgaattaagaatag 
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PTPRO       
PTPRO-Fw_ex1 AGTTCGCCATTGTGAGCC PTPRO-rv_ex1 ACACGCGAGGACAACAAAG 
PTPRO-Fw_ex2 
TTAGCATAACTTTATTGCCAATTA
TC PTPRO-rv_ex2 AGCCCTACGGGAAGAAACAG 
PTPRO-Fw_ex3  ATCGGCCTTTCTCTCTCCTC   PTPRO-rv_ex3 GAGAACATCATTTGGGAAAAGC   
PTPRO-Fw_ex4 AAAGCCCTTCAGGATTGAGTC PTPRO-rv_ex4 
GGGTAAGTCAGTTAATTATAACC
TTTG 
PTPRO-Fw_ex5 
TCTGCTTTTAGAAGTGGTTGAAT
TAC PTPRO-rv_ex5 TCATTTGGGTTTTCTGCTCTC 
PTPRO-Fw_ex6 TCTATACCCAGGGCCTTTCC PTPRO-rv_ex6 TCCCACCAGTTCCATTGTTC  
PTPRO-Fw_ex7 
GAATCTTTTATCTCAATCAGTGTA
ACG PTPRO-rv_ex7 ATTGCCCTGTAAGGTTGTGC 
PTPRO-Fw_ex8 
TCTGAATATTATACCAGCCTCTGT
G PTPRO-rv_ex8 ACCCCTCCGTCAATACCC 
PTPRO-Fw_ex9 GGCCATTGCTAAGACATTCC PTPRO-rv_ex9 CATAAAGGTTTGCCTGTTCCC 
PTPRO-Fw_ex10 
ATTGGAAATCTTTGGCTCTATAT
C PTPRO-rv_ex10 TGAAATTGATGCTCACCCAG  
PTPRO-Fw_ex11  TATGGGATTTCATGCTCTGC   PTPRO-rv_ex11 gacgtgtcaataaatgattgcttag   
PTPRO-Fw_ex12 GGTGGTGCACTGATTCATTC PTPRO-rv_ex12 GAGGAGCTCTTGCTGAATCG 
PTPRO-Fw_ex13 GGGGATGCTTCACCTGC PTPRO-rv_ex13 TTTTGCCCAGATAATTAGCCTTAC 
PTPRO-Fw_ex14 GTCAGATGGGGAATGGGG  PTPRO-rv_ex14 aagcttgggatttctTGGTG 
PTPRO-Fw_ex15 TCATCGTAAGCTCACTGCCC PTPRO-rv_ex15 
TAAAATCCAATATACCGCTATAC
AAC 
PTPRO-Fw_ex16 GGTCAACGTAAGAATGCTTTGTC   PTPRO-rv_ex16 AATCGACTTTGGAGCACACAC 
PTPRO-Fw_ex17 
CGCACATTTATATTTCACAGAAT
G PTPRO-rv_ex17 ACCGGTAACTGCTTTAATTCAC 
PTPRO-Fw_ex18 
CAAATGGGAAGTATAAAGTGCA
G PTPRO-rv_ex18 GCCTCTTTCTTAAGCGTCCC 
PTPRO-Fw_ex19 
TCTATTTTCTCCAAGAAGATTAA
GAAG PTPRO-rv_ex19 GACATGACCGCAACACAAAC 
PTPRO-Fw_ex20 aaagggcttgTGAGCAATAAAC  PTPRO-rv_ex20 GGTATGGCCAGAGATTGGTG   
PTPRO-Fw_ex21 
TTTAACTTAATATTGGATAGAAA
GGGC   PTPRO-rv_ex21 TTGGGAAAGGCTCTCTTTTG 
PTPRO-Fw_ex22 TGAAGCAGCATTTGGTGTTG PTPRO-rv_ex22 CAGCAAGCATTTCATCAACG 
PTPRO-Fw_ex24 TACTGACCAGGAGTGGAACG PTPRO-rv_ex24 TGGTGAGCTGTTCCCCTTAC   
PTPRO-Fw_ex25 Acttgaagccgagaggcag PTPRO-rv_ex25 
GCCTCAAAGCAGTTTGAACATAT
AC   
PTPRO-Fw_ex26 
TGTGTCTCTGTAAATAATGAAAA
TGG PTPRO-rv_ex26 TTTGTCCCATCCATCACATC   
WT1       
WT1-Fw_ex8 CCTTTAATGAGATCCCCTTTTCC WT1-Rv_ex8 GGGGAAATGTGGGGTGTTTCC 
WT1-Fw_ex9 CCTCACTGTGCCCACATTGT WT1-Rv_ex9 GCACTATTCCTTCTCTCAACTGAG 
        
CD2AP       
CD2APex1-Fw GATGGAGGCGACTCTTCG CD2APex1-rv AGAAAGGGCACAGCCTCC 
CD2APex2-Fw 
CAGCCTTGCTGATGTCTTTG    
CD2APex2-rv 
TATCCAGCAGGACACAGAGC 
CD2APex3-Fw GCAGAGCAAAGGTTGGAAAC CD2APex3-rv 
AAATTAAGATTGACTACACAGG
GC 
CD2APex4-Fw 
TTATATAAGTCCTGTGACTAAAC
ATGG CD2APex4-rv 
TTTCTAAAATCCATAGCATCAATT
ACC 
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CD2APex5-Fw CCCATAGGGTGACGATTTTC CD2APex5-rv 
GACTAATTGAAGCTGACTCAAAG
TTC 
CD2APex6-Fw AGGATGTCAAGCGTTTTGTG CD2APex6-rv CAGCCTCCTCATTCATAACC 
CD2APex7-Fw TTAGGGAAAGCTGGGTAACTG CD2APex7-rv TGTAACAAATGCTTCCAACAAG 
CD2APex8-Fw 
TAATGAAATTGTTACTTAACATA
CGG CD2APex8-rv acgtgccaagttttcaggac 
CD2APex9-Fw Ctggccaacagagcaacac CD2APex9-rv 
CAAAAGAATAGTGGCAAAATGT
TC 
CD2APex10-Fw TGTCAAGGATTGAATGAAGAGG CD2APex10-rv TTTGCATTAGATCCAATTTTACC 
CD2APex11-Fw Aattccggtacattgttctttc CD2APex11-rv CTCCCAGAAAACTCCAAGC 
CD2APex12-Fw CTCTGTCACACTTTTCCAGCC CD2APex12-rv GAGCCATTAAGGTCAAAGGTG 
CD2APex13-Fw AATCGGTATTAGGCCATACAATC CD2APex13-rv 
TCAACTGTGTAATTTCAACTTTAT
CC 
CD2APex14-Fw GCACAGGTCAATTTGTGAGTTC CD2APex14-rv 
AATACCAGCATTTGCCACTTG 
CD2APex15-Fw 
TGCTTTATTATCCAAAGACTTACT
ACC CD2APex15-rv TTCCCTATGTTTGATGTCCAC 
CD2APex16-Fw TCCAAATTTGCCACTTATCTTG CD2APex16-rv gaactaccacacccagccAC 
CD2APex17-Fw TCCCATGAACTGGTAGGTTAGG CD2APex17-rv AGGAACCGATTACCCAGTTG 
CD2APex18-Fw GCATGGGAAACTGGATTTTAG CD2APex18-rv GCTGAAGTTCATAGCGTTGC 
LAMB2       
LAMB2-ex1Fw CCCTCGTATAGGTGTGGGC LAMB2-ex1rv GGGCAACTACCAGGACCTAC 
LAMB2-ex2-3Fw GAGGTGGAGCCACTGGATAG LAMB2-ex2-3rv ACAGGAATCGGAAGTCAAGG 
LAMB2-ex4Fw TGGGGCAAAAGTGAGCAG LAMB2-ex4rv cTCTGTCCAGGGGCAATG 
LAMB2-ex5-6Fw TCTTGATGGCTCTGGGTTG LAMB2-ex5-6rv ACTGAGGCCCCAAATAGTCC 
LAMB2-ex7-8Fw GGACATGGGGCAGCAAG LAMB2-ex7-8rv AGGTTCTACCCAGGGCACAG 
LAMB2-ex9Fw ACCCTTGTGACCTGGTTCC LAMB2-ex9rv CTCTCTAGTTCCTGCCCCAG 
LAMB2-ex10-
11Fw GGACTGGCAGTGAGCTAGTTG 
LAMB2-ex10-
11rv ATAGATGTGACACCCCAGCC 
LAMB2-ex12-
13Fw AGACGTGTGGTTGGGATTTC 
LAMB2-ex12-
13rv CCAGTCATAGACGTGTCCACC 
LAMB2-ex14-
15Fw CTGTGGCAGAAGAGGCAAAG 
LAMB2-ex14-
15rv 
CCTGCAGGGAGCTTAGGG 
LAMB2-ex16Fw CCAGATGATTTGTACAGGGC LAMB2-ex16rv TATCCCTCAAGTCCCACACC 
LAMB2-ex17-
18Fw CTCTGGCAATGCCTACGTG 
LAMB2-ex17-
18rv AGGTCCAGAAGGAGGAGAGAG 
LAMB2-ex19-
20Fw CCACCCACACTCCCCTC 
LAMB2-ex19-
20rv CCCACGGTTAAGAGGAAGC 
LAMB2-ex21Fw GTGGGATCAGGGTGAGTTG LAMB2-ex21rv GCACAGTAGTCAAGAGGAGGC 
LAMB2-ex22-
23Fw AGTGTGGGAGGGCATGG 
LAMB2-ex22-
23rv GGTCACTGTGGGGCATTC 
LAMB2-ex24Fw GGGTAGATGGAGGACTTCCC LAMB2-ex24rv TTCAGCCCTGGTCCACTG 
LAMB2-ex25Fw GAGGCCCAGTGGACCAG LAMB2-ex25rv GGCACCTAAATTGGGCAGAG 
LAMB2-ex26Fw ACTAGGCAGGTGGACCAGG LAMB2-ex26rv CAGGCACAGAACAAGTCAGG 
LAMB2-ex27Fw CAGGTGGGTGTAGATGTTCC LAMB2-ex27rv GGAGATACAGACACCGGGAG 
LAMB2-ex28-
29Fw TGAGTCCATACCCCAAAACTG 
LAMB2-ex28-
29rv CTGCCATCCTCTCCTGTACC 
LAMB2-ex30-
31Fw CAGTGGGACAAGGTTATGGG 
LAMB2-ex30-
31rv CTAGGAAGGGCAGGTGTCAG 
LAMB2-ex32Fw TACAGGGTAAGAAATGGGGC LAMB2-ex32rv CCTCGAGGTTCCCCTGG 
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MYO1E       
MYO1-ex1FW AACTTTTGAAGTTCGCCCAG MYO1-ex1rv CGTCCACCTTCTCCACCC 
MYO1-ex2FW TTTGGGAAATTAACAGCATTTTG MYO1-ex2rv acacacgtgagccactgc 
MYO1-ex3FW TGGACAGTCATTGTGAATTCTTG MYO1-ex3rv ATGTCTGCATCATAAAAGCCC 
MYO1-ex4FW 
GGAAAAGAAATTGAGTGTATTG
CC MYO1-ex4rv AAACCACTGCTTATCGACCG 
MYO1-ex5FW AGACAAGGAAGGGAGCTGG MYO1-ex5rv TGGAGCCTCTTACATTTCCC 
MYO1-ex6FW TGCATTCAGAAACCAGGTCC MYO1-ex6rv AAGGCTCCCATTTCCTGTG 
MYO1-ex7FW ATTCAAAGCCTGTTTGGGAC MYO1-ex7rv TCCTCCCTGGCTTCCTAGAC 
MYO1-ex8FW AGGATGCAGGAGTGACTTCG MYO1-ex8rv TTTTGGCCACAGGAAATGG 
MYO1-ex9FW CAGCTGCTGTGCCTTGG MYO1-ex9rv TCCCAATATTCCCATTTGAG 
MYO1-ex10FW TGTGCACATAAGTGCCTCC MYO1-ex10rv cgcacccagccTACTAGTTTTAC 
MYO1-ex11-
12FW CCGTGTAGAATCCAGCTTCC 
MYO1-ex11-
12rv 
GGAACCGAAATCTATTAACAAAA
GAC 
MYO1-ex13FW TTTGTCCATTCAGGGTCTGTC MYO1-ex13rv TCAGAGTTGTCACTTTGCCTG 
MYO1-ex14FW CCTTGCCTAAGAAAGGACCTG MYO1-ex14rv TGAATCAATAAAATACGGCGAG 
MYO1-ex15FW GGGTAGCCATGACAGCTTTG MYO1-ex15rv taggaacacaccaccacacc 
MYO1-ex16FW AGGCTTTCAGCCCCAGAG MYO1-ex16rv AGGGGTGCAGTTCCTTACTC 
MYO1-ex17FW CAAGTCTCCTTTGAAATTTGGTC MYO1-ex17rv GGCTCATCTTGAGCAGAGG 
MYO1-ex18FW TTGGCTGGTAAGAACACGAG MYO1-ex18rv actcgtacgcttgaagtggg 
MYO1-ex19FW GTAGAAAACCAGTGCGGTCC MYO1-ex19rv aagccagctgaggggtg 
MYO1-ex20-
21FW GTCTAAACTGAGGGTCCCTGG 
MYO1-ex20-
21rv acaacgaacacattctgatttg 
MYO1-ex22FW Aggtgtgagccaccatgc MYO1-ex22rv CTTCCTCCTGGCTGTTTGG 
MYO1-ex23FW 
TGTAAAATCTTAGCACTATCTTG
CAG MYO1-ex23rv AGCCAGACCCCACTCTTCTC 
MYO1-ex24FW TGAGCACCGTTTTCTCACTG MYO1-ex24rv TTTGCTCGGGAGACTCGG 
MYO1-ex25FW AGGATCCATAAAACCAACCAG MYO1-ex25rv TGCATTGATTTGCTAATGGG 
MYO1-ex26FW GAAATGTGGAGAGACTTTTGGC MYO1-ex26rv TTGAATGATGGAGATGGAGC 
MYO1-ex27FW ATGCTCCAAACCACCGTTC MYO1-ex27rv GATCTTACAGCAATGTGACTGC 
MYO1-ex28FW CATGGATGGAGCCAAATCAC MYO1-ex28rv CATTGTGGATTGTAAGGGGAG 
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Appendix A 
List of oligonucleotide primer sequences used in the thesis 
Chapter 3.2 Bardet–Biedl Syndrome and Modeling of a Novel BBS5 Mutation 
BBS5       
BBS5-Fw_ex1 GCCTTGGAGCCAGAGAGAC BBS5-RV_ex1 GGGTCCCTAACGCGCAC 
BBS5-Fw_ex2 
GAAGACCTTATTTCTAAATGCAT
GAAC BBS5-RV_ex2 
ACACTGACAAATGATGCTGTTT
C 
BBS5-Fw_ex3 AAGTTCCATATCCATCTCATTCAG BBS5-RV_ex3 TGCAAATTCACCTGACAAAG 
BBS5-Fw_ex6 ggcttgggcaaggtattgag BBS5-RV_ex6 
AAAAGTAATACGCTTTCCTATAA
TGC 
BBS5-Fw_ex7 TCAATTTTGGTATTATTTGCTGC BBS5-RV_ex7 
GGGAGAAAGAACTCATCTAAAA
GTC 
BBS5-Fw_ex8 GCAGTTTAATGAAGGAAGGAGG BBS5-RV_ex8 
TCTGGGGACAATTTCTGTATGA
C 
BBS5-Fw_ex9 tgaagctggatgatggctc BBS5-RV_ex9 ATCCAGGAGCTATGCCCAC 
BBS5-Fw_ex10 TCTCTTTCTGGTTCTTTTCGTG BBS5-RV_ex10 cacctggccTCAAAGTATTTC 
BBS5-
Fw_ex11&12 TCTGCATATTAAGTTCCTTAGCCC 
BBS5-
RV_ex11&12 TCCATGACTTATGGCAGGTG 
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Appendix A 
List of oligonucleotide primer sequences used in the thesis 
Chapter 3.3 A New Syndrome of Autosomal Recessive Distal Renal Yubular 
Acidosis associated with Nephrocalcinosis 
CA2       
CA2-Fw_ex1 GGGAGCCTATAAAAGCTGGTG CA2-RV_ex1 CGGTAAACAGCATGTGCG 
CA2-Fw_ex2 GGTCTGGGTGTACACTTTCCC CA2-RV_ex2 TGGCTCCTTCCATTAAGCTC 
CA2-Fw_ex3 AGGCATGTGTTTCatgtgtg CA2-RV_ex3 TTCACTGGGCGTGAGTTG 
CA2-Fw_ex4 GACCATTGAATAAAATCTGTCAGC CA2-RV_ex4 
TCCTGTATGTTACAAATACTC
TGTCTG 
CA2-Fw_ex5 AGTGGAGAATTTGGGCTCAC CA2-RV_ex5 AACTGCTCATCCAAACACCAC 
CA2-Fw_ex6 TGTGTCTGCTGCTCTCCTACC CA2-RV_ex6 ccaaggtcttCTGCCTTGAC 
CA2-Fw_ex7 Atgagccactgcgcctg CA2-RV_ex7 GACACAAAGCAACCAGGGTC 
ATP6V1B1       
ATP6V1B1-
Fw_ex1 CCAGCTGGACCTGAAGTCTC ATP6V1B1-RV_ex1 GAACCTGGCAGCCCACC 
ATP6V1B1-
Fw_ex2 GTGTGTGAGCAGGGTGTTTG ATP6V1B1-RV_ex2 
CATGGAGGGAAAGGGTAAT
TTAG 
ATP6V1B1-
Fw_ex3&4 AGGAGGAGAAGGGACTTTGC 
ATP6V1B1-
RV_ex3&4 Gtttggtcagagaagctggg 
ATP6V1B1-
Fw_ex5 AGTAGTGAGGGACACAGGGC ATP6V1B1-RV_ex5 GCAGAACTTCCAAGAGTGGG 
ATP6V1B1-
Fw_ex6 GAGAGCAGGGAAGGGTTTG ATP6V1B1-RV_ex6 CAGGAGCTGTCCTCACTGG 
ATP6V1B1-
Fw_ex7 CAGTGGTGCTCAGTGGGAC ATP6V1B1-RV_ex7 CTGAGGGAGACAGGCTGC 
ATP6V1B1-
Fw_ex8 CTGAGGGAGACAGGCTGC ATP6V1B1-RV_ex8 TAGGTCTTGGAAGGGGACG 
ATP6V1B1-
Fw_ex9 TATGTGGTGCATTAGCCCAG ATP6V1B1-RV_ex9 CTCTATTTGCAGGGTGACCG 
ATP6V1B1-
Fw_ex10&11 CCCTTCCTAGCTTCAGCCTC 
ATP6V1B1-
RV_ex10&11 GGGGCAGTGAAACATCTG 
ATP6V1B1-
Fw_ex12&13 ACAATTTGGGGACAGGGG 
ATP6V1B1-
RV_ex12&13 TGTTAGGAATGTGTGTGGGG 
ATP6V1B1-
Fw_ex14 CTGGTGTGGAGCCAGTAACC 
ATP6V1B1-
RV_ex14 CACCACCTCGGAGCCAG  
SLC9A4       
SLC9A4-Fw_ex1 CCGACTTCAGATGTGTGGC SLC9A4-RV_ex1 
CCCGTTATCTATAAGGCATTT
TC 
SLC9A4-Fw_ex2 AGGTACACCCAGACCGTTTC SLC9A4-RV_ex2 CACCCCGAACCCTCATC 
SLC9A4-Fw_ex3 ATGTGCATGCAAAGTGTTCC SLC9A4-RV_ex3 
TCATGTGATGTGGTTCTAAA
CTTTC 
SLC9A4-Fw_ex4 TCATGCATCTGTGGCATTG SLC9A4-RV_ex4 GTTTTAACATTGCGGAAGGG 
SLC9A4-Fw_ex5 GAATTAGGCTGCATTGTTTGC SLC9A4-RV_ex5 
TCTCCGGAAATTTAGTTTGG
G 
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SLC9A4-Fw_ex6 AAAGGAATGGAAAACTGAAATG SLC9A4-RV_ex6 
GTGGGGAAGGAAAGAGGAA
G 
SLC9A4-Fw_ex7 TGTGTGTCTTTCAGAGTTCGC SLC9A4-RV_ex7 ttTATGCCCAGCTTCCAATG 
SLC9A4-Fw_ex8 ATGAATTCCAGGCACTGTCC SLC9A4-RV_ex8 AAATGAGGCAATGAGTCAgc 
SLC9A4-Fw_ex9 CACCTCTTGCCAAATGAAAG SLC9A4-RV_ex9 TGAACATCAACAGACTCCCC 
SLC9A4-
Fw_ex10 GCTTCCTTGGCTGAAAGTTG SLC9A4-RV_ex10 
CTCAGCAGATGACAAACACT
TG 
SLC9A4-
Fw_ex11 TGCCATGTGAAGCTCTTAATTG SLC9A4-RV_ex11 Ctcttggcccacacccc 
SLC9A4-
Fw_ex12 TCCTGCCATGTGGATATTAAGTC SLC9A4-RV_ex12 
TTTCACAGTTATAGGAAGAC
AGACTC 
SLC9A2       
SLC9A2-Fw_ex1 CCTCTGGTTGCAGAGACCC SLC9A2-RV_ex1 AGAAGCTGCTCCATCTGTCG 
SLC9A2-Fw_ex2 CCTGTCTCCCAAATTCCTCC SLC9A2-RV_ex2 
GTTGAGGTGCAGAGAGCCA
C 
SLC9A2-Fw_ex3 GTGTTTGTGCCCAGAGTGAC SLC9A2-RV_ex3 Ctgaccttgtgatccacgc 
SLC9A2-Fw_ex4 GAGATTGCAGGATTTCCGAG SLC9A2-RV_ex4 ACAAAAGGAAAGCCCCATTC 
SLC9A2-Fw_ex5 TTTTCATATTTTGGCCTCACC SLC9A2-RV_ex5 
TTTGCTACTTTGCATCCTGTA
AAC 
SLC9A2-Fw_ex6 TCAAAGCTTAGGAGAAGTTACCC SLC9A2-RV_ex6 TTCAGGAAATGGACAACGTG 
SLC9A2-Fw_ex7 
AGTAGAGTGAAAATTATTGATTTC
AGG SLC9A2-RV_ex7 TGCTTTCAGAATGACCCTGG 
SLC9A2-Fw_ex8  CCAGATTAGCTAAATGCTGCTAC   SLC9A2-RV_ex8 tcagtatttgcAgctgggc   
SLC9A2-Fw_ex9 
TGAAATAAGAGTCACAGAATTTG
G SLC9A2-RV_ex9 CCAGAAGGCATCCTGTTAGC 
SLC9A2-
Fw_ex10 AAGTCTTGGAATTTCTGGGG SLC9A2-RV_ex10 AATGGAATAGCTGTCGGCTC   
SLC9A2-
Fw_ex12 TTACTTGCAATGCCTTCTCTC SLC9A2-RV_ex12 CCACTGTTGCATCAGGTTTC 
MFSD9       
MFSD9-Fw_ex1 GGCTCCCGGGGTAGGTC MFSD9-Rv_ex1 CCGGAAGCTCCAAGAACC 
MFSD9-Fw_ex2 GGCAGCGGATTTGTATGG MFSD9-Rv_ex2 TCATTTCCCACTTACCTTTGG 
MFSD9-Fw_ex3 
TCTGTTGGTTTCTGTGTAATTGTTA
TC  MFSD9-Rv_ex3 
AAAAGCAGGGAATTGTAGG
AAG 
MFSD9-Fw_ex4 CATTTGCATGGTGGTAGTCG MFSD9-Rv_ex4 
AGCAAGACCACAGAGGTGG
C 
MFSD9-Fw_ex5 agctgccttccaaAGAAACC MFSD9-Rv_ex5 Tttggacgatgagtctgtctattc 
MFSD9-
Fw_ex6A CCTTCCCCAAGGAGGTAGTG MFSD9-Rv_ex6A TGTGCAGGTGAGTATGCTGG  
MFSD9-
Fw_ex6B CCAAGGTGACAGGCTACCTC MFSD9-Rv_ex6B TCCAAAGTGCCCTTTTCATC 
TMEM182       
TMEM182-
Fw_ex1&2 AGCTAGGACAGCCTTCTCAAG 
TMEM182-
Rv_ex1&2 
CAATCCAGTCCGCTAGAAGT
G 
TMEM182-
Fw_ex3 TGCTTGTGTAACCCTTGTGC TMEM182-Rv_ex3 TTTTGATCTGGGCATCCTTC 
TMEM182-
Fw_ex4 CTGACTGTGACAATCTGCTGTG TMEM182-Rv_ex4 
TTACTAGAAGGCTGACGCCT
G 
TMEM182-
Fw_ex5 GCTTGTCATCCGGTCAATG TMEM182-Rv_ex5 
TGGGATCAATGAAACAAAAT
G 
POU3F3       
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POU3F3-
Fw_ex1-1 tgctgctgGTGACCAAGG POU3F3-Rv_ex1-1 GCACCAAGCTCTGGGCTc 
POU3F3-
Fw_ex1-2 GCACCAGTGGGTCACAGC POU3F3-Rv_ex1-2 GCCAGCTCTGGCGTGTC 
POU3F3-
Fw_ex1-3 CACCAGTGGGTCACAGCC POU3F3-Rv_ex1-3 CTTCACTGAACGCTCGTCTG 
POU3F3-
Fw_ex1-4 GGGGCCTGGACTCAACAG POU3F3-Rv_ex1-4 ATGCCTGTCTCTGGGTGG 
MRPS9       
MRPS9-Fw_ex1 CTGCGCCGTCTCTAGGC MRPS9-Rv_ex1 GCTGGCTCCACATCCTC 
MRPS9-Fw_ex2 AAGCAAGGCTTTGAGTAGGG   MRPS9-Rv_ex2 
AAACACAGAGCTAAGGGGCT
C 
MRPS9-
Fw_ex3&4 AAACACAGAGCTAAGGGGCTC MRPS9-Rv_ex3&4 TACGATATGTGAGCAACCGC 
MRPS9-Fw_ex5 TGGTTAAATGCAGCTATTTGG MRPS9-Rv_ex5 
CATCAACACACTGTCCTACCT
C  
MRPS9-Fw_ex6 
TCAGAAGTTATAATGTACCATTGC
TC MRPS9-Rv_ex6 
TGAACAAATTTTAGGCTTCA
GG 
MRPS9-Fw_ex7 
AGAGTAGATTGAGGAAATGGAAT
G MRPS9-Rv_ex7 CGTAGGAACACCTGCCTCTG 
MRPS9-Fw_ex8 AGCGTGAAGATGCAGAAGTG MRPS9-Rv_ex8 
GGAAATCCAAAGTAACGGTA
GC  
MRPS9-Fw_ex9 GTCTCAAAGCGCAGGTCTTC MRPS9-Rv_ex9 
CAGAATTAGAAGATCACAAG
CCTTC 
MRPS9-
Fw_ex10 
GAAAAGTATAACAGTGGCATGCA
G MRPS9-Rv_ex10 CGAACTTCAGGCACTAGGAC 
MRPS9-
Fw_ex11 TTACTGGTCTGGTTGCTTTCC MRPS9-Rv_ex11 TGACAGTACTGCCCTCATGC 
GPR45       
GPR45-Fw_ex1-
1 GCAAATCCCAGCTAGTGCTC GPR45-Rv_ex1-1 TGATGATGAGCAGGATGGC 
GPR45-Fw_ex1-
2 TCTGCTGCATGCCCTTC GPR45-Rv_ex1-2 GAAGGCCTTGGTCTTGAAGC 
GPR45-Fw_ex1-
3 ACAACCAGTCGGACAGCC   GPR45-Rv_ex1-3 TGTGCTTAAATTGCCACCAC 
GPR45-Fw_ex1-
4 CAGTCTGCGGTTTAGGGG   GPR45-Rv_ex1-4 GGCATGGGAAGAAATGCAC  
TGFBRAP1       
TGFBRAP1-
Fw_ex1 CGTCTCGGCCTGTGCTC TGFBRAP1-Rv_ex1 Ccactacacctgccccag 
TGFBRAP1-
Fw_ex2-1 GCCTCTGTTTCTGCTTCTTCC 
TGFBRAP1-
Rv_ex2-1 CACAGGGTTCTCGTTCAGTG 
TGFBRAP1-
Fw_ex2-2 CTGTGTGACAACTCCATCAGC   
TGFBRAP1-
Rv_ex2-2 ACACACGCCCAATGTCAC  
TGFBRAP1-
Fw_ex3 ACAGGAAAATGACACCATGC   TGFBRAP1-Rv_ex3 caAGGCCCAGTTCCTAAATG 
TGFBRAP1-
Fw_ex4 AGTTTGGGGAAAGCAGTGTG   TGFBRAP1-Rv_ex4 
TCTGAATGTCCTCTAACTGGT
GAC 
TGFBRAP1-
Fw_ex5 AATTTAACCCTGCCGTGATG TGFBRAP1-Rv_ex5 GTTCTGGCCACAGAGGGAC 
TGFBRAP1-
Fw_ex6 GCTGTTTTGTGTGCCTATGTG TGFBRAP1-Rv_ex6 
GCAAAGAGCCTCAGTAAGG
G 
TGFBRAP1-
Fw_ex7 AATATGGGGAGCTTGGACTG TGFBRAP1-Rv_ex7 
GGCAAAAGTGGTCTCTATCA
AC 
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TGFBRAP1-
Fw_ex8 
TTCTCAACTAATTCTGAGATATGT
GC  TGFBRAP1-Rv_ex8 AAAGCAAAGCTTTTGGGGTC  
TGFBRAP1-
Fw_ex9 AGCTTGAATGTGCAATGACC TGFBRAP1-Rv_ex9 GTTCAATTCCGTCTCTCCAG 
TGFBRAP1-
Fw_ex10 GGGGAGAGCTTTGACTTTCC 
TGFBRAP1-
Rv_ex10 CCCACCCGCTTGATATGAG 
TGFBRAP1-
Fw_ex11 GAAGCCCAGAGCAGCAAG 
TGFBRAP1-
Rv_ex11 
TTTCCATCAGTAAAATCTACC
TTCAG 
TGFBRAP1-
Fw_ex12 CCATGGAGTAATGCATGTCAAC 
TGFBRAP1-
Rv_ex12 
GAGTCTAAAGGTTGGAGTGT
GG 
C2ORF49       
C2ORF49-
Fw_ex1 TCAGAGTGACGACACACGC C2ORF49-Rv_ex1 CAAGCTCGGGTGCAAGC 
C2ORF49-
Fw_ex2 CGCGTGTTATTGTGAAAATGG  C2ORF49-Rv_ex2 Cagtgcctggtgctcaatag 
C2ORF49-
Fw_ex3  ATCCCAGTGAACTGGTTTGC   C2ORF49-Rv_ex3 
GCAGACTGCTCAAGTTTCATT
C 
C2ORF49-
Fw_ex4 ATGGCAGCAGTGATCTTCC C2ORF49-Rv_ex4 
TTCCTAATCAGGGCAAGACA
G 
FHL2       
FHL2-Fw_ex1 CGCTCCCGATAACTACTGTG FHL2-Rv_ex1 GTTCGGGTCCCCTCTCC 
FHL2-Fw_ex2 ACAGTTAATGCCTTTGCGTG FHL2-Rv_ex2 AAACCACAGAGAAACCCGTG 
FHL2-Fw_ex3 GTCCAAGCCCTCCTGTCC FHL2-Rv_ex3 CAGAGGAACGTGCACAAGG 
FHL2-Fw_ex4 GCTCTGAAGGCAGATTGCTG FHL2-Rv_ex4 TGGACCATGGAGGCAAAC 
FHL2-Fw_ex5 GTCCAGTGGCAGTAGCTGAG FHL2-Rv_ex5 TAGGCCTTGTTCAAGCTTCC 
FHL2-Fw_ex6-1 CAGTCCCAGTTGCCTGATTC FHL2-Rv_ex6-1 ACCATCTTCCCACCTAGGGC 
FHL2-Fw_ex6-2 TTCTGGTTTCTTCCAGCCAC  FHL2-Rv_ex6-2 AGACTCAGTGCCTCGACCTG 
NCK2B       
NCK2B-Fw_ex1 GCTGTCCCTCTGAAGCAGTC NCK2B-Rv_ex1 AATGGCTCAATGACAGCCC 
NCK2B-Fw_ex2 TTGGTGCAAAGGATGAAGTG NCK2B-Rv_ex2 
CGAACAGTGTCCCTTGAAAT
G 
NCK2B-Fw_ex3-
1 TAGGGAGTGTGGTGGTGCC NCK2B-Rv_ex3-1 TCTCGAAGTTGAGCTCCTCC 
NCK2B-Fw_ex3-
2 AGCTTCCTGAGCCTGCG NCK2B-Rv_ex3-2 GCGCAAGGCGCATTTAC 
NCK2B-Fw_ex-
4-1 GATTTAGACACAGCTCCCCG NCK2B-Rv_ex-4-1 TAAAGAGGGGTTCCATGAGC 
NCK2B-Fw_ex-
4-2  CTCCCATTTGCCATCCAG   NCK2B-Rv_ex-4-2 
AGTGTCAACAAACGGCTACA
G  
NCK2B-Fw_ex-
4-3  GGAACCGGTGACTCAGAAAG   NCK2B-Rv_ex-4-3 GATTTCCACTCCGCAATGAG 
Hypothetical 
genes        
LOC644617x1A
F TGAAACTCCATGACGAACAC LOC644617x1AF TGAAACTCCATGACGAACAC 
LOC644617x1B
F CTCCCGAGGACATCCAGAC LOC644617x1BF CTCCCGAGGACATCCAGAC 
LOC644617x1C
F TTTCTCATTCCTAACACACagacag LOC644617x1CF 
TTTCTCATTCCTAACACACaga
cag 
LOC644617x1D
F GAGCAATTAGATCCATCAGACC LOC644617x1DF 
GAGCAATTAGATCCATCAGA
CC 
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AK95498x1F GCAGTTGGAAGCAGGATTTC AK95498x1R CTGGAGAACTTCCCCTGC 
AK95498x2AF TCAAGAAAGGGGACACCAAG AK95498x2AR ACTCACAGCGGCTAGTTGG 
AK95498x2BF CCAGGGTTACCCCAGAGTTC AK95498x2BR 
CAAAGCTATAACAAAGGCTC
CC 
AK95498x2CF ACAGTCAGCGGGCTCTGC AK95498x2CR CAAGACTACTGGGACCTGGC 
AK95498x2DF CCCAGGCTAAGGATTTGAGG AK95498x2DR 
GAGAGATCAGTTACCTTTCC
CC 
AK95498x2EF GATGCAAATGGAGGTGGAAG AK95498x2ER 
TTGAGAATCTTTAGGTGACA
ATGG 
AK95498x2F-F GACTTGCCTGAGCGATTTTG AK95498x2F-R AAGAATGATCACTGCTGCCC 
        
AK96498x1Fw CAAGGGGAGAACAGTTAGTGC AK96498x1Rv 
TGAAAATAAGCTCCCAAACC
TAC 
AK96498x2CFw GCTAGAAATATATGAGCCTCCAGC AK96498x2CRv Actgatacaaggatacaagggaag 
AK96498x4AFw GAGCATGGCACAAAGACCTC AK96498x4ARv 
AAATTAACTCACAGCCAAAG
GC 
AK96498x4BFw tgccaattcctgATGTTCTC AK96498x4BRv ctggcttactatatgatcttggg 
AK96498x4CFw GTGGTTGGGAGGATCAAGTG AK96498x4CRv CAAGCCTGGATCATTTTCATC 
AK96498x4DFw CCAAGGAGTTGGCTTTTATTTG AK96498x4DRv Gtctccccagccatgcag 
AK96498x4EFw TGCCCTTTTAGTAGGGGAAG AK96498x4ERv CTCTCAGAGGTCTTTGCAGG 
        
AK96621x1AFw TTGCTATTGTTTTGGCATGG AK96621x1ARv 
GATCATAACTAATGTTGCAA
AGCC 
AK96621x1BFw TCTTGTTCCCGTGTATGTGC AK96621x1BRv 
GGAATGTTGGACATAGGTAT
ACTGG 
AK96621x1CFw TTCAAGCATGGTGACATTCC AK96621x1CRv CTACAGGCACTGGCCCAC 
AK96621x1DFw GGGATTGAGAAACTCCTTGC AK96621x1DRv AGCTCCAGGACACCCTCAC 
AK96621x2Fw ATGCCCTCCTCCTGAGTTC AK96621x2Rv TTCCTAAAGCTTGATGACTGC 
AK96621x3Fw AGTCTCTCTCACCTGCCCC AK96621x3Rv 
AAAATGATGAAGAACTGGCT
AGG 
AK96621x4AFw TGGTGCTATCAATTTGGCTG AK96621x4ARv CAATGCCTCTTCCGTGAGAC 
AK96621x4BFw AGAGCTGTGGATCTGCGTC AK96621x4BRv 
CACAAGACAGAGATCTGGG
G 
        
CR607634-
Fw_ex1 AACATACACGGCAGCAAAATC CR607634-Rv_ex1 
GCAAATGGAAGGGGAAAGA
G 
CR607634-
Fw_ex2 CCTATATTGTGGGAATTGAAATG CR607634-Rv_ex2 ATGAGGGGTTTGCAACAATC 
CR607634-
Fw_ex3 TCAAGCTGCCTCAAAATATCC CR607634-Rv_ex3 
CGGTATAAAGGTCACTGGAA
CC 
CR607634-
Fw_ex4-1 CAGCCACTCGACCTCCTTAG 
CR607634-Rv_ex4-
1 TGTGCACGAAGGCATTG 
CR607634-
Fw_ex4-2 agaagcaaggaatgcagaag 
CR607634-Rv_ex4-
2 Cactgaactgcatgagaacaag 
        
AX746619-
Fw_ex1-1 GGAGTGGCTTCCCTCAGAAG 
AX746619-Rv_ex1-
1 
GGACAGAGCTTGGCACTAG
G 
AX746619-
Fw_ex1-2 CTTTCTGTGGCTCTCCCATC 
AX746619-Rv_ex1-
2 TGCTCAGTGCAGGTTGATTG 
AX746619- AGCGAGGATCTTGCCATCTC AX746619-Rv_ex1- TGATGACTGCATATTGCTTAT
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Fw_ex1-3 3 CAC 
AX746619-
Fw_ex2 AGTCTCTCTCACCTGCCCC AX746619-Rv_ex2 
AAAATGATGAAGAACTGGCT
AGG 
AX746619-
Fw_ex3-1 TGGTGCTATCAATTTGGCTG 
AX746619-Rv_ex3-
1 CAATGCCTCTTCCGTGAGAC 
AX746619-
Fw_ex3-2 AGAGCTGTGGATCTGCGTC 
AX746619-Rv_ex3-
2 
CACAAGACAGAGATCTGGG
G 
        
CR609970-
Fw_ex1 
TCAACAGGTTGAAACGTAAGAGT
AG CR609970-Rv_ex1 
CAGTGTGAAAAGCTGAATCG
G 
CR609970-
Fw_ex2-1 ggaaggcctagaaaatcatgaag 
CR609970-Rv_ex2-
1 Aacttcagttgctgtacttttcag 
CR609970-
Fw_ex2-2 ccctgagaaagcccagatac 
CR609970-Rv_ex2-
2 Tctgatgagaaattggctgatac 
CR609970-
Fw_ex2-3 gcaataccaaattggataaaccc 
CR609970-Rv_ex2-
3 cactatttgcaacttctcccttg 
Gene 
expression 
primers       
SLC9A2Exp-
Fw_A Ttggagagtccctgctgaat SLC9A2Exp-Rv_A ttcatagtcattgcacaagcag 
SLC9A2Exp-
Fw_B Ccactggtggagtttcttga SLC9A2Exp-Rv_B Cactggacgtgaccttcctt 
POU3F3Exp-
Fw_A agttcgccaagcagttcaag POU3F3Exp-Rv_A Gcacttgaggaagtggctct 
POU3F3Exp-
Fw_B Gttctcgcagaccaccatct POU3F3Exp-Rv_B Cttgaggaagtggctctcca 
TGFBRAPExp-
Fw_A cgatcgtcaagaggataggg TGFBRAPExp-Rv_A 
Tgtggcaacgatcactcttc 
TGFBRAPExp-
Fw_B Gtccgggagctgatctctct TGFBRAPExp-Rv_B 
Ctgcagcagcatcttggtta 
TMEM182Exp-
Fw Tcgccagccattttctctac TMEM182Exp-Rv tgctgggatcaatgaaacaa 
MFSD9Exp-Fw Tgtttgtcctggctagagtcc MFSD9Exp-Rv Caggcccttctctgtactgc 
MRPSExp-Fw cccctgagttgcaaacaaat MRPSExp-Rv acaaaccacttgggaaaagg 
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Appendix A 
List of oligonucleotide primer sequences used in the thesis 
Chapter 3.4 Bilateral Renal Agenesis  
FGF1       
FGF1-Fw_ex1 
CAGCTCTGTGGCATGGTAT
C FGF1-Rv_ex1 
TCCAAGTAGCATTACATT
TGCAC 
FGF1-Fw_ex2 
AAAGTGCATTTTGTGCCTT
TG FGF1-Rv_ex2 
TAAATGTGCACCTTCCTCC
C 
FGF1-Fw_ex3 
TCCTATCGGCAAAAGCGT
AG FGF1-Rv_ex3 
AGTTTGCCTCACTCCATGT
AAC 
FGF1-Fw_ex4-1 tgaggcatggagagctttag FGF1-Rv_ex4-1 
GGGGAATCACAGATAGGG
TTTAC 
FGF1-Fw_ex4-2 AGTCTGGGTCTGGGTTTGG FGF1-Rv_ex4-2 
CCCTTTCTTTCTCTGCACT
CC 
FGF1-Fw_ex4-3 
GGTGACTTCAGGTGGAGA
GC FGF1-Rv_ex4-3 
GCATTTTATAGGCATTGG
GC 
FGF1-Fw_ex4-4 CCGAACCTCACCTGACCTC FGF1-Rv_ex4-4 
TCATATGAAACAGGAGCT
AACACTC 
FGF1-Fw_ex4-5 
TGATACTGATGCCATGTA
AAGG FGF1-Rv_ex4-5 
TGCCCTGGGAGAAGATAC
AG  
FGF1-Fw_ex4-6 
CAAACTCAAGCATAACAT
TGGC FGF1-Rv_ex4-6 AATGGGAATGTCCCCAGG 
FGF1-Fw_ex4-7 
AATCAGCCAAAGAGCCTG
TC FGF1-Rv_ex4-7 ACACCTCAGGGATGCTGG 
GFRA3       
GFRA3-Fw_ex1 
CCTCGGAAAGAGCAACCT
C GFRA3-Rv_ex1 GCTCCAGTTCCCCTTGTTC 
GFRA3-Fw_ex2 
GGAATATCCCTCTCCCAAC
C GFRA3-Rv_ex2 ATGTGGCCCATATCCTGC 
GFRA3-Fw_ex3 GAGGTCTGAGCCAGCAGC GFRA3-Rv_ex3 CCTTCCTCCAGGGTCCAG 
GFRA3-Fw_ex4 GTTCCTGTGGAACCTGGG GFRA3-Rv_ex4 AGGAAGGAGTGGCGTGTG 
GFRA3-
Fw_ex5&6 cctgggcaagagagagtgag   
GFRA3-
Rv_ex5&6 TCCTTCCCTTGAGTCCAGC 
GFRA3-Fw_ex7 
CCTTGGGAGCCTGAGAAA
TC GFRA3-Rv_ex7 
CTGCCTAGTTTGGGTTTTC
C  
GFRA3-Fw_ex8-
1 
GGCTGAGGTAGTGAAAGG
GC 
GFRA3-Rv_ex8-
1 
GGTGATCCTGGTAGTCAA
GAGG 
GFRA3-Fw_ex8-
2 CATGCTGCCCCTCCTTG 
GFRA3-Rv_ex8-
2 tgtgttctttcatctataacaccc 
TGFB2       
TGFB2-Fw_ex1-
1 
CTTTGTTGAAGGCAGACA
CG 
TGFB2-Rv_ex1-
1 
TCCTTCTCTTGCTCCAAAC
G 
TGFB2-Fw_ex1-
2 AGCCAGGGTGTCGCAAG 
TGFB2-Rv_ex1-
2 GAACTGACGGGAGGGGC 
TGFB2-Fw_ex1-
3 CTGCTGCTCCTGCTCTCAG 
TGFB2-Rv_ex1-
3 
AAGCGCTCAGCACACAGT
AG 
TGFB2-Fw_ex1-
4 
TTTCCACTTTTGGAACTAC
TGG 
TGFB2-Rv_ex1-
4 
 
AACTGAAAAGGAGGTGGT
GG   
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TGFB2-Fw_ex2 GTGCCAGGCATCTCTTCAG TGFB2-Rv_ex2 
TCCCCACAGGAGACAAAC
AC 
TGFB2-Fw_ex3 
TTCCCTTATGGTTTCTTGG
G TGFB2-Rv_ex3 Tgtactctagcctgtgacagagag 
TGFB2-
Fw_ex4&5 
GCAAATAGCCTGGTGTTG
TG 
TGFB2-
Rv_ex4&5 
CCAAATGAATGAAACTCC
CC 
TGFB2-Fw_ex6 
TGGCTGACTATATTTGATG
AAGG TGFB2-Rv_ex6 
GGGCAAAGGCAGTTTAAG
AG 
TGFB2-Fw_ex7 
TGGTGGTAGAGTGAGGGT
GG TGFB2-Rv_ex7 
CAGCAGGTGCACATGGTA
AC 
TGFB2-Fw_ex8-
1 
ACGAATTGCGTTCATTTTC
C 
TGFB2-Rv_ex8-
1 
CGGTACGTACAGCAACTC
CAC 
TGFB2-Fw_ex8-
2 
CCTACTTTGTAAGTGAGA
GAGACAAG 
TGFB2-Rv_ex8-
2 
TTTTAAGGTCTGAAGTTTG
ACCAG 
TGFB2-Fw_ex8-
3 
AAAAGAAACTTTCAGTCA
GAATAAGTC   
TGFB2-Rv_ex8-
3 
CCACTGAACTCGAACCCA
TC 
TGFB2-Fw_ex8-
4 
TTTGCCCTACTTGTGCTTT
G 
TGFB2-Rv_ex8-
4 
CTCTTCTGCAATGATGTG
GC 
TGFB2-Fw_ex8-
5 
CCAGGTCAGCATAAGTCA
TTTTG 
TGFB2-Rv_ex8-
5 
GGGAAATAAAGACCTTAC
AGAACC 
TGFB2-Fw_ex8-
6 
TCTGCAGACATTTTCCTCT
CAG 
TGFB2-Rv_ex8-
6 
TCCTTGATGGATATGGCC
TG 
TGFB2-Fw_ex8-
7 ACCTTTCCGATTGCCCTC 
TGFB2-Rv_ex8-
7 
TGATGGTTTGTTTCTAGAT
GGTG 
REN       
REN-Fw_ex1 ATTGCAATCACCCCATGC REN-Fw_ex1 
GTGTTGGGAAGGTGGGAA
C 
REN-Fw_ex2 
CACTGTGGTGGAGGTACA
GC REN-Fw_ex2 
AAAGCCCTAGGTCCATGA
GG 
REN-Fw_ex3 
AGAGTGAAGCCAGGCAAG
AC REN-Fw_ex3 
CAGGATTGCTCATGCACA
G 
REN-Fw_ex4 CCCACAATGCACCCTGC REN-Fw_ex4 GGTCAGGAGAGGCCTGG 
REN-Fw_ex5 
AGACCAGACTCCAACCAA
GG REN-Fw_ex5 
TCCACTCCCCATCTCTTCT
C 
REN-Fw_ex6 acagcagggctgatgagg REN-Fw_ex6 
ATTCTAGGTCAGGTGCTC
GG 
REN-Fw_ex7 
GAGTTGCTGGGTCCTGGA
G REN-Fw_ex7 
GTAATGCAGTCCTTCCCC
AC 
REN-Fw_ex8 CCCATCAGCCTtctgtctg REN-Fw_ex8 
TTTGTGAGCCGATACCAG
G 
REN-Fw_ex9 AGCGCAGGACTCCTTGTC   REN-Fw_ex9 
TTGAGGGTCTCTGTCCAG
C 
REN-Fw_ex10 ACGATGGGGCAAAATGG REN-Fw_ex10 
GCTAGGCGAATGTGTAGC
TTG 
CR2       
CR2-Fw_ex1 CTTGTCCCACCCTCACCG CR2-Rv_ex1 AGAAACTTTCCCTGCCCG 
CR2-Fw_ex2 
GAGTTTGGGAGTAAGCAG
GG CR2-Rv_ex2 
CAGGAGGGTACAAAACGT
GG 
CR2-Fw_ex3&4 
ccccttgATTCTAGATTGTGA
AG CR2-Rv_ex3&4 
CAGAGATCCTCACAGAGG
AGAC 
CR2-Fw_ex5 
TGCTGTTCTTCAGCACAAA
C  CR2-Rv_ex5 
GAGTCTGTAAGGTAATGA
CTGAACC 
CR2-Fw_ex6 
AGCATCTGGGGCATTCTTT
G CR2-Rv_ex6 
AGCCCACAACCCCTTCTT
C  
CR2-Fw_ex7&8 
TGGCTCAGTTTCTTTCTGT
GG CR2-Rv_ex7&8 
ATAGAGCCTGCAGTGTGT
GC 
CR2-Fw_ex9 GAAGTTGGTGCTGATGTT CR2-Rv_ex9 TGCAACCATAACTATTGG
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GG CAG 
CR2-Fw_ex10 
TGGTGGTTCTTTGTTCTTT
GG CR2-Rv_ex10 
CTTGCCTCTTTCCATGATG
C 
CR2-Fw_ex11 
TCCAGAGTTGTCCTTCTCT
TTG CR2-Rv_ex11 
TGAAGGTCAAGTTAATCC
ACAAAAC 
CR2-Fw_ex12 
TTTTGCATGCAGTTTGAAG
AG CR2-Rv_ex12 
CCTGCCCTCTCTAATCCTC
C 
CR2-Fw_ex13 
AATGAAGACCGCTCACCT
TG CR2-Rv_ex13 
TGTCAAGTGCAGATTCAA
AACC 
CR2-Fw_ex14 
GCAGGCTATGTGTTCCTCT
G CR2-Rv_ex14 
ATTTTAAGTTGAAAGTAC
CCAACTG  
CR2-Fw_ex15 
GGGAAATTTCTGCTTTCTT
GG CR2-Rv_ex15 
TGAGGGAAACTCTCACTC
TCTTC 
CR2-Fw_ex16 
AAATCGACTTGGAAGGGA
GC CR2-Rv_ex16 
TCCAACTCTATGCCAAAG
TGAC 
CR2-Fw_ex17 
TCAGAACAATGTAGGTGA
TCGTC CR2-Rv_ex17 
GCTTCTGTGTTTAGTTTCA
GACAAG 
CR2-Fw_ex18 
CAACTGCTACATTGAAAC
ATGGTC CR2-Rv_ex18 
CGCTTATTGATAAATACA
AGTTGAAGG 
CR2-Fw_ex19-1 
CTAATAGACTTGATGCTTT
GTTGG CR2-Rv_ex19-1 
GATTAACACCACCAGAGG
AGG 
CR2-Fw_ex19-2 
GCCAGGCCATGGCTATAA
AC CR2-Rv_ex19-2 
GACCAAGTGATGGGATCC
TG 
FLVCR1       
FLVCR1-
Fw_ex1-1 AGGGCCGTAGTCATGCAG 
FLVCR1-
Rv_ex1-1 
GAAGATCAGGAGCACCAC
G 
FLVCR1-
Fw_ex1-2 AGAGGAGACCCAGGCCC 
FLVCR1-
Rv_ex1-2 
ACAGGCCATAGTTCTCAC
GG 
FLVCR1-
Fw_ex2 
AATTTTCAAAGCACCTTTA
TAAACAC 
FLVCR1-
Rv_ex2 
GGGCATGGAAGAATGAA
AC 
FLVCR1-
Fw_ex3 
GAAATCAGTGAAAATGAA
AACCC 
FLVCR1-
Rv_ex3 
AATCCACAATGCTGAAAG
GC 
FLVCR1-
Fw_ex4 
TCCACAATTGTCACATAAT
ATTCC 
FLVCR1-
Rv_ex4 
CCCTTAATCTCATGACCCT
GC 
FLVCR1-
Fw_ex5 
TGAAAAGGTGTGGGAATG
TG  
FLVCR1-
Rv_ex5 
AAAAGCAAATTGTCCTTT
AAAATC 
FLVCR1-
Fw_ex6 
ATGGACAAGAAGGGGTGA
AC 
FLVCR1-
Rv_ex6 
TTGAAGAAACTTTGGATG
AACTG 
FLVCR1-
Fw_ex9 
CCAAGAAAGACTTTGAGC
TGC 
FLVCR1-
Rv_ex9 
TGGTTCTTGGTCTGTGGG
AC 
FLVCR1-
Fw_ex10-1 
GCATTAATCAAGTCTGATC
TGC 
FLVCR1-
Rv_ex10-1 
TCATCTGAAAGCCTGATC
CC 
FLVCR1-
Fw_ex10-2 
AAGGCTGGGTTTGTATGT
GG 
FLVCR1-
Rv_ex10-2 
AGAGCATGTACCTGGGCA
TAG 
FLVCR1-
Fw_ex10-3 
TCATGGATAAATGCTAAC
GCTG 
FLVCR1-
Rv_ex10-3 
TCAAAATTGCTATTCACTT
CAAGG 
FLVCR1-
Fw_ex10-4 
ATTTCCACAGTGCCTACCA
C 
FLVCR1-
Rv_ex10-4 tgccattcgcattcaagc 
FLVCR1-
Fw_ex10-5 gttaggccatccttgcattg 
FLVCR1-
Rv_ex10-5 ggatacttgtccctccaatctc 
FLVCR1-
Fw_ex10-6 ccagcctgggagataaagtg   
FLVCR1-
Rv_ex10-6 
TCTGGCTGGATTCAAGTT
CC 
FLVCR1-
Fw_ex10-7 caagtatcccaactatatcaGGCAG 
FLVCR1-
Rv_ex10-7 
TGTTCCAAACCTCAGGAA
CTC 
FLVCR1-
Fw_ex10-8 
TCCAATCATTAGCTTCCTT
TG 
FLVCR1-
Rv_ex10-8 tcacctagtgatgccacagc 
FLVCR1-
Fw_ex10 
TGAAAGTTGTCTGTAATAT
GTCAAGC 
FLVCR1-
Rv_ex10 
CCATGCACTACCTCATTCC
C 
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ESRRG       
ESRRG-Fw_ex1 
CCAAGTAAGAGGCATCCA
GC  ESRRG-Rv_ex1 
ATTGTCACATTTCCCTCTG
C 
ESRRG-Fw_ex2 tttggtctctgtgcttgacac ESRRG-Rv_ex2 
CACCATTAAAGCTTAACA
GTAAGAGG 
ESRRG-Fw_ex3 
TTGGGAAGCTAATGTTTCC
TG ESRRG-Rv_ex3 TTTTGCCTCCCATCCCC 
ESRRG-Fw_ex4 
GGTATTTGATTGGTCTCAA
ACATAG ESRRG-Rv_ex4 
ACATAGAGCCAACTGGGA
GG 
ESRRG-Fw_ex5 
GCCATAATTGGAATATTTA
GCG ESRRG-Rv_ex5 
GGATTCTATTAGGATATG
CAAAACTC 
ESRRG-Fw_ex6 
TGTTGCATTATGAAATTAT
GGC ESRRG-Rv_ex6 
CCTAAAGAAGTTAAGGAG
AGGGG 
ESRRG-Fw_ex7-
1 
GAAATGCAAGACTCTGAA
CAAATC 
ESRRG-Rv_ex7-
1 aaaagaaagaaggcaggcag  
ESRRG-Fw_ex7-
2 TCttctttcctctttcttcccac 
ESRRG-Rv_ex7-
2 
AATGATAAGAAGCAGCCG
ATG 
ESRRG-Fw_ex7-
3 
GAGAGAACCAACGTTCCT
AAAAG 
ESRRG-Rv_ex7-
3 
TGCACTCCTGACAATTCT
ACG 
ESRRG-Fw_ex7-
4 
TGCAATTTATGTTGTGTGC
C 
ESRRG-Rv_ex7-
4 
GGGAGCAGCTACTAACAC
TGG 
ESRRG-Fw_ex7-
5 
TGAAAGTCAAGTCAGGTT
CCAG  
ESRRG-Rv_ex7-
5 
GAGCGAGTTAATAACAAC
ATCTGAG 
ESRRG-Fw_ex7-
6 
GGATGTACAATTCCTCAG
GAGAC 
ESRRG-Rv_ex7-
6 
CCATCTCAGGTTTTCAGTT
GG 
ESRRG-Fw_ex7-
7 
AACAGAAAATACAACTCC
TGGG 
ESRRG-Rv_ex7-
7 
CAATCACCAACACCCATT
TTC 
ESRRG-Fw_ex7-
8 
CCTTGTAGTTACACTTGTG
TTTCAATC 
ESRRG-Rv_ex7-
8 
GGGCAGTGTTTATCAATT
TGG 
CENPF       
CENPF-Fw_ex1 
TAAAATCCATCCGAAAGG
GC CENPF-Rv_ex1 
GGAGAGTGATCCCAGAGG
C 
CENPF-Fw_ex2 
TCATTAATTTCTGAGACTT
TGTTTCC CENPF-Rv_ex2 
CAGTTTTAAATACCAGCA
CTTCTCTG 
CENPF-Fw_ex3 
TGTTCATATGGCTTATTGC
AGC CENPF-Rv_ex3 
TCTTCCACTCTTTCAAGTT
ACGG 
CENPF-Fw_ex4 
TCTGGGAATGTAAGGCAT
TG CENPF-Rv_ex4 
TGCAGAATTAAAATCTCA
AGCTAAAC 
CENPF-Fw_ex5 
TGATCTGTGAATTCCTTCA
TGG CENPF-Rv_ex5 
TGAGCCCAAAACCTTTTC
TC 
CENPF-Fw_ex6 
TGTTAACTTCTTGGGATTA
TGGC CENPF-Rv_ex6 
CACCTGTGAAATTACCTC
AAGC 
CENPF-Fw_ex7 
TTTGTTTCGTCAAAGATTT
CAG CENPF-Rv_ex7 tgcccaacttaaaacagctttc 
CENPF-Fw_ex8 
ATAGTTCCTAAACATAAA
TTGTGTGC CENPF-Rv_ex8 
ACAACTCCCCTTTCCAAG
TG 
CENPF-Fw_ex9 
TAGGATGCTCATGCCTCAC
C CENPF-Rv_ex9 
AACAAGTACAAGGAACA
AGAGGG  
CENPF-
Fw_ex10 
TTGATATTCCATGACCATT
TTATTG 
CENPF-
Rv_ex10 CTTTTCCCCTTGCACTTGG 
CENPF-
Fw_ex11 
GGGACCTTTATTAAGGCA
GAAG  
CENPF-
Rv_ex11 
ATCCCCTCTCACGGGAAT
AG 
CENPF-
Fw_ex12-1 
TTTGTTTGGATTTTGCCAG
G 
CENPF-
Rv_ex12-1 
CTGAGAACTCAGCTTTCT
GCTG 
CENPF-
Fw_ex12-2 
GAGTAAGAACGCTGGAGA
TGG 
CENPF-
Rv_ex12-2 
TGACTTGTTTCAGCCACA
AAAC 
CENPF-
Fw_ex12-3 
GCCATCCTACAAAATAGA
GTTGATTC  
CENPF-
Rv_ex12-3 
TCTTTTCCTGTGCTGCTTT
G 
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CENPF-
Fw_ex12-4 
TCCAGAAAAGTGAGAGTT
TTGC 
CENPF-
Rv_ex12-4 
CAAGATCCATCTGAGGTT
TAAAATTAC  
CENPF-
Fw_ex12-5 
TGAACAGCTGATGAAGGT
AATG 
CENPF-
Rv_ex12-5 
CACCATGGAGAAGACCAC
TG 
CENPF-
Fw_ex12-6 
GAAAATATGTGAAATACT
GCAGGC 
CENPF-
Rv_ex12-6 
CTACACTGCACTGGTTTG
CTG 
CENPF-
Fw_ex12-7 
TCTTGTGTGCCTGACAGCT
C 
CENPF-
Rv_ex12-7 
CATTTTCCTCAAGTTCTGG
TTTG 
CENPF-
Fw_ex13-1 
GTGTTTAGCAGAGGCCAC
G 
CENPF-
Rv_ex13-1 
TGAGGCCTTCAGAAGTTT
CTAC 
CENPF-
Fw_ex13-2 
GCTAAATGAAATGAAAGA
ATTAGACTC  
CENPF-
Rv_ex13-2 
ACTCACTTTGATGAGACT
CAAGC 
CENPF-
Fw_ex13-3 
GAGAGAAACCAGCTTCGT
GG 
CENPF-
Rv_ex13-3 
AGTGAATCATTCTCCCGC
TC  
CENPF-
Fw_ex13-4 
TCGAGAAACTGAGAGTTC
GC 
CENPF-
Rv_ex13-4 
TTTCATCAGCTTCTAGGCG
G 
CENPF-
Fw_ex13-5 
ATGAGGCAGTAGCAGCCT
TG 
CENPF-
Rv_ex13-5 
GCCTTCTCAAGTTCAAGA
CACTC 
CENPF-
Fw_ex13-6 
GAGGTCTGGAATTAGATG
TTGTTAC 
CENPF-
Rv_ex13-6 
CATGTCCCAAAGAATCAG
CC 
CENPF-
Fw_ex14 
GGCTAAAATAAATGGCAT
GAATATG 
CENPF-
Rv_ex14 
CAACAGAAGGTCTTACAG
GAACC 
CENPF-
Fw_ex15 
TGAATACATTGCTAAGGA
TTATAGCAC 
CENPF-
Rv_ex15 
ACCTGGGGAAAAGATCGT
G 
CENPF-
Fw_ex16 TTTTAGCTGTGCCTCCTGG 
CENPF-
Rv_ex16 
ACCATTAAAATCACTACC
ACCTG 
CENPF-
Fw_ex17 
AACCACATTGTCAGTTGG
GG  
CENPF-
Rv_ex17 
TCCCAAGATAAGCACAAA
ATTC 
CENPF-
Fw_ex18 
TTATCTGCTTCACGATGCC
C 
CENPF-
Rv_ex18 
GCAGACTATTGCTTATGA
ACGTC 
CENPF-
Fw_ex19 
TCTTTTCCACTGTAGATAG
AATTGG 
CENPF-
Rv_ex19 
TCCTCACCCAGGTACTAC
TGC 
CENPF-
Fw_ex20-1 
TCTCTGTTAGATGGGGCCT
G 
CENPF-
Rv_ex20-1 
TCAGCTCTGAGAAATTCC
CG 
CENPF-
Fw_ex20-2 
CATTGCCATTCCTCTACTG
C 
CENPF-
Rv_ex20-2 
TTCACGTGTATAAGAGGC
TGTTG 
MIR205       
MIR205-Fw_ex1 
CCTGAAGCTTTGCTGAGA
GG MIR205-Rv_ex1 ggtggtgtgcgcttgtagtc 
MIR205-Fw_ex2 cccctcaagtagctgggac MIR205-Rv_ex2 
GTTTCTTTTGCCCCTAAGG
C 
MIR205-Fw_ex3 
AACTCACCTTTCTGGGGCT
C MIR205-Rv_ex3 
CCTCCCAACATGTACAGT
CC 
MIR205-Fw_ex4 
TCCTCAGACAATCCATGTG
C MIR205-Rv_ex4 
CTAAAGGGGAGGTGGCTT
AG 
CAMK1G       
CAMK1G-
Fw_ex1 
ACGGTCCTGGGAAAGAAA
AC 
CAMK1G-
Rv_ex1 
CACGCTTCCCATTAAGCA
AG 
CAMK1G-
Fw_ex2 
TGTTTGAGAAAGCAGCTG
ACC 
CAMK1G-
Rv_ex2 
CTAACCTCCCACTGCAGG
C 
CAMK1G-
Fw_ex3 ctggaagtgtaagatgtcTGCC 
CAMK1G-
Rv_ex3 
CTTTGGGTGCAGAAATCC
AG 
CAMK1G-
Fw_ex4 
TGCATTATTTGTCTGTACA
ACCTG 
CAMK1G-
Rv_ex4 
CAGCGACCAACCTCCTGT
AG 
CAMK1G-
Fw_ex5 
GCTTCAAAGCAAACACCT
TCTC 
CAMK1G-
Rv_ex5  ATGACCCATGCAGCTTCC   
CAMK1G-
Fw_ex6 
TCAAGGGGAAGGAAAATA
CTTG 
CAMK1G-
Rv_ex6 
GGCATGTGGTTGAATGTA
GC 
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CAMK1G-
Fw_ex7 
GGCATGTGGTTGAATGTA
GC 
CAMK1G-
Rv_ex7 
AACGAGAAGGGGTAAGC
AGG 
CAMK1G-
Fw_ex8 CAGAGAGGCTGGCTCAGG  
CAMK1G-
Rv_ex8 
AGCTCATTTCTCTTGGCAG
C   
CAMK1G-
Fw_ex9 
TTTCCATCAGTCATGAAAT
CTG 
CAMK1G-
Rv_ex9 
GGAAATGCAATATGAATG
AGTCAG 
CAMK1G-
Fw_ex10 
CCCTGGATGAGTGTAAAT
AGCC 
CAMK1G-
Rv_ex10  AGCCCTTATGTCAGCCCC   
CAMK1G-
Fw_ex11 
GTTTAAGCTCCAAGGCCCT
C 
CAMK1G-
Rv_ex11 
TCCATTTCTTTCAGTCCTG
TTG 
CAMK1G-
Fw_ex12 
GAACTACCACCTCTGCCCT
G 
CAMK1G-
Rv_ex12 GCATGGGGCTCTCCTCTG  
CAMK1G-
Fw_ex13-1 
 
TGTGAGTGATGGGGTCTG
AG   
CAMK1G-
Rv_ex13-1 
AGCTGCCTGTCATTCATG
C  
CAMK1G-
Fw_ex13-2 
TACCCAGACTCCCACTCTG
C   
CAMK1G-
Rv_ex13-2 
TCCAGACATGCTCAGAAG
TCC 
LAMB3       
LAMB3-Fw_ex1 
CTGCCAGATTCCTGAGAC
CC LAMB3-Rv_ex1 
AGATACAGTCCTCCTCCC
GC 
LAMB3-Fw_ex2 
GGGCTAGTGTGCTCTAGG
GG LAMB3-Rv_ex2 
AAACTCTCCTTCTCCCTGT
GG 
LAMB3-Fw_ex3 
CTGAAAGATACTGGGGTG
GC LAMB3-Rv_ex3 acaaatgGCAGCTCACACAC 
LAMB3-Fw_ex4 
CACAGAGGAGATATGCTG
GG LAMB3-Rv_ex4 
TAAGAAATGCCTGGGAAA
CC 
LAMB3-Fw_ex5 GCTTCCTTCAGGGCTGG LAMB3-Rv_ex5 GCTCCTCCATGGCTCCAC 
LAMB3-Fw_ex6 
CTCTGCTTGTGTCTCCACG
G   LAMB3-Rv_ex6 
GTGTGGCTGTGTGAACAG
TG 
LAMB3-Fw_ex7 
AACTCGGGGCACACTATT
TG   LAMB3-Rv_ex7 
ATTTCCATGACCTGGGCT
C 
LAMB3-Fw_ex8 
TCTATGTGCCTCTAACTTC
CTTTC   LAMB3-Rv_ex8 
TCTGTAGTCTGCCCTGGTC
C 
LAMB3-Fw_ex9 CATCCCTGGTGCCCTTC LAMB3-Rv_ex9 
CCAGGTGAGATCATCAAG
GC  
LAMB3-
Fw_ex10 gccagtgagcttttgtggag 
LAMB3-
Rv_ex10 
GAGGAGATGGGGAGTAA
CAGAC 
LAMB3-
Fw_ex11  agcctggctcctggaatc   
LAMB3-
Rv_ex11 AAGCCGTGGGTCTGGTG   
LAMB3-
Fw_ex12 TGGATGTGTGTCCTCTGGG   
LAMB3-
Rv_ex12 
CAGAGAGGCTGGTGCTCA
G 
LAMB3-
Fw_ex13 
CAGGGTAAGGCAGAGGCT
G 
LAMB3-
Rv_ex13 GCAGACCTACACGCCCC 
LAMB3-
Fw_ex14 
GACAGCTGCTTCTGTCTCC
C   
LAMB3-
Rv_ex14 
GTACTGGAACCCCTGGAG
C  
LAMB3-
Fw_ex15&16 
CTGAGGGGATAGCTGCTT
TG 
LAMB3-
Rv_ex15&16 
GCAGTTGGTGTGTGACAA
GC 
LAMB3-
Fw_ex17 
GGGTGGGATTGGTTATTG
AG   
LAMB3-
Rv_ex17 
GGGGATCTATCCTGTCTG
CC 
LAMB3-
Fw_ex18 
CTGCTGAGAGGTTCCCTTG
G 
LAMB3-
Rv_ex18 
 
GCTGGCTGATGCACTGAA
C   
LAMB3-
Fw_ex19 
 
AGAGGCCTCGTATCTCTG
GG   
LAMB3-
Rv_ex19 AGGAGCAAAACGCCAGC 
LAMB3-
Fw_ex20 
CGAACCACACATTGATTC
AC   
LAMB3-
Rv_ex20 
CATTTTCTATGCCTGGTGC
C 
LAMB3- GCTGCCTGATGAGTTGGA LAMB3- AGTGTGCAAAGTCCTCCT
Appendix A 
 
151 
 
Fw_ex21 G Rv_ex21 CTG  
LAMB3-
Fw_ex22 
 
TTTGGCCACAGGTCTTTAG
G   
LAMB3-
Rv_ex22 TCAGAAGCCTTGGGTTGG  
LAMB3-
Fw_ex23-1 
GTTGGGAGTCTTGGGGAG
TC  
LAMB3-
Rv_ex23-1 
TGTAACTGTCCCATTGGCT
C 
LAMB3-
Fw_ex23-2 
GAATGCTTTCCATCTCCAG
G 
LAMB3-
Rv_ex23-2 
CCCAAATGGGAGACAGAA
AC 
G0S2       
G0S2-Fw_ex1 ACACAGTCGGAGCGTGC  G0S2-Rv_ex1 
AGCAGGAGAGGGGCTTCA
G 
G0S2-Fw_ex2-1  TGGGAGCCGTTCTTTGG   G0S2-Rv_ex2-1 GAGTCAGGCTCCTGTGCG 
G0S2-Fw_ex2-2 AGGCAAGCAGCAGGACAC G0S2-Rv_ex2-2 
TAAGAACCCATCACCATC
GC 
HSD11B1       
HSD11B1-
Fw_ex1 
ATGAAATCCACCACACAG
GC 
HSD11B1-
Rv_ex1 
AGGAACACTCAAGCACCC
C 
HSD11B1-
Fw_ex2 
GAAGGAATTTTGCTGCCA
AC   
HSD11B1-
Rv_ex2 
TGCGATATGCTAGCTTCT
GTG   
HSD11B1-
Fw_ex3-4 
CCGTTACTTCAGAGACTAC
CCC 
HSD11B1-
Rv_ex3-4 CTGGCATCATCCCTGGC 
HSD11B1-
Fw_ex5 
CCACCCTATGCCTTCGATA
C   
HSD11B1-
Rv_ex5 acactgggcctgttggg 
HSD11B1-
Fw_ex6-1 
AGTGGTTGATGTCTCCAG
GC 
HSD11B1-
Rv_ex6-1 
TTAGAGGAACTCCTTCCA
TTTG 
HSD11B1-
Fw_ex6-2 
TGTTCTGTCTCATGTTTAT
CTGAGC 
HSD11B1-
Rv_ex6-2 
CACCAAACAAAGATTAGG
GTG 
TRAF3IP3       
TRAF3IP3-
Fw_ex1 
GTGCCTACTGATGGGAGG
AG 
TRAF3IP3-
Rv_ex1 
GAGCATCTTCTGCCCTAC
CC 
TRAF3IP3-
Fw_ex2 GGCTCCCTGGAAACTTCTG 
TRAF3IP3-
Rv_ex2 
ATTTCAGAGCATCTGGCT
CC  
TRAF3IP3-
Fw_ex3 
CCCCTGGTCTAGGGAGAT
AG 
TRAF3IP3-
Rv_ex3 
CTCCTTGTCCAGAGAGGG
TC 
TRAF3IP3-
Fw_ex4&5 
AGAGTCTTTCAAGAGGCT
CCAG   
TRAF3IP3-
Rv_ex4&5 
GGACATGGAAATTCATTG
TGTTC 
TRAF3IP3-
Fw_ex6&7 
CACTGCCTCCTGACTTGAT
TC 
TRAF3IP3-
Rv_ex6&7 
GATTAACCTGGAGGATCG
GG 
TRAF3IP3-
Fw_ex8 
AGTAAGTGGCATGTGACC
CC 
TRAF3IP3-
Rv_ex8 
TGAGAAAACCCCTTCTCT
TACTG  
TRAF3IP3-
Fw_ex9 
TGTGCTGGGCAGTAGAAT
AGG 
TRAF3IP3-
Rv_ex9 
GGTGGTGTTTCTCGAAAG
TAAG 
TRAF3IP3-
Fw_ex10&11 aggatttggcacacagaagc   
TRAF3IP3-
Rv_ex10&11 
TCTTTCATCACCATCCCTC
C 
TRAF3IP3-
Fw_ex12 
AACCTCCACCCCAACACT
G 
TRAF3IP3-
Rv_ex12 
AAAGCCAATCAACCAATC
AAG 
TRAF3IP3-
Fw_ex13 
AAGACCATGACAAGACAG
CATC   
TRAF3IP3-
Rv_ex13 
 
CCTACTCTGGGTGCCTTTT
G   
TRAF3IP3-
Fw_ex14 ttcaacacacagcaGATGGG 
TRAF3IP3-
Rv_ex14 aggtcatgtagtccatcccg   
TRAF3IP3-
Fw_ex15 
 
CCTTCCTCAGAGGTGTGG
G   
TRAF3IP3-
Rv_ex15 
CAGGTTTCTCTGCTATTTC
GC 
TRAF3IP3-
Fw_ex16 CAGTCTCCCCTGCCTGG 
TRAF3IP3-
Rv_ex16 
 
TTGGTTAAAGAAGGAATC
GTCC   
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TRAF3IP3-
Fw_ex17 
TTTGCCTATATCTTTTCCA
ATCC 
TRAF3IP3-
Rv_ex17 
GACCACCAGTATGCTTAA
ATATGTG 
C1orf74       
C1orf74-
Fw_ex1-1 
GTGTCTGGCTGAAAGATG
CC 
C1orf74-
Rv_ex1-1 
GATAAGTCCCTCTGCAGC
CC 
C1orf74-
Fw_ex1-2 AGCGTCACCCTTCTGTCTG 
C1orf74-
Rv_ex1-2 
GATGATTATTTGCCATCCC
C 
IRF6       
IRF6-Fw_ex1 TTCTTGCAACTCGCCAATC   IRF6-Rv_ex1 GATGGGTCCTACCCCACC 
IRF6-Fw_ex2 
CAGACACTGGATTGTTGT
ATGG IRF6-Rv_ex2 
CCACCATGATGAGGGAGA
AG 
IRF6-Fw_ex3 CCAGTGGCTGGCCTAATTC IRF6-Rv_ex3 
TTCTCTCTGTTTCACCAGA
GTTTTAG 
IRF6-Fw_ex4 TTTGCAGTGGCTCTGGG IRF6-Rv_ex4 
CCATCTTAAACTGTGTAA
ATCAGGC 
IRF6-Fw_ex5 GTCAGCTGCAGGGGTGG IRF6-Rv_ex5 
TGACAGTCCCAAGGTCAA
AAC   
IRF6-Fw_ex6 
TCTCAGAGCATCAGCAAG
TG IRF6-Rv_ex6 
TGAAGTTAGAAAGCAGGA
CAGG 
IRF6-Fw_ex7 
CTGGTTGAAAGGTGGCTT
G IRF6-Rv_ex7 
GACAGGGATAGTGGAAG
GAATG 
IRF6-Fw_ex8 
TTGTTGAGTGGATGTGGA
ATG IRF6-Rv_ex8 GGGGCTTAAGCATTGGC 
IRF6-Fw_ex9-1 
TGTCCTTCAATCTTGGGTC
C IRF6-Rv_ex9-1 aaactcccaggccaaatctc 
IRF6-Fw_ex9-2 
TTTGTGATTCTCCAAATAT
GCC IRF6-Rv_ex9-2 
TTCTGTGTCAACAGCTTCC
C 
IRF6-Fw_ex9-3  GGCTGGCTGGTTGCTTAG   IRF6-Rv_ex9-3 
GATACAGCTGCATTGTTC
TATACC 
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Appendix B 
List of Companies Addresses 
 
QIAGEN Inc. 27220 Turnberry Lane, Valencia, CA 91355, USA 
Fisher Scientific, 300 Industry Drive, Pittsburgh, PA 15275, USA 
Life Technologies, 3175 Staley Road Grand Island, NY 14072, USA 
Thermo Scientific 3411 Silverside Rd, Bancroft Building, Wilmington, DE 19810, 
USA 
Zymo Research Corporation, 17062 Murphy Ave., Irvine, CA 92614, U.S.A 
Amersham Biosciences Corp. 800 Centennial Ave, P.O. Box 1327 Piscataway, NJ 
08855-1327 
Corning Life Sciences 31 Mayfield Avenue Edison, New Jersey 08837, United States 
Beckman Coulter, Inc. Diagnostics Division Headquarters 250 South Kraemer 
Boulevard Brea CA 92821-6232 
PE Applied Biosystems, 777 Lincoln Centre Dr, Foster City, CA 94404  
SoftGenetics, LLC. 100 Oakwood Ave, Suite 350. State College, PA 16803. USA. 
Invitrogen (Life Technologies Ltd). 3 Fountain Drive Inchinnan Business Park, 
Paisley PA4 9RF, UK 
Affymetrix 3420 Central Expressway, Santa Clara, CA 95051  
Metabion International AG, lena-christ-str. 44/I, 82152 martinsried, Germany 
Gene Tools, LLC, 1001 Summerton Way, Philomath, OR 97370 USA 
Geneservice Ltd, 2 Cambridge Science Park, Milton Road, Cambridge, CB4 0FE, UK 
Mutagenex Inc. P.O. Box 68 Piscataway, NJ 08855, USA 
Ambion, 2130 Woodward, Austin, TX 78744-1832, USA 
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Sigma-Aldrich Company Ltd. The Old Brickyard, New Road, Gillingham, Dorset SP8 
4XT, UK 
Abcam plc. 330 Cambridge, Science Park, Cambridge, CB4 0FL, UK. 
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